In cy t e  C o rpo r a t i on  P ag e  1  o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
C l in i ca l  S tud y  P ro t o co l  
INCB  5 04 65- 2 02 /  NCT 0 2 9 9 8 4 7 6
A  Ph a s e  2 ,  Mu l t i c en t e r ,  I n t e rn a t i ona l ,  Op en -Lab e l ,  Sa f e t y  and  
E f f i c a c y  S tud y  of  INCB 05046 5  in  Sub je c t s  W ith  R e l ap s ed  o r  
R e f r a c t o r y  Di f fu s e  La r g e  B -C e l l  Lymph om a  (C ITADEL - 202 ) 
P rodu c t : INCB 0 5 0 4 6 5  
IND  Numb e r :  1 2 1 , 4 7 4  
Eud raCT Numb e r : 2 0 1 6 -0 0 2 2 0 5 -1 9  
Ph a s e  o f  Stud y :  2  
Sp on so r : In cy t e  C o rp o r a t ion  
1 8 0 1  Au gu s t in e  Cu t-O f f  W i lm in g ton ,  DE  1 9 8 0 3  
D a t e  o f  P ro t o co l : 2 6  MAY  2 0 1 6  
D a t e  o f  Am endm en t (V e r s ion )  1 :  3 0  AUG  2 0 1 6  
D a t e  o f  Am endm en t  (V e r s ion )  2 :  0 9  NOV  2 0 1 6  
D a t e  of  Am endm en t  (V e r s ion )  3 :  2 3  FEB  2 0 1 7  D a t e  o f  Am endm en t  (V e r s ion )  4 :  0 5  NOV  2 0 1 9  
Th i s s t u dy  w i l l  b e  p e r f o rm ed  i n  a c co rd an c e  w i t h  e th i c a l  p r i n c i p l e s  t h a t  h av e  th e i r  o r i g in  i n  t h e  D e c l a r a t i on  o f  
H e l s in k i  an d  con du c t ed  in  adh e r en c e  t o  t h e  s tu dy  P ro t o co l,  Good  C l i n i c a l  P r a c t i c e s  a s  d e f i n ed  i n  T i t l e  21  o f  t h e  
US C od e  o f  F ed e r a l  R egu l a t i on s  P a r t s  11 ,  50 ,  54,  56 ,  an d  31 2 ,  a s  w e l l  a s  ICH  GCP  con s o l id a t ed  g u i d e l i n e s  (E6 )  an d  app l i c ab l e  r eg u l a t o ry  r equ i r em en t s .  
Th e  i n f o rm a t i o n  i n  t h i s  d o c um en t  i s c o n f i d e n t i a l .   N o  p a r t  o f  t h i s  i n f o rm a t i o n  m ay  b e  d u p l i c a t e d ,  r e f e r e n c e d ,  o r  
t r a n sm i t t e d  i n  a n y  f o rm  o r  b y  a n y  m e a n s  ( e l e c t r o n i c ,  m e c h a n i c a l ,  p h o t o c o p y ,  r e c o r d i n g ,  o r  o t h e rw i s e )  w i t h o u t  t h e  p r i o r  
w r i t t e n  c o n s e n t  o f  I n c y t e  C o r p o r a t i o n .
 
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  2  o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
INVEST IGATOR ' S  AGREEMENT 
I  h a v e  r e a d  th e  INCB  5 04 6 5 - 2 0 2  P r o to c o l  Am e n dm e n t  4  ( d a t e d  0 5  NOV  20 1 9 )  a n d  ag r e e  to  
c o n d u c t  th e  s tu dy  a s  o u t l in e d .   I  ag r e e  to  m a in t a in  th e  c o n f id e n t i a l i ty  o f  a l l  in f o rm a t io n  r e c e iv e d  
o r  d e v e lo p e d  in  c o n n e c t io n  w i th  th i s  P r o to c o l .  
  
   
(P r in t e d  N am e  o f  I n v e s t ig a to r )    
   
   
(S ig n a tu r e  o f  I n v e s t ig a to r )   (D a t e )  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  3  o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
SYNOPS IS 
N am e  o f  In v e s t ig a t ion a l  P rodu c t :  INCB 0 5 0 4 6 5  
T i t l e  o f  S tud y :  A  P h a s e  2 ,  Mu l t i c en t e r ,  I n t e rn a t io n a l ,  O p en - L ab e l ,  S a f e ty  an d  E f f i c a cy  S tu d y  o f  
INCB 0 5 0 4 6 5  in  S u b j e c t s  W i th  R e l ap s ed  o r  R e f r a c to r y  D i f f u s e  L a rg e  B - C e l l  L ym p h om a 
P ro to c o l  Numb e r :  INCB  5 0 4 6 5 - 2 0 2  S tud y  Ph a s e :  2  
Ind i ca t i on :   D i f f u s e  l a rg e  B- c e l l  lym p h om a  
P r im a ry  Ob j e c t iv e:  
•  To  a s s e s s  th e  e f f i c a cy  o f  INCB 0 5 0 4 6 5 in  t e rm s  o f  o b j e c t iv e  r e sp o n s e  r a t e  (ORR )  i n  su b j e c t s  w i th  
r e l ap s e d  o r  r e f r a c to ry  d i f fu s e  l a rg e  B - c e l l  lym p h om a  (DLBCL )  in  G ro u p  A .  
S e cond a ry  Ob j e c t i v e s:  •  To  a s s e s s  th e  d u r a t io n  o f  r e sp o n s e  (DOR )  in  G ro u p  A .  
•  To  a s s e s s  p ro g r e s s io n- f r e e  su rv iv a l  (PFS )  i n  G ro u p  A .  
•  To  a s s e s s  o v e r a l l  su rv iv a l  (OS )  in  G r o u p  A . 
•  To  ch a r a c t e r i z e  th e  s a f e ty  o f  INCB 0 5 0 4 6 5  in  G ro u p  A  an d  G ro u p  B .  
P r im a ry  Endp o in t:  
•  O b j e c t iv e  r e sp o n s e  r a t e in  G ro u p  A ,  d e f in ed  a s  th e  p e r c en t ag e  o f  su b j e c t s  w i t h  a  c om p l e t e  
r e sp o n s e / com p l e t e  m e t ab o l i c  r e sp o n s e  (CR /CMR )  o r  p a r t i a l  r e sp o n s e /p a r t i a l  m e t a b o l i c  r e sp o n s e  
(PR /PMR )  a s  d e f in e d  b y  r e v i s ed  r e sp o n s e  c r i t e r i a  fo r  l ym p h om a s ,  a s  d e t e rm in ed  b y  an  I n d ep en d en t  
R ev i ew  C omm i t t e e  ( IRC ) . 
S e cond a ry  Endp o in t s:  
•  D u r a t io n  o f  r e sp o n s e  in  G r o u p  A ,  d e f in e d  a s  th e  t im e  f rom  f i r s t  d o c um en t ed  ev id e n c e  o f  CR/CMR  o r  
PR /PMR u n t i l  d i s e a s e  p ro g r e s s io n  o r  d e a t h  f rom  an y  c au s e  am o n g  su b j e c t s  w h o  a ch i ev e  an  o b j e c t iv e  
r e sp o n s e ,  a s  d e t e rm in ed  b y  r ad i o g r ap h i c  d i s e a s e  a s s e s sm en t  p ro v id ed  b y  an  IRC .  
•  P ro g r e s s io n -f r e e  su rv iv a l  i n  G ro u p  A ,  d e f i n ed  a s  th e  t im e  f rom  th e  d a t e  o f  th e  f i r s t  d o s e  o f  s tu d y  d ru g  
u n t i l  th e  e a r l i e s t  d a t e  o f  d i s e a s e  p ro g r e s s io n ,  a s  d e t e rm in ed  b y  r a d io g r ap h i c  d i s e a s e  a s s e s sm en t  
p ro v id ed  b y  an  IRC ,  o r  d e a t h  f rom  an y  c au s e .  
•  OS in  G ro u p  A ,  d e f in e d  a s  th e  t im e  f rom  th e  d a t e  o f  th e  f i r s t  d o s e  o f  s t u d y  d ru g  u n t i l  d e a th  b y  an y  
c au s e .  
•  S a f e ty  a s  m e a su r ed  b y  c l in i c a l  a s s e s sm en t s,  in c lu d in g  v i t a l  s ig n s  an d  p h y s i c a l  e x am in a t io n s ,  1 2 - l e ad  
e l e c t r o c a rd i o g r am s  (ECG ) ,  ch em i s t ry  an d  h em a to lo g y  l ab o r a to ry  v a lu e s ,  an d  ad v e r s e  ev en t s  (AE s ) .  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  4  o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
Ov e r a l l  Stud y  D e s ign :   Th i s  i s  a  P h a s e  2 ,  m u l t i c en t e r ,  in t e rn a t io n a l ,  o p en- l ab e l  s t u d y  d e s ig n ed  to  
ev a lu a t e  th e  s a f e ty  an d  e f f i c a cy  o f  INCB 0 5 0 4 6 5  2 0  m g  o n c e  d a i ly  fo r  8  w e ek s  fo l low ed  b y  2 0  m g  o n c e  
w e ek ly , adm in i s t e r ed  o r a l ly  to  su b j e c t s  w i t h  r e l ap s ed  o r  r e f r a c t o ry  DLBCL  ( s e e  S e c t i o n 1 . 4  fo r  d o s e  r a t io n a l e ) .   Th e  s t u d y  co n s i s t s  o f  2  g ro u p s :   G ro u p  A  a n d  G ro u p  B .   I n  G ro u p  A ,  1 0 0  su b j e c t s  w h o w e r e  
n o t  p r ev io u s ly  t r e a t e d  w i th  a  B ru t o n 's  ty ro s in e  k in a s e  ( BTK)  in h ib i to r  ( eg ,  ib ru t in i b )  w i l l  b e  en ro l l ed .   I n  
G ro u p  B ,  u p  to  2 0  su b j e c t s  w h o w e r e  p r ev io u s ly  t r e a t e d  w i th  a  BTK  in h ib i to r  ( eg ,  ib ru t i n ib )  w i l l  b e  
en ro l l e d .   S u b j e c t s  w i l l  b e  e v a lu a t ed  fo r  ORR  b y  a n  in d ep en d e n t  r ev i ew  comm i t t e e  ( IRC )  an d  fo l low ed  
fo r  D OR ,  PFS,  an d  OS .   S u b j e c t s  m ay  r e c e iv e  t r e a tm en t  u n t i l  d i s e a s e  p ro g r e s s io n ,  d e a t h ,  u n a c c e p t a b l e  
to x i c i ty ,  o r  co n s en t  w i th d r aw a l .  
A n  in t e r im  fu t i l i ty  an a ly s i s  i s  p l an n ed  w h en  th e  f i r s t  4 0  su b j e c t s  i n  G ro u p  A  h av e  b e en  t r e a t ed  an d  h av e  
b e en  ev a l u a t ed  f o r  r e sp o n s e  o r  h av e  p e rm an en t ly  d i s co n t in u ed  s tu d y  t r e a tm en t  b e c au s e  o f  d i s e a s e  
p ro g r e s s io n ,  w i th d r aw a l  o f  co n s en t ,  o r  d e a th .   G ro u p  A  o f  th e  s tu d y  w i l l  b e  t e rm in a t ed  fo r  fu t i l i ty  i f  
≤  1 3  o f  t h e  4 0  su b j e c t s  h av e  r e s p o n d e d  ( i e ,  CR /CMR  o r  PR /PMR)  b a s ed  o n  a s s e s sm en t s  p ro v id e d  b y  th e  
IRC ;  o th e rw i s e  th e  s t u d y  w i l l  co n t i n u e .   A  t im e ly  a s s e s sm en t  o f  r e sp o n s e  w i l l  b e  p e r fo rm ed  to  av o id  th e  
r i sk  o f  o v e r en r o l lm en t .  N o  fo rm a l  fu t i l i ty  an a ly s i s  w i l l  b e  co n d u c t ed  f o r  G r o u p  B .  
N o t e :  W i th  Am en dm en t  4 ,  P ro to co l - r eq u i r ed  p ro c ed u r e s  h av e  b e en  r ed u c ed  fo r  o n g o in g  su b j e c t s .   
S tud y  Popu l a t ion :  S u b j e c t s  w i th  hi s to lo g i c a l ly  co n f i rm ed  r e l ap s ed  o r  r e f r a c to ry  DLBCL  w h o  h av e  
r e c e iv ed  2  t o  5  p r io r  th e r ap i e s .  
K ey  In c lu s ion  C r i t e r ia :  
•  M en  a n d  w om en ,  ag ed  1 8  y e a r s  o r  o ld e r  ( ex c ep t  in  S o u th  Ko r e a ,  ag ed  1 9  o r  o ld e r ) .  
•  R e l ap s ed  o r  r e f r a c to ry  DLBCL , w h i ch  h a s  b e en  h i s t o l o g i c a l ly  d o cum en t ed ,  d e f i n ed  a s  h av in g  r e c e iv ed  
a t  l e a s t  2  b u t  n o  m o r e  th an  5  p r i o r  t r e a tm en t  r eg im en s  ( eg ,  an  an t i -CD 2 0  an t ib o d y ,  an  an t i -CD 2 0  
an t ib o d y  w i th  o r  w i th o u t c h em o th e r ap y ,  o r  c h em o th e r a p y  a lo n e )  an d  in e l ig ib l e  f o r  h ig h - d o s e  
ch em o th e r a p y  su p p o r t ed  b y  au to lo g o u s  s t em  c e l l  t r an s p l an t .  
•  Mu s t  h av e  ≥  1  m e a su r ab l e  (≥  2  cm  in  l o n g e s t  d im en s io n )  o r  ≥  1  m e a su r ab l e  e x t r an o d a l  l e s io n  (>  1  cm  
in  lo n g e s t  d im en s io n )  l e s io n  o n  com p u t ed  tom o g r ap h y  (CT )  s c an  o r  m ag n e t i c  r e so n an c e  im ag in g  (MR I ) .  
•  S u b j e c t s  m u s t  b e  w i l l in g  to  u n d e rg o  an  in c i s io n a l  o r  ex c i s io n a l  lym p h  n o d e  b io p sy  o f  a c c e s s ib l e  
ad en o p a th y  o r  p ro v id e  th e  m o s t  r e c en t ,  av a i l ab l e  a r c h i v ed  tum o r  b io p sy .  
•  E a s t e rn  C o o p e r a t iv e  O n co l o g y  G ro u p  p e r fo rm an c e  s t a tu s  0  to  2 .  
K ey  E x c lu s ion  C r i t e r i a : 
•  P r im a ry  m ed i a s t in a l  ( th ym i c )  l a rg e  B- c e l l  lym p h om a .  
•  Kn ow n  b ra in  o r  c en t r a l  n e r v o u s  sy s t em  m e t a s t a s e s  o r  h i s to ry  o f  u n co n t ro l l ed  s e i z u r e s .  
•  A l lo g en e i c  s t em  c e l l  t r an s p l an t  w i t h in  th e  l a s t  6  m o n th s ,  o r  a c t iv e  g r a f t  v e r su s  h o s t  d i s e a s e  f o l low in g  
a l l o g en e i c  t r an sp l an t ,  o r  au t o lo g o u s  s t em  c e l l  t r an sp l an t  w i t h in  th e  l a s t  3  m o n th s .  
•  U s e  o r  ex p e c t ed  u s e  d u r in g  th e  s tu d y  o f  an y  p ro h i b i t ed  m ed i c a t i o n s ,  in c lu d in g  p o t e n t  cy to ch rom e  P 4 5 0  
3A 4  in h ib i to r s  o r  in d u c e r s  w i th in  1 4  d ay s  o r  5  h a l f- l iv e s  (w h i ch ev e r  i s  lo n g e r )  b e f o r e  th e  f i r s t  d o s e  o f  
s tu d y  d ru g .  
•  P r io r  t r e a tm en t  w i th  th e  fo l l ow in g :  
− G ro u p  A :   P r i o r  t r e a tm en t  w i th  a s e l e c t iv e  p h o sp h a t i d y l in o s i to l  3 - k in a s e  (
P I 3K ) δ  in h ib i t o r  ( eg ,  
id e l a l i s ib ) ,  a  p a n -P I 3K  in h i b i to r ,  o r  a  BTK  i n h ib i t o r  ( e g ,  ib ru t in i b ) .  
− G ro u p  B :   P r i o r  t r e a tm en t  w i th  a s e l e c t iv e  P I 3K δ  in h i b i to r  ( eg ,  id e l a l i s ib )  o r  a  p a n -P I 3K  in h ib i to r .  
INCB0 5 0 4 6 5 /S tud y  D ru g ,  D o sa g e ,  and  Mod e  o f  Adm in i s t ra t ion :  INCB 0 5 0 4 6 5  w i l l  b e  adm in i s t e r ed  o r a l ly  a t  a  d o s e  o f  2 0  m g  on c e  d a i ly  fo r  8  w e ek s  fo l low ed  b y  2 0  m g  o n c e  w e ek ly  to  su b j e c t s  in  a  f a s t ed  
s t a t e .   S u b j e c t s  m ay  h av e  do s e  r ed u c t i o n s  o r  i n t e r ru p t i o n s  b a s ed  u p o n  c l in i c a l  a n d  l ab o r a to ry  a s s e s sm en t s . 
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  5  o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
R e f e r en c e  Th e rap y ,  D o sa g e,  and  M od e  o f  Adm in i s t ra t i on :  N o t  ap p l i c ab l e . 
R equ i r ed  con com i tan t  m ed i ca t ion s :   A l l  s u b j e c t s  m u s t  r e c e iv e  p ro p h y l ax i s  ag a i n s t  P n eum o c y s t i s  
j i r o v e c i i  p n eum o n i a  f rom  t h e  s t a r t  o f  s t u d y  t r e a tm en t  a n d  sh o u ld  co n t in u e  fo r  2  t o  6  m o n th s  a f t e r  th e  l a s t  
d o s e  o f  s tu d y  t r e a tm en t .  
S tud y  S ch edu l e /P ro c edu r e s :  D u r in g  s c r e e n in g  an d  e v e ry  2 1  d ay s  f rom  th e  d a t e  o f  f i r s t  s tu d y  d ru g  
adm in i s t r a t io n  (D ay  1 ) ,  a  s t u d y  v i s i t  w i l l  b e  co n d u c t ed  th a t  in c lu d e s  a  p h y s i c a l  e x am in a t io n ,  c l in i c a l  
l ab o r a t o ry  t e s t s ,  an d  an  a s s e s s m en t  o f  AEs .   
 
D u r in g  s c r e en in g ,  su b j e c t s  w i l l  h av e  an  o b j e c t iv e  a s s e s sm en t  o f  d i s e a s e  s t a tu s  p e r f o rm ed  b y  f lu o ro d e o x y g lu co s e  (FDG )  p o s i t ro n  em i s s io n  tom o g r ap h y  (PET )  an d  d i ag n o s t i c  q u a l i ty  CT  s c an  o r  MR I .   
S u b j e c t s  w i l l  a l so  h av e  a  b o n e  m a r row  b io p sy  p e r fo rm ed  a t  s c r e en in g u n l e s s  t h e  su b j e c t  h a s  FDG - av id  
d i s e a s e  o r  h a s  u n d e rg o n e  a  r e c e n t  b o n e  m a r row  b io p sy .   D i s e a s e  s t a tu s  w i l l  b e  su b s eq u en t ly  a s s e s s ed  b y  
PET- CT /MR I  a t  W e ek s  9 ,  1 8 ,  2 7 ,  an d  ev e ry  1 8  w e ek s  th e r e a f t e r  u n t i l  d i s e a s e  p ro g r e s s io n .   O n- s tu d y  b o n e  m a r row  b io p s i e s  w i l l  b e  r e q u i r e d  o n ly  i f  n e ed ed  to  c o n f i rm  a  CR/CMR .  
S u b j e c t s  w i th d r aw n  f r om  s tu d y  t r e a tm en t  fo r  r e a so n s  o th e r  th an  d i s e a s e  p ro g r e s s io n  w i l l  b e  fo l low ed  fo r 
d i s e a s e  a s s e s sm en t  u n t i l e i t h e r  r ad io lo g i c  d i s e a s e  p r o g r e s s i o n ,  th e  s t a r t  o f  a  n ew  an t i c an c e r  th e r ap y ,  o r  
d e a th  (w h i ch ev e r  o c cu r s  f i r s t ) .  
S u b j e c t s  w i th d r aw n  f r om  s tu d y  t r e a tm en t  b e c au s e  o f  d i s e a s e  p ro g r e s s io n  w i l l  b e  f o l low ed  ap p ro xim a t e ly  
ev e ry  1 2  w e ek s  fo r  s u b s e q u en t  a n t i c an c e r  th e r a p i e s  an d  su rv iv a l .  
N o t e :  W i th  Am en dm en t  4 ,  P ro to co l - r eq u i r ed  p ro c ed u r e s  h av e  b e en  r ed u c ed  fo r  o n g o in g  su b j e c t s .  
E s t ima t ed  Du ra t ion  o f  Pa r t i c ip a t ion :  S u b j e c t  p a r t i c i p a t io n  t h ro u g h  s a f e ty  fo l low - u p  i s  ex p e c t ed  t o  
av e r ag e  ap p ro x im a t e ly  1 1  m o n th s ,  w h i ch  in c lu d e s  t h e  fo l low in g :  
•  A  s c r e en in g  p e r io d  l a s t in g  u p  to  2 8  d ay s .  
•  A  t r e a tm en t  p e r io d  l a s t in g  a s  lo n g  a s  th e  su b j e c t  i s  r e c e i v in g  b en e f i t ,  to l e r a t in g  th e  r eg im en ,  an d  h a s  n o t  
m e t  w i th d r aw a l  c r i t e r i a  ( ap p ro xim a t e ly  9  m o n th s ) .  
•  A  s a f e ty  fo l low - u p  p e r io d  l a s t in g  3 0  to  3 5  d ay s .  
S u b j e c t s  w i l l  b e  fo l low e d  f o r  ap p ro x im a t e ly  1 2  m o n th s  a f t e r  th e  s a f e ty  fo l low -u p  p e r i o d .  
E s t ima t ed Numb e r  o f  Sub j e c t s :  Th e  t a rg e t  en r o l lm en t  fo r  th i s  s tu d y  i s  1 0 0  to  1 2 0  su b j e c t s .  
P r in cip a l  C o o rd in a t in g  In v e s t ig a to r :   ,  MD ,   
 
S ta t i s t i ca l  M e th od s :  D a t a  f rom  G ro u p  A  an d  G ro u p  B  w i l l  b e  a n a ly z ed  s ep a r a t e ly .   R e sp o n s e  d a t a  w i l l  
b e  an a ly z ed  w h en  a l l  su b j e c t s  h av e  r e c e iv ed  a t  l e a s t  1  p o s tb a s e l i n e  d i s e a s e  a s s e s sm en t ,  o r  h av e  
p ro g r e s s ed ,  w i th d r aw n  f rom  th e  s tu d y ,  o r  d i ed .   T h e r e  w i l l  n o t  b e  a n y  s t a t is t i c a l  c om p a r i so n  b e tw e e n  th e  2  g ro u p s .   
S amp l e  S i z e : 
G ro u p  A :   1 0 0  su b j e c t s  w i l l  b e  en ro l l ed .   I f  th e  t ru e  ORR  i s  0 . 5 0 ,  th en  t h e r e  i s  ab o u t  9 0%  p r o b ab i l i ty  o f  
o b s e rv in g  th e  low e r  b o u n d  o f  th e  9 5%  co n f i d en c e  i n t e r v a l  o f  ORR  ≥  3 5% .     
G ro u p  B :   U p  to  2 0  su b j e c t s  w i l l  b e  en r o l l ed .   Th e r e  i s  8 7%  p ro b ab i l i ty  o f  o b s e rv i n g  ≥  6  r e sp o n d e r s  in  
2 0  su b j e c t s .    
P r im a ry  An a ly s i s :  G ro u p  A  o n ly :   Th e  ORR  a s  d e t e rm in ed  b y  th e  IRC  an d  i t s  9 5%  ex a c t  b in om i a l  co n f id en c e  in t e rv a l s  (C I s )  w i l l  b e  c a l c u l a t ed .   Th e  ORR  a s  d e t e rm in ed  b y  th e  i n v e s t ig a to r s  an d  i t s  9 5%  C I  
w i l l  b e  p ro v id ed  a s  a  s en s i t i v i ty  an a ly s i s .    
S e cond a ry  An a ly s e s :    
G ro u p  A :   Th e K ap l an- M e i e r  e s t im a t io n  o f  m ed i an  DOR  an d  PFS  (p e r  IRC )  an d  OS  w i l l  b e  p r e s en t ed  
w i th  r e sp e c t iv e  9 5%  C I s .    
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  6  o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
A l l  s a f e ty  d a t a ,  in c lu d in g  AEs ,  l ab o r a to ry  d a t a ,  v i t a l  s i g n s ,  an d  ECG s ,  w i l l  b e  summ a r i z ed  d e s c r ip t iv e ly .  
L ev e l  o f  S ign i f i can c e :  Th e r e  w i l l  n o t  b e  a n y  s t a t i s t i c a l  com p a r i so n b e tw e en  t h e  2  g ro u p s .   W i t h in  e a c h  
g ro u p ,  2 - s id ed  9 5%  C I s  w i l l  b e  r ep o r t ed  fo r  a l l  an a ly s e s  w h en  ap p ro p r i a t e .       
In t e r im  An a ly s i s :    A n  in t e r im  fu t i l i ty  an a ly s i s  i s  p l a n n ed  f o r  G r o u p  A .   Th e  an a ly s i s  w i l l  b e  co n d u c t ed  
w h en  4 0  su b j e c t s  h av e  b e e n  t r e a t ed  an d  ev a lu a t ed  fo r  r e sp o n s e  o r  h av e  p e rm an en t l y  d i s co n t in u ed  s tu d y  
t r e a tm en t  b e c au s e  o f  d i s e a s e  p ro g r e s s io n ,  w i th d r aw a l  o f  co n s en t ,  o r  d e a th .   G r o u p  A w i l l  b e  t e rm in a t ed  
fo r  fu t i l i ty  i f  ≤  1 3  o f  th e  4 0  su b j e c t s  r e sp o n d ed  ( i e ,  CR /CMR o r  PR /PMR)  b a s e d  o n  a s s e s sm en t s  p ro v id ed  
b y  th e  IRC .   Th e  fu t i l i ty  b o u n d a ry  i s  c a l cu l a t ed  u s in g  a  sp en d in g  fu n c t io n  o f  HSD ( - 4 ) .   N o  fo rm a l  fu t i l i ty  
an a ly s i s  w i l l  b e  co n d u c t ed  f o r  G ro u p  B .  
Ind ep end en t  D a ta  Mon i to r in g  C omm i t t e e :  A n  in d ep en d en t  D a t a  Mo n i to r in g  C omm i t t e e  ( IDMC ) w i l l  
b e  e s t ab l i sh ed  an d  w i l l  r ev i ew  d a t a  a t  p r e d e t e rm in ed  in t e rv a l s  a s  sp e c i f i e d  in  th e  IDMC  ch a r t e r .  
 
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  7  o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
TABLE  OF  CONTENTS 
SYNOPS IS  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3  
L IST  OF  ABBREV IAT IONS  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 3  
1 . INTRODUCT ION  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 6  
1 . 1 . D i f f u s e  L a rg e  B- C e l l  L ymp h om a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 6  
1 . 2 . T r e a tm e n t  f o r  R e l a p s e d /R e f r a c to ry  DLBCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 6  
1 . 3 . INCB 0 5 0 4 6 5  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 7  
1 . 4 . S tu dy  R a t io n a l e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 8  
1 . 5 . Po t e n t i a l  R i sk s  a n d  B e n e f i t s  o f  th e  T r e a tm e n t  R eg im e n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 9  
2 . STUDY  OB JECT IVES  AND ENDPO INTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 0  
2 . 1 . S tu dy  O b j e c t iv e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 0  
2 . 1 . 1 . P r im a ry  O b j e c t iv e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 0  
2 . 1 . 2 . S e c o n d a ry  O b j e c t iv e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 0  
 2 0 
2 . 2 . S tu dy  E n d p o in t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 0  
2 . 2 . 1 . P r im a ry  E n d p o in t  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 0  
2 . 2 . 2 . S e c o n d a ry  E n d p o in t s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 0  
 2 1 
3 . SUB JECT  EL IG IB IL ITY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 1  
3 . 1 . Su b j e c t  I n c lu s io n  C r i t e r i a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 1  
3 . 2 . Su b j e c t  E x c lu s io n  C r it e r i a  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 2  
4 . INVEST IGAT IONAL  PLAN  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 4  
4 . 1 . O v e r a l l  S tu dy  D e s ig n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 4  
4 . 2 . M e a su r e s  T a k e n  to  A v o id  B i a s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 5  
4 . 3 . N umb e r  o f  Su b j e c t s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 5  
4 . 3 . 1 . P l a n n e d  N umb e r  o f  Su b j e c t s  a n d  S i t e s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 5  
4 . 3 . 2 . R e p l a c em e n t  o f  Su b j e c t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 5  
4 . 4 . D u r a t io n  o f  T r e a tm e n t  a nd  Su b j e c t  P a r t i c ip a t io n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 5  
4 . 5 . O v e r a l l  S tu dy  D u r a t io n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 6  
4 . 6 . S tu dy  T e rm in a t io n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 6  
5 . TREATMENT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 6  
5 . 1 . T r e a tm e n t  A s s ig nm e n t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 6  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  8  o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
5 . 1 . 1 . Su b j e c t  N umb e r in g  a n d  T r e a tm e n t  A s s ig nm e n t  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 6  
5 . 1 . 2 . R a n d om i z a t io n  a n d  B l in d in g  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 7  
5 . 2 . INCB 0 5 0 4 6 5  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 7  
5 . 2 . 1 . D e s c r ip t io n  a n d  A dm in i s t r a t io n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 7  
5 . 2 . 2 . Su p p ly ,  P a c k ag ing ,  a n d  L a b e l in g  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 7  
5 . 2 . 3 . S to r a g e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 8  
5 . 2 . 4 . I n s t r u c t io n  to  Su b j e c t s  f o r  H a n d l ing  INCB 0 5 0 4 6 5  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 8  
5 . 3 . T r e a tm e n t  Comp l i a n c e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 8  
5 . 4 . T r e a tm e n t  I n t e r r u p t io n s  an d  A d ju s tm e n t s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 8  
5 . 4 . 1 . C r i t er i a  a n d  P r o c e d u r e s  fo r  D o s e  I n t e r r u p t io n s  a nd  R e d u c t io n s  o f  
INCB 0 5 0 4 6 5  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 8  
5 . 4 . 2 . Su p p o r t iv e  C a r e  G u id e l in e s  f o r  D i a r r h e a /Co l i t i s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 1  
5 . 4 . 3 . D e f in i t io n  f o r  Immu n e -R e l a t e d  A d v e r s e  E v e n t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 1  
5 . 5 . S tu dy  T r e a tm e n t  D i s c o n t in u a t io n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 1  
5 . 5 . 1 . C r i t e r i a  f o r  S tu dy  T r e a tm e n t  D i s c o n t in u a t io n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 2  
5 . 5 . 2 . P r o c e d u r e s  f o r  S tu dy  T r e a tm e n t  D i s c o n t in u a t io n  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 2  
5 . 6 . Co n c om i t a n t  M e d i c a t io n s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 3  
5 . 6 . 1 . P n e um o c y s t i s  J i ro v e c i i P r o p hy l a x i s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 3  
5 . 6 . 2 . Su p p o r t iv e  C a r e  M e a su r e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 3  
5 . 6 . 3 . R e s t r i c t e d  M e d i c a t io n s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 3  
5 . 6 . 4 . P r o h ib i t e d  M e d i c a t io n s  a n d  T h e r a p i e s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 4  
6 . STUDY  ASSESSMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 4  
6 . 1 . S c r e e n ing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 8  
6 . 2 . T r e a tm e n t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 9  
6 . 3 . E n d  o f  T r e a tm e n t  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 9  
6 . 4 . F o l low -U p . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 9  
6 . 4 . 1 . S a f e ty  F o l low- U p . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 9  
6 . 4 . 2 . D i s e a s e  S t a tu s  F o l low- Up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 9  
6 . 4 . 3 . Su r v iv a l  F o l low -U p . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 0  
6 . 5 . E n d  o f  S tu dy  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 0  
6 . 6 . U n s c h e d u l e d  V i s i t s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 0  
7 . CONDUCT  OF  STUDY  ASSESSMENTS  AND  PROCEDURES . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 0  
7 . 1 . A dm in i s t r a t io n  o f  I n f o rm e d  Co n s e n t  F o rm  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 0  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  9  o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
7 . 2 . I n t e r a c t iv e  R e sp o n s e  T e ch n o lo gy  P r o c e d u r e  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 0  
7 . 3 . D emo g r a p hy  a n d  M e d i c a l  H i s to ry  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 1  
7 . 3 . 1 . D emo g r a p h i c s  a nd  M e d i c a l  H i s to ry  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 1  
7 . 3 . 1 . 1 . P r io r  a n d  Co n c om i t a n t  M e d i c a t io n s  a n d  P r o c e d u r e s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 1  
7 . 4 . S a f e ty  A s s e s sm e n t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 1  
7 . 4 . 1 . A d v e r s e  E v e n t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 1  
7 . 4 . 2 . Comp r e h e n s iv e  Phy s i c a l  E x am in a t io n s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 2  
7 . 4 . 2 . 1 . D i s e a s e- Sp e c i f i c  Phy s i c a l  E x am in a t io n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 2  
7 . 4 . 3 . V i t a l  S ig n s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 2  
7 . 4 . 4 . Tw e lv e- l e a d  E l e c t r o c a r d io g r am s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 2  
7 . 4 . 5 . L a b o r a to ry  A s s e s sm e n t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 3  
7 . 4 . 5 . 1 . Ch em i s t ry  a n d  H em a to lo gy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 4  
7 . 4 . 5 . 2 . P r e g n a n cy  T e s t in g  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 4  
7 . 4 . 5 . 3 . S e r o lo gy  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 4  
7 . 4 . 5 . 4 . H IV  S c r e e n ing  T e s t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 4  
7 . 5 . E f f i c a cy  A s s e s sm e n t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 4  
7 . 5 . 1 . FDG-PET  o r  Comb in e d  PET - CT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 4  
7 . 5 . 2 . Comp u t e d  T omo g r a p hy  S c a n  o r  M ag n e t i c  R e so n a n c e  Im ag in g  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 4  
7 . 5 . 3 . B o n e  M a r r ow  E x am in a t io n  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 5  
7 . 5 . 4 . I n d e p e n d e n t  R e v i ew  Comm i t t e e  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 5  
7 . 5 . 5 . R e sp o n s e  C r i t e r i a  –  T h e  L ug a n o  C l a s s i f i c a t io n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 5  
7 . 5 . 6 . ECOG  P e r f o rm a n c e  S t a tu s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 7  
 4 8 
 4 8 
 4 9 
 4 9 
 4 9 
 4 9 
 4 9 
 5 0 
7 . 8 . O th e r  S tu dy  P r o c e d u r e s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 0  
7 . 8 . 1 . A dm in i s t r a t io n  o f  S tu dy  D r ug . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 0  
7 . 8 . 2 . D i s t r ib u t io n  o f  Su b j e c t  R em in d e r  C a r d s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 0  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  10 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
7 . 8 . 3 . D a t a  Co l l e c t io n  f o r  Su r v iv a l  F o l low -U p . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 0  
8 . SAFETY  MON ITOR ING  AND  REPORT ING . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 1  
8 . 1 . A d v e r s e  E v e n t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 1  
8 . 1 . 1 . D e f in i t io n s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 1  
8 . 1 . 2 . R e p o r t in g  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 1  
8 . 2 . L a b o r a to ry  T e s t  A b n o rm a l i t i e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 3  
8 . 3 . S e r io u s  A d v e r s e  E v e n t s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 3  
8 . 3 . 1 . D e f in i t io n s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 3  
8 . 3 . 2 . R e p o r t in g  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 4  
8 . 4 . A d v e r s e  E v e n t s  o f  Sp e c i a l  I n t e r e s t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 5  
8 . 5 . P r e g n a n cy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 5  
8 . 6 . W a r n in g s  a n d  P r e c a u t io n s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 6  
8 . 7 . I n d e p e n d e n t  D a t a  Mo n i to r in g  Comm i t t e e  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 6  
8 . 8 . P r o d u c t  Comp l a in t s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 6  
9 . STAT IST ICS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 7  
9 . 1 . S tu dy  Po p u l a t io n s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 7  
9 . 2 . S e l e c t io n  o f  S amp l e  S i z e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 7  
9 . 3 . L e v e l  o f  S ig n i f i c a n c e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 7  
9 . 4 . S t a t i s t i c a l  A n a ly s e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 8  
9 . 4 . 1 . E f f i c a cy  A n a ly s e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 8  
9 . 4 . 1 . 1 . P r im a ry  E f f i c a cy  A n a ly s e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 8  
9 . 4 . 1 . 2 . S e c o n d a ry  E f f i c a cy  A n a ly s e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 8  
 5 9 
9 . 4 . 2 . S a f e ty  A n a ly s e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 9  
9 . 4 . 2 . 1 . A d v e r s e  E v e n t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 9  
9 . 4 . 2 . 2 . C l in i c a l  L a b o r a to ry  T e s t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 9  
9 . 4 . 2 . 3 . V i t a l  S ig n s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 9  
9 . 4 . 2 . 4 . E l e c t r o c a r d iog r am s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 0  
 6 0 
 6 0 
9 . 5 . A n a ly s e s  f o r  th e  I n d e p e nd e n t  D a t a  Mo n i to r ing  Comm i t t e e  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 1  
9 . 6 . I n t e r im  A n a ly s i s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 1  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  11 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
1 0 . ETH ICAL  CONS IDERAT IONS  AND  ADM IN ISTRAT IVE  
PROCEDURES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 2  
1 0 . 1 . I n v e s t ig a to r  R e sp o n s ib i l i t i e s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 2  
1 0 . 2 . A c c o u n t a b i l i ty ,  H a n d l ing ,  a n d  D i sp o s a l  o f  S tu dy  D r ug  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 3  
1 0 . 3 . D a t a  M a n ag em e n t . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 4  
1 0 . 4 . D a t a  P r iv a cy  a n d  Co n f id e n t i a l i ty  o f  S tu dy  R e c o r d s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 4  
1 0 . 5 . F in a n c i a l  D i s c lo su r e . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 5  
1 0 . 6 . Pu b l i c a t io n  Po l i cy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 5  
1 1 . REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 6  
APPEND IX A . INFORMAT ION  REGARD ING  EFFECT IVENESS  OF  
CONTRACEPT IVE  METHODS  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 8  
APPEND IX B . CYTOCHROME  P4 5 0  AND  P -GLYCOPROTE IN  INH IB ITORS  
AND  CYTOCHROME  P4 5 0  INDUCERS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 9  
APPEND IX C . PROTOCOL  AMENDMENT  SUMMARY  OF  CHANGES . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 4  
 
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  12 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
L IST  OF  TABLES 
T a b l e 1 : D e s c r ip t io n  a n d  A dm in i s t r a t io n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 7  
T a b l e 2 : G u id e l in e s  f o r  I n t e r r u p t io n  a n d  R e s t a r t in g  S tu dy  D r ug  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 9  
T a b l e 3 : D o s e  L e v e l s  f o r  INCB 0 50 4 6 5 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 0  
T a b l e 4 : S c h e d u l e  o f  A s s e s sm e n t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 5  
T a b l e 5 : S c h e d u l e  o f  L a bo r a to ry  A s s e s sm e n t s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 6  
T a b l e 6 : S c h e d u l e  o f  A s s e s sm e n t s  f o r  O ng o ing  Su b j e c t s  in  A l l  Co h o r t s  U p o n  
Imp l em e n t a t io n  o f  P r o to c o l  Am e n dm e n t  4  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 7  
T a b l e 7 : S c h e d u l e  o f  L a b o r a to ry  A s s e s sm e n t s  f o r  O ng o ing  Su b j e c t s  in  A l l  Co h o r t s  
U p o n  Imp l em e n t a t io n  o f  P r o to c o l  Am e n dm e n t  4  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 7  
T a b l e 8 : L a b o r a to ry  T e s t s :   R e q u i r e d  A n a ly t e s  (N o t  A p p l i c a b l e  A f t e r  Imp l em e n t a t ion  
o f  P r o to c o l  Am e n dm e n t  4 )  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 8  
T a b l e 9 : L ug a n o  C l a s s i f i c a t io n  f o r  R e sp o n s e  A s s e s sm e n t  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 6  
T a b l e 1 0 : E a s t e r n  Co o p e r a t iv e  O n co lo gy  G r o u p  P e r f o rm a n c e  S c o r e s  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 8  
  
4 8 
T a b l e 1 2 : C r i t e r i a  f o r  C l in i c a l ly  N o t a b l e  V i t a l  S ig n  A b n o rm a l i t i e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 0  
T a b l e 1 3 : C r i t e r i a  f o r  C l in i c a l ly  N o t a b l e  E l e c t r o c a r d iog r am  A b n o rm a l i t i e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 0  
 
L IST  OF  F IGURES  
F ig u r e 1 : S tu dy  D e s ig n . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 5  
 
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  13 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
L IST  OF  ABBREV IAT IONS  
T h e  f o l low in g  a b b r e v i a t io n s  a n d  sp e c i a l  t e rm s  a r e  u s e d  in  th i s  c l in i c a l  s tu d y  P r o to c o l .  
Abb r ev ia t ion D e f in i t ion 
5PS  5 - p o in t  s c a l e  
AE a d v e r s e  e v en t  
ALT a l an in e  am in o t r an s f e r a s e  
ANC ab so l u t e  n eu t ro p h i l  co u n t  
ASCT au to lo g o u s  s t em  c e l l  t r an sp l an t  
AST a sp a r t a t e  am in o t r an s f e r a s e  
BTK B ru to n 's  ty ro s i n e  k in a s e  
CFR C o d e  o f  F ed e r a l  R eg u l a t io n s  
CL/F  o r a l  d o s e  c l e a r an c e  
CLL  ch ro n i c  lym p h o cy t i c  l eu k em i a  
CMR com p l e t e  m e t ab o l i c  r e sp o n s e  
CMV cy tom eg a lo v i ru s  CR com p l e t e  r e sp o n s e  
CT com p u t ed  tom o g r ap h y  
CTCAE C omm o n  T e rm in o lo g y  C r i t e r i a  fo r  A d v e r s e  E v en t s  CYP cy to ch rom e  P 4 5 0  
DLBCL d i f fu s e  l a rg e  B - c e l l  l ym p h om a DNA d eo x y r ib o n u c l e i c  a c id  
DOR d u r a t io n  o f  r e s p o n s e  
eCRF  e l e c t r o n i c  c a s e  r ep o r t  fo rm  
ECG e l e c t r o c a rd i o g r am  
ECOG E a s t e rn  C o o p e r a t iv e  O n co l o g y  G ro u p  
EOT en d  o f  t r e a tm en t  
FDA F o o d  an d  D ru g  A dm in i s t r a t io n  
FDG f lu o ro d e o x y g lu co s e  
FL fo l l i cu l a r  lym p h om a  
GCP G o o d  C l ini c a l  P r a c t i c e  
HB sA g h ep a t i t i s  B  su r f a c e  an t ig en  
HBV h ep a t i t i s  B  v i ru s  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  14 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
Abb r ev ia t ion D e f in i t ion 
HCV h ep a t i t i s  C  v i ru s  
HDC h ig h- d o s e  ch em o th e r ap y  
H IPAA H e a l t h  I n su r an c e  P o r t ab i l i t y  an d  A c co u n t ab i l i ty  A c t o f  1 9 9 6  
H IV h um an  imm u n o d e f i c i en cy  v i ru s  
IB  I nv e s t ig a to r ' s  B ro ch u r e  
ICF  in fo rm ed  co n s en t  fo rm   
ICH  I n t e rn a t i o n a l  C o n f e r e n c e  o n  H a rm o n i s a t io n  
IDMC  in d ep en d en t  D a t a  Mo n i to r i n g  C omm i t t e e IEC  in d ep en d en t  e th i c s  comm i t t e e  
IN  I nv e s t ig a to r  N o t i f i c a t io n  
IP I  I n t e rn a t i o n a l  P ro g n o s t i c  I nd ex  
i rAE  imm u n e - r e l a t e d  ad v e r s e  ev en t  
IRB  i n s t i tu t io n a l  r ev i ew  b o a rd  
IRC  in d ep en d en t  r ev i ew  comm i t t e e  
IV  in t r av en o u s  
IWRS  in t e r a c t iv e  w eb  r e sp o n s e  sy s t em  
LD i lo n g e s t  t r an sv e r s e  d i am e t e r  o f  l e s i o n  
M edDRA M ed i c a l  D i c t i o n a ry  fo r  R eg u l a to ry  A c t iv i t i e s 
MR I m ag n e t i c  r e so n an c e  im ag in g 
NC I N a t io n a l  C an c e r  I n s t i t u t e  
NHL N o n-H o d g k in  L ym p h om a  
ORR o b j e c t iv e  r e sp o n s e  r a t e  
OS o v e r a l l  su rv iv a l 
pAKT  p h o sp h o ry l a t ed  p r o t e in  k in a s e  B  
PCR p o lym e r a s e  ch a in  r e a c t io n  
PD p ro g r e s s iv e  d i s e a s e   
PET p o s i t ro n  em i s s io n  tom o g r ap h y  
PFS p ro g r e s s io n - f r e e  su rv iv a l  
P I 3K  p h o sp h a t id y l in o si to l  3 - k in a s e  
P JP P n eum o c y s t i s  j i r o v e c i i p n e um o n i a  
PK p h a rm a co k in e t i c  
PMD p ro g r e s s iv e  m e t ab o l i c  d i s e a s e  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  15 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
Abb r ev ia t ion D e f in i t ion 
PMR p a r t i a l  m e t ab o l i c  r e sp o n s e  
PPD c ro s s - p ro d u c t  o f  t h e  l o n g e s t  t r a n sv e r s e  d i am e t e r  an d  p e rp en d i cu l a r  d i am e t e r  
PR p a r t i a l  r e sp o n s e  
QD o n c e  d a i ly  
RNA r ib o n u c l e i c  a c id  
SAE s e r io u s  ad v e r s e  e v en t  
SD i sh o r t e s t  ax i s  p e rp en d i cu l a r  to  th e  l o n g e s t  t r a n sv e r s e  d i am e t e r  
SPD sum  o f  th e  p ro d u c t  o f  t h e  p e rp en d i c u l a r  d i am e t e r s  fo r  m u l t ip l e  l e s io n s  
SUSAR su sp e c t e d  u n ex p e c t ed  s e r io u s  ad v e r s e  r e a c t io n  
TEAE t r e a tm en t - em e rg en t  ad v e r s e  ev en t  
ULN u p p e r  l im i t  o f  n o rm a l  
V /F v o lum e  o f  d i s t r i b u t io n  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  16 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
1 .  INTRODUCT ION  
1 . 1 .  D i f fu s e  L a r g e  B- C e l l  L ymph om a 
N o n-H o dg k in  lymp h om a  (NHL )  i s  th e  mo s t  c ommo n  h em a to lo g i c  m a l ig n a n cy ,  w i th  o v e r  
3 8 5 , 0 0 0  n ew  c a s e s  d i ag no s e d  in  2 0 1 2  ( T o r r e e t  a l  2 0 1 5 ) .   I n c id e n c e  r a t e s  o f  NHL  t e n d  to  b e  h ig h e r  in  N o r th  Am e r i c a ,  W e s t e r n  E u r o p e ,  N o r th e r n  E u r o p e ,  a nd  A u s t r a l i a  c omp a r e d  w i th  th e  
r e s t  o f  th e  w o r ld ;  i t  h a s  b e e n  e s t im a t e d  th a t  o v e r  80 , 0 0 0  n ew  c a s e s  o f  NHL  a n d  a p p r o x im a t e ly  
2 0 , 0 0 0  d e a th s  d u e  to  NHL  o c c u r r e d  in  th e  U n i t e d  S t a t e s  in  2 0 1 5  ( S i e g e l e t  a l  2 0 1 5 ) .   B e tw e e n  1 9 7 5  a n d  2 0 1 1 ,  th e  in c id e n c e  o f  n ew  c a s e s  o f  NHL  in  th e  U n i t e d  S t a t e s  h a s  n e a r ly  d o u b l e d  f r om  
1 1  to  2 0  c a s e s  p e r  1 0 0 , 0 00  p e o p l e ,  b u t  th e  p r o p o r t io n  o f  d e a th s  h a s  s low ly  d e c r e a s e d  
( N a t io n a l C a n c e r  I n s t i tu t e  [NC I]  2 0 1 4 ) .  
D i f f u s e  l a rg e  B - c e l l  lymp h om a  (DLBCL )  i s  a  su b ty p e  o f  NHL .   D i f f u s e  l a rg e  B- c e l l  lymp h om a  
i s  a n  a g g r e s s iv e  f o rm  o f  NHL  a n d  i s  th e  mo s t  c ommo n  NHL  su b ty p e ,  a c co u n t in g  f o r  
a p p r o x im a t e ly  3 0%  o f  a l l  c a s e s .   T h e  in c id en c e  i s  h ig h e r  in  m e n  th a n  w om en  a n d  g e n e r a l ly  in c r e a s e s  w i th  ag e ,  w i th  th e  m e d i a n  ag e  a t  o n s e t  g e n e r a l ly  o c c u r r ing  w i th in  th e  s ix th  d e c a d e  
( Sw e r d low  e t  a l  2 0 0 8) .   D i f f u s e  l a rg e  B- c e l l  lymp h om a  c a n  d e v e lo p  a s  a  t r a n s f o rm a t io n  f r om  a  
l e s s  a g g r e s s iv e  f o rm  o f  lymp h om a  o r  a s  a  f i r s t  o c c u r r e n c e  o f  lymp h om a  ( c a l l e d  d e  n o v o ) .   P r o g n o s i s  v ar i e s  a c r o s s  p a t i e n t s  w i th  DL BCL .   Su b ty p e ,  p a t i e n t  c h a r a c t e r i s t i c s ,  d i s e a s e  b u r d e n ,  
a n d  p r io r  r e sp o n s e  to  th e r a py  a f f e c t  c l in i c a l  o u t c om e ,  b u t  a l l  su b ty p e s  a r e  co n s id e r e d  ag g r e s s iv e  
a n d  f a t a l  i f  l e f t  u n t r e a t e d  ( M a r t e l l i e t  a l  2 0 1 3 ) .   D e sp i t e s ig n i f i c a n t  p r og r e s s  in  th e  m a n ag em e n t  o f  p a t i e n t s  w i th  DLBCL ,  a n  u nm e t  n e e d  s t i l l  e x i s t s  ( F o o n  e t  a l  2 0 1 2 ) .  
1 . 2 .  T r e a tm en t  f o r  R e l ap s ed /R e f r a c t o r y  DLBCL 
A l th o u g h  th e  u s e  o f  f i r s t - l in e  r i tu x im a b  h a s  b e e n  a s so c i a t e d  w i th  su b s t a n t i a l  r e d u c t io n  in  r e l a p s e  r a t e s ,  u p  to  2 0 %  o f  p a t i en t s  w i th  low  I n t e r n a t io n a l  P r o g n o s t i c  I n d e x  ( IP I )  r i sk  a n d  u p  to  5 0%  o f  p a t i e n t s  w i th  IP I  s c o r e  >  2  w i l l  r e l a p s e .   R e l a p s e d  p a t i e n t s  a n d  p a t i e n t s  w i th  d i s e a s e  th a t  f a i l s  to  
r e sp o n d  to  f i r s t - l in e  th e r apy  h a v e  a  p o o r  p r og n o s i s  ( M a r t e l l i e t  a l  2 0 1 3 ,  Cu l t r e r a a n d  D a l i a  2 0 1 2 ) .   
P a t i e n t s  in  th i s  s e t t in g  a r e  g e n e r a l ly  d iv id e d  in to  2  c a t eg o r i e s :   th o s e  w i th  ch emo s e n s i t iv e  d i s e a s e  w h o  a r e  p o t e n t i a l ly  e l ig ib l e  f o r  h ig h - d o s e  c h emo th e r a py  (HDC) / a u to log o u s  s t em  c e l l  t r a n sp l a n t  
( ASCT)  a n d  th o s e  w h o  a r e  r e f r a c to ry  to  c h emo th e r a py  o r  a r e  n o t  m e d i c a l ly  f i t  f o r  a n  ag g r e s s iv e  
c h emo th e r a py  r eg im e n .   S a lv a g e  c h emo th e r a py  i s  g e n e r a l ly  in a d e q u a t e ;  r e sp o n s e  r a t e s  r a ng e  f r om  3 0%  to  6 0% ,  b u t  l e s s  th a n  1 0%  o f  p a t i e n t s  a c h i e v e  lo ng - t e rm  d i s e a s e- f r e e  su r v iv a l .   T h e  
PARMA  s tu dy  d emo n s t r a t e d  th e  b e n e f i t  o f  HDC /ASCT  v e r su s  s t a n d a r d  c h emo th e r a py  f o r  
r e l a p s e d  o r  r e f r a c to ry  DLBCL ;  o v e r a l l  su r v iv a l  (OS)  a n d  5 - y e a r  e v en t - f r e e  su r v iv a l  w e r e  s ig n i f i c a n t ly  imp r o v e d  in  t r a n sp l a n t e d  p a t i e n t s  c omp a r e d  w i th  n o n t r a n sp l an t e d  p a t i e n t s  
( Ph i l ip e t  a l  1 9 9 1 ) .   F o r  p a t i e n t s  in e l ig ib l e  f o r  ASCT  o r  r e l a p s e d  a f t e r  t r a n sp l a n t ,  b e n d amu s t in e  
in  c omb in a t io n  w i th  r i tu x im a b  d emo n s t r a t e d  e n c ou r a g in g  r e su l t s ;  in  a  mu l t i c e n t e r  Ph a s e  2  s tu dy ,  a n  o v e r a l l  r e sp o n s e  r a t e  o f  5 9%  w a s  o b s e r v e d  (F i s c h e r e t  a l  2 0 1 1 ) .   I n  a d d i t io n ,  a  n umb e r  o f  
n o v e l  ag e n t s  a r e  u n d e rg o in g  e v a lu a t io n  f o r  DLBCL ,  in c lu d ing  immu n omo d u l a t in g  ag e n t s ,  
m e c h a n i s t i c  t a rg e t  o f  r a p amy c in in h ib i to r s ,  p r o t e a som e  in h ib i to r s ,  h i s to n e  d e a c e ty l a s e  in h ib i to r s ,  a n d  a n t i - a ng iog e n i c  ag e n t s .   
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  17 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
1 . 3 .  INCB 0 50 4 65  
R e f e r  to  th e  INCB 0 5 0 4 65  IB  f o r  c u r r e n t  in f o rm a t io n  o n  INCB 0 5 0 4 6 5 .  
Ph o sp h a t idy l in o si to l  3 - k in a s e s  ( P I 3K s )  b e lo n g  to  a  f am i ly  o f  l ip id  s ig n a l ing  k in a s e s  th a t  
p h o sp h o ry l a t e  p h o sp h o in o s i t id e s  o f  th e  in o s i to l  r in g  ( C a n t l ey 2 0 0 2 ) .   Ph o sp h a t idy l in o s i to l  
3 - k in a s e s a r e  d iv id e d  in to  3  c l a s s e s  (C l a s s  I ,  I I ,  a nd  I I I )  a c c o r d in g  to  th e i r  s t r u c tu r e ,  r eg u l a t io n ,  a n d  su b s t r a t e  s p e c i f i c i ty .   C l a s s  I  P I 3K s ,  w h i ch  in c lu d e  P I 3Kα ,  P I 3Kβ ,  P I 3K γ ,  a n d  P I 3K δ ,  a r e  
d u a l - sp e c i f i c i ty  l ip id  a n d  p r o t e in  k in a s e s  th a t  c a t a ly z e  th e  p h o sp h o ry l a t io n  o f  
p h o sp h a t idy l in o s i to l - 4 , 5 - b i sp h o sp h a t e ,  g iv ing  r i s e  to  p h o sp h a t idy l in o s i to l- 3 , 4 , 5 - t r i sp h o sp h a t e .   Ph o sp h a t idy l in o s i to l - 3 , 4 ,5 - t r i sp h o sp h a t e  f u n c t io n s  a s  a  s e c o n d  m e s s e ng e r  th a t  c o n t r o l s  a  n umb e r  
o f  c e l lu l a r  p r o c e s s e s ,  in c lu d in g  g r ow th ,  su r v iv a l ,  ad h e s io n ,  a n d  m ig r a t io n .   T h e  r e c og n i t io n  th a t  
a b e r r a n t  s ig n a l  t r a n sd u c t io n  o c c u r s  in  m a l ig n a n t  B - lymp h o cy t e s  v i a  th e  P I 3K  p a thw ay s  r e su l t in g  in  d i s e a s e  p r og r e s s io n  h a s  l e d  to  a  f o c u s  o n  ag e n t s  th a t  mo d u l a t e  th e s e  s ig n a l in g  p a thw ay s .    
INCB 0 5 0 4 6 5  i s  a  p o t e n t  in h ib i to r  o f  P I 3K δ  ( IC
50 v a lu e  =  1 . 1  ±  0 . 5  nM ) ,  w i th  a p p r o x im a t e ly  
2 0 , 0 0 0 - f o ld  s e l e c t iv i ty  f o r  th e  o th e r  P I 3K  f am i ly  m emb e r s .   INCB 0 5 0 4 6 5  d o e s  n o t  s ig n i f i c a n t ly  
in h ib i t  (<  3 0%  in h ib i t io n )  a  b r o a d  p a n e l  o f  k in a s e s  w h e n  t e s t e d  a t  a  c o n c e n t r a t io n  o f  1 0 0  nM  
( r e f e r  to  th e  INCB 0 5 0 4 65  I n v e s t ig a to r' s  B r o c h u r e  [ IB ;  INCB 0 5 0 4 6 5  IB ] ) .   INCB 0 5 0 4 6 5  i s  
p o t e n t  ( IC50 v a lu e s  o f  ≤  10  nM )  in  c e l l - b a s e d  a s s ay s  r e l e v a n t  to  th e  p a th og en e s i s  o f  B - c e l l  
m a l ig n a n c i e s ,  su c h  a s  P I 3K δ-m e d i a t e d  s ig n a l ing  a n d  g r ow th  o f  h um a n  B - c e l l  l in e s .   T h i s  e f f e c t  
i s  n o t  d u e  to  g e n e r a l  cy to to x i c i ty .   Comp a r e d  w i th in h ib i t io n  o f  B - c e l l  p r o l i f e r a t io n ,  
INCB 0 5 0 4 6 5  i s  s im i l a r ly  p o t e n t  in  b lo c k in g  h e lp e r  T - c e l l  d i f f e r e n t i a t io n  b u t  i s  >  1 0 0  t im e s  l e s s  p o t e n t  in  a s s ay s  th a t  m e a su r e  e f f e c t s  o n  h um a n  T -c e l l  a n d  n a tu r a l  k i l l e r  c e l l  p r o l i f e r a t io n  o r  
mo n o cy t e  f u n c t io n .   
  
 
 
 
  I nh ib i t io n  o f  tumo r  g r ow th  a n d  su p p r e s s io n  o f  P I 3K /p r o t e in  k in a s e  B  
s ig n a l ing  w a s  o b s e r v e d  a t  p l a sm a  c o n c e n t r a t io n s  th a t  a p p r o x im a t e d  th e  IC
90 ( 7 7  nM )  f o r  pAKT  
in h ib i t io n  o f  P f e i f f e r  c e l l s  in  h um a n  w h o l e  b lo o d  ( INCB 0 5 0 4 6 5  IB ) .   P r e c l ini c a l  to x i c o lo g y  
s tu d i e s  su p p o r t e d  e v a lu a t io n  o f  INCB 0 5 0 4 6 5  in  hum a n  c l in i c a l  s tu d i e s  ( INCB 0 5 0 4 6 5  IB ) .  
INCB 0 5 0 4 6 5  i s  b e ing  e v a lu a t e d  a s  a  mo n o th e r a py  in  a  Ph a s e  1 /2 ,  d o s e - e s c a l a t io n  a n d  e xp a n s io n  
s tu dy  ( INCB  5 0 4 6 5 - 1 0 1 ,  NCT 0 2 0 1 8 8 6 1 ,  F o r e r o- To r r e s e t  a l  2 0 1 6 ) .   A s  o f  02  SEP 2 0 1 6 ,  d a t a  w e r e  a v a i l a b l e  f o r  4 6  su b j e c t s  w h o  r e c e iv e d  INCB0 5 0 4 6 5  a dm in i s t e r e d  o r a l ly  a t  o n c e  d a i ly  QD )  
d o s e s  o f  5  mg ( n  =  1 ) ,  1 0  mg ( n  =  3 ) ,  1 5  mg  ( n  =  3 ) ,  2 0  mg ( n  =  1 5 ) ,  3 0  mg  ( n  =  2 0 ) ,  a n d  4 5  mg  
( n  =  4 ) .   T h e  m e d i a n  d u r a t io n  o f  t r e a tm e n t  w a s  1 0 4  d ay s.   A d v e r s e  e v e n t s (AE s )  o b s e r v e d  in  ≥  2 0%  o f  su b j e c t s  w e r e n a u s e a ,  d i a r r h e a ,  v om i t in g ,  n e u t r o p e n i a ,  f a t ig u e ,  hy p o k a l em i a ,  a n d  f e v e r .   
N o  ≥  G r a d e  3  t r e a tm e n t- r e l a t e d  AE s  w e r e  r e p o r t e d  in  ≥  1 0%  o f  su b j e c t s .   S e r io u s  AE s (SAE s )  
th a t  o c c u r r e d  in  ≥  2  su b j e c t s  in c lu d e d  c o l i t i s  ( n  =  3 ) ,  d i a r r h e a  ( n  =  3 ) ,  a n d  py r e x i a ,  p n e umo n i a ,  d e hy d r a t io n ,  e x f o l i a t iv e  d e rm a t i t i s ,  a n d  hy p o t e n s io n  ( n  =  2  e a c h ) .   E l e v e n  o f th e  4 6  su b j e c t s  
( 2 4% )  d i s c o n t in u e d  s tu dy  t r e a tm e n t  d u e  to  th e  f o l low in g  AE s:   c o l i t i s ,  d i a r r h e a ,  p n e umo n i t i s ,  
r a sh ,  e x f o l i a t iv e  d e rm a t i t i s ,  p so r i a s i s ,  n e u t r o p e n i a ,  f a t ig u e ,  p n e umo n i a ,  a n d  hy p e r c a l c em i a .   A l l  b u t  1  o f  th e s e  e v e n t s  o c cu r r e d  a f t e r  th e  9 - w e e k  d i s e a s e  a s s e s sm e n t .   N o  l iv e r  f u n c t io n  t e s t  
a b n o rm a l i t i e s  >  G r a d e  1  w e r e  r e p o r t e d w h i l e  su b j e c t s  w e r e  r e c e iv ing  s tu dy  t r e a tm e n t .   N o  
d o s e - l im i t in g  to x i c i t i e s  w e r e  id e n t i f i e d ,  a n d  th e  m ax imum  to l e r a t e d  d o s e  w a s  n o t  r e a c h e d .  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  18 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
A s  o f  0 2  SEP  2 0 1 6 ,  2 0  o b j e c t iv e  r e sp o n s e s  a s  r e po r t e d  by  in v e s t ig a to r s  w e r e  o b s e r v e d  a t  d o s e s  
≥  1 0  mg  QD  in  4 1  e v a lu ab l e  su b j e c t s  w i th  DLBCL,  f o l l i c u l a r  lymp h om a  (FL ) ,  H o dg k in  
ly mp h om a ,  m a rg in a l  zo n e  lymp h om a ,  c h r o n i c  lymp h o cy t i c  l e u k em i a  (CLL ) ,  a n d  m a n t l e  c e l l  
l ymp h o m a.   T h e s e  r e su l t s  in c lu d e  3  c omp l e t e  m e t a b o l i c  r e sp o n s e s  (C MR s ) a n d  2  p a r t i a l  m e t a b o l i c  r e sp o n s e s  (P MR s )  o b s e r v e d  amo ng  th e  1 4  e v a lu a b l e  su b j e c t s  w i th  DLBCL.   O b j e c t iv e  
r e sp o n s e s  f o r  th e s e  5  su b j e c t s  o c c u r r e d  by  th e  t im e  o f  th e  9 - w e e k  d i s e a s e  a s s e s sm e n t .  T h e  
d u r a t io n  o f  t r e a tm e n t  f o r  th e s e  5  su b j e c t s  r a ng e d  f rom  a p p r o x im a t e ly  1 3  to  4 5  w e e k s ,  w i th  1  su b j e c t  r em a in ing  o n  s tu dy  t r e a tm e n t  a t  th e  t im e  o f  th e  d a t a  c u to f f .   
 
 
1 . 4 .  S tud y  R a t i on a l e 
A b e r r a n t  a c t iv a t io n  o f  P I 3K δ  h a s  b e e n  a s so c i a t e d  w i th  in c r e a s e d  m a l ig n a n t  B -c e l l  p r o l i f e r a t io n  a n d  su r v iv a l .   A n o th e r  P I 3K δ  in h ib i to r ,  id e l a l i s ib ,  r e c e iv e d  a p p r o v a l  f r om  th e  FDA   f o r  th e  
t r e a tm e n t  o f  p a t i e n t s  w i th  r e l a p s e d  CLL,  in  c omb in a t io n  w i th  r i tu x im a b ,  a n d  a l so  r e c e iv e d  
a c c e l e r a t e d  a p p r o v a l  f r om  th e  FDA  f o r  th e  t r e a tm e n t  o f  p a t i e n t s  w i th  r e l a p s e d  f o l l i c u l a r  B - c e l l  n o n -H o dg k in  lymp h om a  (FL )  o r  r e l a p s e d  sm a l l lymp h o cy t i c  lymp h om a .   I d e l a l i s ib  w a s  a l so  
a p p r o v e d  by  th e  E u r o p e an  M e d i c in e s  Ag e n cy  f o r  p a t i e n t s  w i th  c h r o n i c  CLL  w h o  h a v e  r e c e iv e d  
a t  l e a s t  1  p r io r  th e r a py  o r  in  c e r t a in  f i r s t - l in e  s e t t in g s  a n d  f o r  FL  th a t  i s  r e f r a c to ry  to  a t  l e a s t  2  l in e s  o f  t r e a tm e n t .   T h e  a p p r o v a l s  w e r e  b a s e d  o n  o b j e c t iv e  r e sp o n s e  r a t e  (ORR )  a n d  
d emo n s t r a t e  th a t  in h ib i t io n  o f  P I 3K δ  c a n  b e  a n  e f f e c t iv e  s t r a t egy  in  th e  t r e a tm e n t  o f  som e  B - c e l l  
m a l ig n a n c i e s . 
INCB 0 5 0 4 6 5  i s  a  p o t e n t  a n d  s e l e c t iv e  in h ib i to r  o f  P I 3K δ  in  e n zym e  a n d  B - c e l l  p r o l i f e r a t io n  
a s s ay s .   B a s ed  o n  em e rg in g  s a f e ty ,  e f f i c a cy ,   d a t a  f r om  th e  o ng o ing  
S tu dy  INCB  5 0 4 6 5 - 1 0 1  ( s e e  S e c t io n  1 . 3 ) ,  su b j e c t s  w i th  r e l a p s e d  o r  r e f r a c to ry  DLBCL  w h o  h a v e  
r e c e iv e d  2  to  5  p r io r  r eg im e n s  a n d  w h o  a r e  in e l ig ib l e  f o r  HDC /ASCT  w i l l  r e c e iv e  INCB 0 5 0 4 6 5  
a dm in i s t e r e d  o r a l ly  a t  a  do s e  o f  2 0  mg  QD f o r  8  w e e k s  f o l low e d  by  2 0  mg  o n c e  w e e k ly .   T h i s  
d o s e  w a s  c h o s e n  b a s e d  on  em e rg ing  e f f i c a cy  a n d  s a f e ty  d a t a  f r om  th e  o ng o in g  S tu dy  INCB  5 0 4 6 5 - 1 0 1  ( s e e  S e c t io n  1 . 3 ) .   
  
F u r th e rmo r e ,  2 0  mg  QD  h a s  d emo n s t r a t e d  e f f i c a cy  in  DLBCL  ( 2  CMR s  in  2  su b j e c t s )  a n d  in  o th e r  ty p e s  o f  n o n -H o dg k in  lymp h om a s  ( 9  o b j e c t iv e  r e sp o n s e s  in  9  su b j e c t s  w i th  n o n -H o d g k in  
lymp h om a ) .   H ow e v e r ,  24%  ( n  =  1 1 )  o f  a l l  su b j e c t s  in  s tu dy  INCB  5 0 4 6 5 - 10 1  d i s c o n t in u e d  
s tu dy  t r e a tm e n t  d u e  to  a n  AE .   A l l  b u t  1  o f  th e s e  ev e n t s  o c c u r r e d  a f t e r  th e  9 - w e e k  d i s e a s e  a s s e s sm e n t .  Amo n g  th e  su b j e c t s  w i th  a n  o b je c t iv e  r e sp o n s e  ( n  =  2 0 ) ,  7  ( 3 5% )  d i s c o n t in u e d  s tu dy  
t r e a tm e n t  d u e  to  a n  AE .   Co n s e q u e n t ly ,  a f t e r  a dm in i s t r a t io n  o f  2 0  mg  QD  fo r  8  w e e k s ,  th e  d o s ing  
r eg im e n  w i l l  b e  r e d u c e d  to  2 0  mg  o n c e  w e e k ly .   Th i s  o n c e -w e e k ly  r eg im e n  i s  p r o p o s e d  to  m a in t a in  r e sp o n s e  w h i l e  p r o v id in g  t im e  o f f  f r om  p a thw ay  in h ib i t io n ,  w h i c h  m ay  r e d u c e  th e  
f r e q u e n cy  o f  AE s .    
 
 
  T h i s  o n c e - w e e k ly  r eg im e n i s  s im i l a r  to  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  19 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
th a t  o f  a n o th e r  P I 3K  in h ib i to r  ( c o p a n l i s ib ) ,  w h i c h  i s  a dm in i s t e r e d  in t r a v e n ou s ly  o n  D ay s  1 ,  8 ,  
a n d  1 5  o f  a  2 8 - d ay  cy c l e ,  a n d  w h i c h  a c h i e v e d  7  o b j e c t iv e  r e sp o n s e s  in  9  su b j e c t s  w i th  
n o n -H o dg k in  lymp h om a  ( P a tn a ik e t  a l  2 0 1 6 ) .   Amo n g  th e  5 1  su b j e c t s  w h o  r e c e iv e d  s tu dy  d r ug ,  
4  d i s c o n t in u e d  t r e a tm e n t  d u e  to  a n  AE .   T h e r e  w e r e  2  e v e n t s  o f  G r a d e  3  n on in f e c t io u s  p n e umo n i t i s ,  1  e v e n t  o f  G r a d e  3  d i a r r h e a ,  a n d  n o  e v e n t s  o f  c o l i t i s .  
T h e  p r im a ry  o b j e c t iv e  o f  th i s  s tu dy  i s  to  e v a lu a t e  th e  e f f i c a cy  o f  INCB 0 5 0 46 5  in  th i s  p a t i e n t  
p o p u l a t io n .   T h e  ORR  i s  a n  a c c e p t a b l e  p r im a ry  e nd p o in t  in  th i s  s in g l e - a rm ,  Ph a s e  2  s tu dy  e v a lu a t ing  su b j e c t s  w h o  h a v e  r e c e iv e d  2  to  5  p r io r  l in e s  o f  th e r a py  a n d  in  w h i c h  n o  c omp a r a to r  
e x i s t s .  
1 . 5 .  P o t en t ia l  R i sk s  and  B en e f i t s  o f  th e  T r e a tm en t  R e g im en 
N o n c l in i c a l  d a t a  su p p o r t e d  a n  in i t i a l  d o s e  o f  5  mg  QD  in  th e  f i r s t - in - h um a n  s tu dy  
( INCB  5 0 4 6 5 - 1 0 1 )  b a s e d  o n  a d e q u a t e  e xp o su r e  m a rg in s  a n d  th e  l a c k  o f  f ind in g s  in  r e c o v e ry  
a n im a l s  a f t e r  d r ug  w i th d r aw a l ( INCB 0 5 0 4 6 5  IB ) .   Po t e n t i a l  r i sk s  w i th  a dm i n i s t r a t io n  o f  
INCB 0 5 0 4 6 5  b a s e d  o n  p r e c l in i c a l  f in d ing s  in c lu d e  lymp h o id  d e p l e t io n  ( INCB 0 5 0 4 6 5  IB ) .   T h i s  m ay  r e su l t  in  in f e c t io n s ,  f e v e r ,  o r  cy to k in e  r e l e a s e  r e su l t in g  in  f e v e r ,  c h i l l s ,  hy p o t e n s io n ,  
w h e e z in g ,  a n d /o r  r a sh .  
Pn e umo n i t i s  a n d  c o l i t i s  h a v e  b e e n  r e po r t e d  in  su b j e c t s  t r e a t e d  w i th  th e  P I 3K δ  in h ib i to r  id e l a l i s ib  
( G o p a l  e t  a l  2 0 1 4 ) ,  a n d  th e s e  e v e n t s  h a v e  b e e n  o b s e r v e d  f o r  a n o th e r  P I 3K δ,  INCB 0 4 0 0 9 3  
( INCB 0 4 0 0 9 3  IB ) .   I n  M a r c h  2 0 1 6 ,  s e v e r a l  s tu d i e s  e v a lu a t in g  id e l a l i s ib  a dm in i s t e r e d  in  
c omb in a t io n  w i th  s e v e r a l  lymp h om a  s t a n d a r d - o f - c a r e  th e r a p i e s  ( eg ,  a n t i –CD 2 0- c o n t a in ing  r eg im e n s )  w e r e  t e rm in a t ed  b e c a u s e  of  a n  in c r e a s e d  r i sk  o f  d e a th  a n d  SAE s  du e  to  in f e c t io n s  a n d  
r e sp i r a to ry  d i so r d e r s  in  su b j e c t s  a dm in i s t e r e d  th e  id e l a l i s ib  c omb in a t io n s .   T h e  r e l e v a n c e  o f  th e s e  
f in d in g s  w i th  r e sp e c t  to  INCB 0 5 0 4 6 5  a dm in i s t e r ed  a s  a  mo n o th e r a py  i s  c u r r e n t ly  u n k n ow n .   T o  r e d u c e  th e  r i sk  o f  in f e c t io n  w i th  P n e um o c y s t i s  j i ro v e c i p n e umo n i a  (P JP ) ,  a l l  su b j e c t s  t a k in g  
INCB 0 5 0 4 6 5  mu s t  a l so  t a k e  a  p r o p hy l a c t i c  a n t ib io t i c  ( s e e  S e c t io n 5 . 6 . 1 ) .  
T h e r e  a r e  n o  p r e c l in i c a l  d a t a  a v a i l a b l e  to  d a t e  o n th e  p o t e n t i a l  p h o to to x i c i t y  o f  INCB 0 5 0 4 6 5 .   
T h e r e f o r e ,  su b j e c t s  e n r o l l e d  in  th i s  s tu dy  t a k ing  INCB 0 5 0 4 6 5  w i l l  b e  in s t r u c t e d  by  th e  s i t e  s t a f f  
to  t a k e  p r e c a u t io n  to  p r o t e c t  th em s e lv e s  f r om  th e  su n /u l t r a v io l e t  l ig h t .   T h i s  in c lu d e s  w e a r in g  
lo n g  s l e e v e s ,  lo n g  t r o u s e r s ,  h a t s ,  a n d  su n g l a s s e s .  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  20 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
2 .  STUDY  OB JECT IVES  AND  ENDPOINTS  
2 . 1 .  S tud y  Ob j e c t iv e s 
2 . 1 . 1 .  P r im a r y  Ob j e c t iv e 
•  T o  a s s e s s  th e  e f f i c a cy  o f  INCB 0 5 0 4 6 5  in  t e rm s  o f  ORR  in  su b j e c t s  w i th  r e l a p s e d  o r  
r e f r a c to ry  DLBCL in  G ro u p  A .  
2 . 1 . 2 .  S e c onda r y  Ob j e c t iv e s 
•  T o  a s s e s s  th e  d u r a t io n  of  r e sp o n s e  (D OR ) in  G r o up  A .  
•  T o  a s s e s s  p r og r e s s io n- f r e e  su r v iv a l  (PFS )  in  G r o up  A .  •  T o  a s s e s s  OS in  G r o u p  A .  
•  T o  c h a r a c t e r i z e  th e  s a f e ty  o f  INCB 0 5 0 4 6 5  in  G r ou p  A  a n d  G r o u p  B .  
2 . 2 .  S tud y  Endp o in t s 
2 . 2 . 1 .  P r im a r y  Endpo in t 
•  O b j e c t iv e  r e sp o n s e  r a t e in  G r o u p  A ,  d e f in e d a s  th e  p e r c e n t ag e  o f  su b j e c t s  w i th  a  
CR/CMR  o r  PR/PMR  a s  d e f in e d  by  r e v i s e d  r e sp on s e  c r i t e r i a  f o r  lymp h om a s  
( Ch e so n  e t  a l  2 0 1 4) ,  a s  d e t e rm in e d  by  a n  I n d e p e nd e n t  R e v i ew  Comm i t t e e  ( IRC ) .  
2 . 2 . 2 .  S e c onda r y  Endpo in t s 
•  D u r a t io n  o f  r e sp o n s e  in  G r o u p  A ,  d e f in e d  a s  th e  t im e  f r om  f i r s t  d o c um e n t ed  e v id e n c e  
o f  CR/CMR  o r  PR/PMR  u n t i l  d i s e a s e  p r o g r e s s io n  o r  d e a th  f r om  a ny  c a u s e  amo n g  
su b j e c t s  w h o  a c h i e v e  a n  o b j e c t iv e  r e sp o n s e ,  a s  d e t e rm in e d  by  r a d iog r a p h i c  d i s e a s e  
a s s e s sm e n t  p r o v id e d  by  an  IRC .  
•  P r o g re s s io n - f r e e  su r v iv a l  in  G r o u p  A ,  d e f in e d  a s  th e  t im e  f r om  th e  d a t e  o f  th e  f i r s t  
d o s e  o f  s tu dy  d r ug  u n t i l  th e  e a r l i e s t  d a t e  o f  d i s e a s e  p r o g r e s s io n ,  a s  d e t e rm in e d  by  r a d io g r a p h i c  d i s e a s e  a s s e s sm e n t  p r o v id e d  by  a n  IRC ,  o r  d e a th  f r om  a ny  c au s e .  
•  OS in  G r o u p  A ,  d e f in e d  a s  th e  t im e  f r om  th e  d a t e  o f  th e  f i r s t  d o s e  o f  s tu dy  d r u g  u n t i l  
d e a th  by  a ny  c a u s e .  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  21 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
•  S a f e ty  a s  m e a su r e d  by  c l in i c a l  a s s e s sm e n t s,  in c lu d in g  v i t a l  s ig n s  a n d  p hy s i c a l  
e x am in a t io n s ,  1 2 - l e a d  e l e c t r o c a r d iog r am s  (ECG ) ,  c h em i s t ry  a n d  h em a to logy  
l a b o r a to ry  v a lu e s ,  a n d  AE s .  
3 .  SUB JECT  EL IG IB IL ITY 
D e v i a t io n s  f r om  e l ig ib i l i ty  c r i t e r i a  a r e  n o t  a l low e d  b e c a u s e  th ey  c a n  p o t e n t i a l ly  j e o p a r d i z e  th e  s c i e n t i f i c  in t eg r i ty  o f  th e  s tu dy ,  r eg u l a to ry  a c c e p t ab i l i ty ,  a n d /o r  su b j e c t  s a f e ty .   T h e r e f o r e ,  
a d h e r e n c e  to  th e  c r i t e r i a  a s  sp e c i f i e d  in  th e  Pr o to co l  i s  e s s e n t i a l .  
3 . 1 .  Sub j e c t  In c lu s ion  C r i t e r i a 
A  su b j e c t w h o  m e e ts  a l l  o f  th e  f o l low in g  c r i t e r i a  m ay  b e  in c lu d e d  in  th e  s tu dy :  
1 .  M e n  a n d  w om e n ,  ag e d  18  y e a r s  o r  o ld e r  ( e x c e p t  in  So u th  K o r e a ,  ag e d  1 9  o r  o ld e r ) .  
2 .  Re l a p s e d  o r  r e f r a c to ry  DLBCL ,  w h i c h  h a s  b e e n  h i s to lo g i c a l ly  d o c um e n t e d ,  d e f in e d  a s  
h a v in g  r e c e iv e d  a t  l e a s t  2  b u t  n o  mo r e  th a n  5  p r io r  t r e a tm e n t  r eg im e n s   ( eg ,  a n  a n t i -CD 2 0  
a n t ib o dy ,  a n  a n t i -CD 2 0  an t ib o dy  w i th  o r  w i th o u t  ch emo th e r a py ,  o r  c h emo th e r a py  a lo n e )  a n d  in e l ig ib l e  f o r  HDC /ASCT .  
3 .  G r o u p  B  o n ly :   Mu s t  h a v e  r e c e iv e d  p r io r  B r u to n ' s  ty r o s in e  k in a s e  (BTK)  inh ib i to r  
th e r a py  ( eg ,  ib r u t in ib ) .  
4 .  Su b j e c t s  mu s t  b e  w i l l in g  to  u n de r g o  a n  in c i s io n a l  o r  e x c i s io n a l  lymp h  n o d e  b io p sy  o f  
a c c e s s ib l e  a d e n o p a thy  o r  p r o v id e  th e  mo s t  r e c e n t ,  a v a i l a b l e  a r c h iv e d  tumo r  b io p sy .  
5 .  Mu s t  h a v e  ≥  1  m e a su r a b l e  n o d a l  l e s io n  ( ≥  2  cm  in  lo n g e s t  d im e n s io n )  o r  ≥  1  m e a su r a b l e  
e x t r a n o d a l  l e s io n  (>  1  cm  in  lo n g e s t  d im e n s io n )  o n  c o mp u t e d  tomo g r a p hy  (CT )  s c a n  o r  
m a g n e t i c  r e so n a n c e  im ag in g  (MR I ) . 
6 .  ECOG  p e r f o rm a n c e  s t a tu s  0  to  2  ( s e e  T a b l e 1 0 ) .  
7 .  A d e q u a t e  h em a to lo g i c ,  h e p a t i c ,  a n d  r e n a l  f u n c t io n ( v a lu e s  mu s t  n o t  b e  a c h i e v e d  w i th  
g r ow th  f a c to r s ) :  
a .  A b so lu t e  n e u t r o p h i l  c o u n t  (ANC )  ≥  1 . 0  ×  1 0
9/L .  
b .  H emo g lo b in  ≥  8 . 0  g /dL . 
c .  P l a t e l e t  c o u n t  ≥  5 0  ×  1 09/L .  
d .  T o t a l  b i l i r u b in  ≤  1 .5  ×  u p p e r  l im i t  o f  n o rm a l  ( ULN) .  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  22 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
e .  A l a n in e  am in o t r a n s f e r a s e  (ALT )/ a sp a r t a t e  am in o t r a n s f e r a s e  ( AST)  ≤  3 . 0  ×  ULN  o r  
≤  5  ×  ULN  in  th e  p r e s e n c e  o f  l iv e r  m e t a s t a s e s . 
f .  C a l c u l a t e d  c r e a t in in e  c l e a r a n c e  ≥  5 0  mL /m in  by  th e  Co c k c r o f t -G a u l t  E q u a t io n  o r  th e  
e s t im a t e d  g lom e r u l a r  f i l t r a t io n  r a t e  ≥  5 0  mL /m in /1 . 7 3  m2 u s in g  th e  Mo d i f i c a t io n  o f  
D i e t  in  R e n a l  D i s e a s e  f o rmu l a . 
8 .  W i l l in g n e s s  to  a v o id  p r e g n a n cy  o r  f a th e r ing  c h i ld r e n  b a s e d  o n  th e  c r i t e r i a  b e low :  
a .  Wom a n  o f  n o n c h i ld b e a r in g  p o t e n t i a l  (i e ,  su rg i c a l ly  s t e r i l e  w i th  a  hy s t e r e c tomy  a n d /o r  
b i l a t e r a l  o o p h o r e c tomy  OR  ≥  1 2  mo n th s  o f  am e n o r r h e a  a n d  a t  l e a s t  5 5  y e a r s  o f  ag e) .  
b .  Wom a n  o f  c h i ld b e a r ing  p o t e n t i a l  w h o h a s  a  n eg a t iv e  s e r um  p r eg n a n cy  t e s t  a t  
s c r e e n ing  a n d  w h o  ag r e e s  to  t a k e  a p p r o p r i a t e  p r e c a u t io n s  to  a v o id  p r eg n a n cy  (w i th  a t  
l e a s t  9 9%  c e r t a in ty )  f r om  s c r e e n ing  th r o ug h  s a f e ty  f o l low - u p .   P e rm i t t e d  m e th o d s  th a t  a r e  a t  l e a s t  9 9%  e f f e c t iv e  in  p r e v e n t in g  p r eg n a n cy  ( s e e  A p p e n d ix  A)  sh o u ld  b e  c ommu n i c a t e d  to  th e  su b j e c t  a n d  th e i r  u n d e r s t a n d in g  c o n f i rm e d .  
c .  M a n  w h o  ag r e e s  to  t a k e  a p p r o p r i a t e  p r e c a u t io n s  to  a v o id  f a th e r ing  c h i ld r en  (w i th  a t  
l e a s t  9 9%  c e r t a in ty )  f r om  s c r e e n ing  th r o ug h  a t  l e a s t  9 3  d ay s  a f t e r  th e  l a s t  d o s e  o f  s tu dy  t r e a tm e n t .   P e rm i t t e d  m e th o d s  th a t  a r e  a t  l e a s t  9 9%  e f f e c t iv e  in  p r e v en t in g  p r eg n a n cy  ( s e e  A p p e n d ix  A)  sh o u ld  b e  c ommu n i c a t e d  to  th e  su b j e c t  a n d  th e i r  u n d e r s t a n d ing  c o n f i rm e d .  
9 .  A b i l i ty  to  c omp r e h e n d  an d  w i l l in g n e s s  to  s ig n  a n  in f o rm e d  c o n s e n t  f o rm  ( ICF ) .   
3 . 2 .  Sub j e c t  E x c lu s ion  C r i t e r ia  
A  su b j e c t w h o  m e e ts  a ny  o f  th e  f o l low in g  c r i t e r i a  w i l l  b e  e x c lu d e d  f r om  th e  s tu dy :  
1 .  P r im a ry  m e d i a s t in a l  ( thym i c )  l a rg e  B- c e l l  lymp h om a .  
2 .  K n ow n  b r a in  o r  c e n t r a l  n e r v o u s  sy s t em  m e t a s t a s e s  o r  h i s to ry  o f  u n c o n t r o l l ed  s e i zu r e s .  
3 .  A l lo g e n e i c  s t em c e l l  t r a n sp l a n t  w i th in  th e  l a s t  6  m o n th s ,  o r  a c t iv e  g r a f t  v e r su s  h o s t  
d i s e a s e  f o l low ing  a l log e n e i c  t r a n sp l a n t,  o r  a u to lo g o u s  s t em  c e l l  t r a n sp l a n t  w i th in  th e  l a s t  
3  mo n th s  b e f o r e  th e  d a t e  o f  th e  f i r s t  d o s e  o f  s tu dy  d r u g .  
4 .  U s e  o f  immu n o su p p r e s s iv e  th e r a py  w i th in  2 8  d ay s  o f  th e  d a t e  o f  s tu dy  d r ug  
a dm in i s t r a t io n .   Immu n o su p p r e s s iv e  th e r a py  in c lu d e s ,  b u t  i s  n o t  l im i t e d  to ,  cy c lo sp o r in e  A ,  t a c r o l imu s,  o r  h ig h - d o s e  c o r t i c o s t e r o id s .   Su b j e c t s  r e c e iv in g  
c o r t i c o s t e r o id s  mu s t  b e  a t  a  d o s e  l e v e l  ≤  1 0  mg /d ay  w i th in  7  d ay s  o f  s tu dy  d r u g  
a dm in i s t r a t io n .  
5 .  P r io r  t r e a tm e n t  w i th  th e  fo l low in g : 
a .  G r o u p  A :   P r io r  t r e a tm e n t  w i th  a s e l e c t iv e  
P I 3K δ  in h ib i to r  ( e g ,  id e l a l i s ib ) ,  a  p a n - P I 3K  
in h ib i to r ,  o r  a  BTK  in h ib i to r  ( eg ,  ib r u t in ib ) .  
b .  G r o u p  B :   P r io r  t r e atm e n t  w i th  a  s e l e c t iv e  P I 3K δ  in h ib i to r  ( e g ,  id e l a l i s ib )  o r  a  
p a n -P I 3K  in h ib i to r .  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  23 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
6 .  R e c e ip t  o f  a n t i c a n c e r  m ed i c a t io n s  o r  in v e s t ig a t io n a l  d r u g s  w i th in  th e  f o l low in g  in t e r v a l s  
b e f o r e  th e  d a t e  o f  th e  f i r s t  d o s e  o f  s tu dy  d r ug :  
a .  <  1 0  w e e k s  f r om  c omp l e t io n  o f  a ny  r a d io -  o r  to x in - immu n o c o n ju g a t e s .   
b .  <  6  w e e k s  f o r  m i tomy c in-C  o r  n i t r o so u r e a s .  
c .  <  4  w e e k s  f o r  immu n o th e r a py .  d .  <  3  w e e k s  f o r  r a d io th e r apy .    e .  <  2  w e e k s  f o r  a ny  in v e s t ig a t io n a l  ag e n t  o r  o th e r  a n t i c a n c e r  m e d i c a t io n s .  
7 .  P r io r  t r e a tm e n t- r e l a t e d  tox i c i t i e s  th a t  h a v e  n o t  r e so lv e d  to  ≤  G r a d e  1  b e f o r e  th e  d a t e  o f  
s tu dy  d r ug  a dm in i s t r a t ion  d a t e  e x c e p t  f o r  s t a b l e  ch r o n i c  to x i c i t i e s  (≤  G r a d e  2 )  n o t  
e xp e c t e d  to  r e so lv e  ( eg ,  s t a b l e  G r a d e  2  p e r ip h e r a l  n e u r o to x i c i ty ) .  
8 .  Co n c u r r e n t  a n t i c a n c e r  th e r a py  ( eg ,  c h emo th e r a py ,  r a d i a t io n  th e r a py ,  surg e ry ,  
immu n o th e r a py ,  b io log i c  th e r a py ,  h o rmo n a l  th e r apy ,  in v e s t ig a t io n a l  th e r a py ,  o r  tumo r  emb o l i z a t io n ) .  
9 .  U s e  o r  e xp e c t e d  u s e  d u r in g  th e  s tu dy  o f  a ny  p r o h ib i t e d  m e d i c a t io n s ,  in c lu d in g  p o t e n t  
cy to c h r om e  P4 5 0  ( CYP)  3A 4  in h ib i to r s  o r  in d u c e r s  ( s e e  A p p e n d ix  B)  w i th in  1 4  d ay s  o r  5  h a l f - l iv e s  (w h i c h e v e r  i s  lo n g e r )  b e f o r e  th e  d a t e  o f  s tu dy  d r ug  a dm in i s t r a t io n .  
1 0 .  S ig n i f i c a n t  c o n c u r r e n t ,  u n c o n t r o l l e d  m e d i c a l  c o n d i t io n  in c lu d in g ,  b u t  n o t  l im i t e d  to ,  
r e n a l ,  h e p a t i c ,  h em a to log i c a l ,  g a s t r o in t e s t in a l ,  e n do c r in e ,  p u lmo n a ry ,  n e u r o lo g i c a l ,  c e r e b r a l ,  o r  p sy ch i a t r i c  d i s e a s e .  
1 1 .  Cu r r e n t  o r  p r ev io u s  o th e r  m a l ig n a n cy  w i th in  3  y e a r s  o f  s tu dy  e n t ry ,  e x c e p t  c u r e d  b a s a l  o r  
sq u amo u s  c e l l  sk in  c a n c e r ,  su p e r f i c i a l  b l a d d e r  c a n c e r ,  p r o s t a t e  in t r a e p i th e l i a l  n e o p l a sm ,  c a r c in om a  in  s i tu  o f  th e  c e r v ix ,  o r  o th e r  n o n in v a s iv e  o r  in d o l e n t  m a l ig n a n cy  w i th o u t  
sp o n so r  a p p r o v a l .  
1 2 .  H i s to ry  o f  s t r o k e  o r  in t r a c r a n i a l  h emo r r h ag e  w i th in  6  mo n th s  o f  th e  d a t e  o f  s tu dy  d r ug  
a dm in i s t r a t io n .  
1 3 .  Ch r o n i c  o r  c u r r e n t  a c t iv e  in f e c t io u s  d i s e a s e  r e q u i r in g  sy s t em i c  a n t ib io t i c s ,  a n t i f u n g a l ,  o r  
a n t iv i r a l  t r e a tm e n t ,  a n d  exp o su r e  to  a  l iv e  v a c c in e  w i th in  3 0  d ay s  o f s tu dy  d ru g  
a dm in i s t r a t io n .  
1 4 .  K n ow n  h um a n  immu n o d e f i c i e n cy  v i r u s  (H IV )  in f e c t io n  o r  p o s i t iv i ty  o n  immu n o a s s ay .   
N o t e :   H IV  s c r e e n ing  t e s t  i s  o p t io n a l  f o r  su b j e c t s  en r o l l e d  in  th e  U n i t e d  S t a t e s ,  b u t  su b j e c t s  w i th  k n ow n  H IV  in f e c t io n  e n r o l l e d  in  th e  U n i t e d  S t a t e s  w i l l  b e  ex c lu d e d .  
1 5 .  L iv e r  d i s e a s e:  
a .  E v id e n c e  o f  h e p a t i t i s  B  v i r u s  (HBV )  o r  h e p a t i t i s  C  v i r u s  (HCV )  in f e ct io n  o r  r i sk  o f  
r e a c t iv a t io n :   HBV  DNA  a n d  HCV  RNA  mu s t  b e  u n d e t e c t a b l e .   Su b j e c t s  c a n n o t  b e  
p o s i t iv e  f o r  h e p a t i t i s  B  su r f a c e  a n t ig e n  (HB sAg )  o r  a n t i– h e p a t i t i s B  c o r e  an t ib o dy .   Su b j e c t s  w h o  h a v e  p o s i t iv e  a n t i -HB s  a s  th e  o n ly  ev id e n c e  o f  p r io r  e xp o su r e  m ay  p a r t i c ip a t e  in  th e  s tu dy  p ro v id e d  th a t  th e r e  i s  b o th  1 )  n o  k n ow n  h i s to ry  o f  HBV  in f e c t io n ,  a n d  2 )  v e r i f i e d  r e c e ip t  o f  h e p a t i t i s  B  v a c c in e . 
1 6 .  C l in i c a l ly  s ig n i f i c a n t  c a rd i a c  d i s e a s e ,  in c lu d in g  un s t a b l e  a ng in a ,  a c u t e  my o c a r d i a l  
in f a r c t io n ,  a n d  o r  c a r d i a c  c o n d u c t io n  i s su e s  w i th in  6  mo n th s  o f  th e  d a t e  o f  s tu dy  d r ug  
a dm in i s t r a t io n .   
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  24 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
1 7 .  Cu r r e n t  N ew  Y o r k  H e a r t  A s so c i a t io n  C l a s s  I I to  IV  c o ng e s t iv e  h e a r t  f a i lu r e  o r  
u n c o n t r o l l e d  a r r hy thm i a .  
1 8 .  P re s e n c e  o f  a n  a bn o rm a l  EC G  th a t  i s  c l in i c a l ly  m e a n in g f u l .   S c r e e n ing  QT c  in t e r v a l  
>  4 5 0  m i l l i s e c o n d s  i s  e x c lu d e d  ( c o r r e c t e d  by  F r id e r i c i a ) .   I n  th e  e v e n t  th a t  a  s in g l e  QT c  i s  
>  4 5 0  m i l l i s e c o n d s ,  th e  su b j e c t  m ay  e n r o l l  i f  th e  av e r ag e  QT c  f o r  3  ECG s  i s  
<  4 5 0  m i l l i s e c o n d s.   
1 9 .  U n a b l e  to  sw a l low  o r a l  m e d i c a t io n ,  m a l a b so r p t io n  sy n d r om e ,  d i s e a s e  s ig n i f i c a n t ly  
a f f e c t in g  g a s t r o in t e s t in a l  f u n c t io n ,  to t a l  r e s e c t io n  o f  th e  s tom a c h  o r  sm a l l  b ow e l ,  u l c e r a t iv e  c o l i t i s ,  symp tom a t i c  in f l amm a to ry  b ow e l  d i s e a s e ,  o r  p a r t i a l  o r  comp l e t e  b ow e l  
o b s t r u c t io n .  
2 0 .  K n ow n  hy p e r s e n s i t iv i ty  o r  s e v e r e  r e a c t io n  to  INCB 0 5 0 4 6 5  o r  i t s  e x c ip i e n t s  
( INCB 0 5 0 4 6 5  IB ) .    
2 1 .  Cu r r e n t ly  p r eg n a n t  o r  b r e a s t f e e d ing .  
2 2 .  A ny  c o n d i t io n  th a t  w o u ld ,  in  th e  in v e s t ig a to r 's  jud gm e n t ,  in t e r f e r e  w i th  f u l l  p a r t i c ip a t io n  
in  th e  s tu dy ,  in c lu d in g  a dm in i s t r a t io n  o f  s tu dy  d r ug  a n d  a t t e n d ing  r e q u i r e d  s t u dy  v i s i t s;  
p o s e  a  s ig n i f i c a n t  r i sk  to  th e  su b j e c t ;  o r  in t e r f e r e  w i th  in t e r p r e t a t io n  o f  s tudy  d a t a .  
4 .  INVEST IGAT IONAL  PLAN 
4 . 1 .  O v e r a l l  S tud y  D e s i gn 
Th i s  i s  a  Ph a s e  2 ,  mu l t i c e n t e r ,  in t e r n a t io n a l,  o p e n - l a b e l  s tu dy  d e s ig n e d  to  e v a lu a t e  th e  s a f e ty  a n d  
e f f i c a cy  o f  IN CB 0 5 0 4 6 5  20  mg  QD f o r  8  w e e k s  f o l low e d  by  2 0  mg  o n c e  w e e k ly .   T h e  s tu dy  
d r u g  w i l l  b e  a dm in i s t e r ed  o r a l ly  to  su b j e c t s  w i th  r e l a p s e d  o r  r e f r a c to ry  DLBCL  ( s e e  F ig u r e 1 ) .   
T h e  s tu dy  c o n s i s t s  o f  2  g r o u p s :   G r o u p  A  a n d  G r ou p  B .   I n  G r o u p  A ,  1 0 0  su b j e c t s  w h o w e r e  n o t  p r e v io u s ly  t r e a t e d  w i th  a  BTK  in h ib i to r  ( eg ,  ib r u t in ib )  w i l l  b e  e n r o l l e d .   I n  G r o u p  B ,  u p  to  
2 0  su b j e c t s  w h o w e r e  p r ev io u s ly  t r e a t e d a  BTK  inh ib i to r  ( e g ,  ib r u t in ib )  w i l l  b e  e n r o l l e d .   
Su b j e c t s  w i l l  b e  e v a lu a t ed f o r  ORR  by  a n  in d e p e nd e n t  r e v i ew  c omm i t t e e  ( IRC )  a n d  f o l low e d  f o r  DOR,  PFS ,  a n d  OS .   Su b j e c t s  m ay  r e c e iv e  t r e a tm en t  u n t i l  d i s e a s e  p r o g r e s s io n ,  d e a th ,  
u n a c c e p t a b l e  to x i c i ty ,  o r  c o n s e n t  w i th d r aw a l .   A n  in t e r im  f u t i l i ty  a n a ly s i s  i s  p l a n n e d  w h e n  th e  
f i r s t  4 0  su b j e c t s  in  G r o u p  A  h a v e  b e e n  t r e a t e d  a n d  h a v e  b e e n  e v a lu a t e d  f o r  r e sp o n s e  o r  h a v e  p e rm a n e n t ly  d i s c o n t in u ed  s tu dy  t r e a tm e n t  b e c a u s e  o f  d i s e a s e  p r og r e s s io n ,  w i th d r aw a l  o f  c o n s e n t ,  
o r  d e a th .   G r o u p  A  o f  th e  s tu dy  w i l l  b e  t e rm in a t e d  f o r  f u t i l i ty  i f  ≤  1 3  o f  th e  4 0  su b j e c t s  h a v e  
r e sp o n d e d  ( i e ,  CR /CMR  o r  PR /PMR )  b a s e d  o n  a s s e s sm e n t s  p r o v id e d  by  th e  IRC ;  o th e rw i s e  th e  s tu dy  w i l l  c o n t in u e .   A  t im e ly  a s s e s sm e n t  o f  r e sp on s e  w i l l  b e  p e r f o rm e d  to  a v o id  th e  r i sk  o f  
o v e r e n r o l lm e n t .   N o  f o rm a l  f u t i l i ty  a n a ly s i s  w i l l  b e  c on d u c t e d  f o r  G r o u p  B . 
Su b j e c t s  w h o h a v e  r e l a p s e d  o r  r e f r a c to ry ,  h i s to lo g i c a l ly  c o n f i rm e d  DLBCL  w i l l  b e  s c r e e n e d  f o r  
e l ig ib i l i ty .   T h o s e  w h o  m e e t  th e  e l ig ib i l i ty  c r i t e r i a  w i l l  b e  a dm in i s t e r e d  s tu d y  d r ug  ( s e e  
S e c t io n 5 . 2 ) .   Su b j e c t s  w i l l  b e  mo n i to r e d  f o r  s a f e ty  a n d  e f f i c a cy  p e r io d i c a l ly  u n t i l  d i s e a s e  
p r o g r e s s io n ,  d e a th ,  u n a c c e p t a b l e  to x i c i ty ,  o r  w i th d r aw a l  o f  in f o rm e d  c o n s en t .   A n  in d e p e n d e n t  D a t a  Mo n i to r in g  Comm i t t e e  (I DMC)  w i l l  r e v i ew  s a f e ty  d a t a p e r io d i c a l ly  a s  s t a t e d  in  th e  I DMC  
c h a r t e r .  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  25 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
A f t e r  t r e a tm e n t  d i s c o n t in u a t io n ,  su b j e c t s  w i l l  b e  f o l low e d  f o r  s a f e ty  a n d  su r v iv a l .   Su b j e c t s  w h o  
h a v e  d i s c o n t in u e d  s tu dy  t r e a tm e n t  d u e  to  r e a so n s  o th e r  th a n  d i s e a s e  p r og r e s s io n  w i l l  b e  f o l low e d  
f o r  e i th e r  r a d io log i c  d i s e a s e  p r og r e s s io n ,  th e  s t a r t  o f  a  n ew  a n t i c a n c e r  th e r apy ,  o r  d e a th ,  
w h i c h e v e r  c om e s  f i r s t.   Th e  s tu dy  w i l l  b e  c lo s e d  no  l a t e r  th a n  2  y e a r s  a f t e r  th e  f i r s t  d o s e  o f  INCB 0 5 0 4 6 5  i s  a dm in i s t e r e d  to  th e  l a s t  p a t i e n t  e n r o l l e d ,  a t  w h i c h  p o in t  a n  a n a ly s i s  o f  OS w i l l  b e  
c o n d u c t e d .  
N o t e :  W i th  Am e n dm e n t  4 ,  P r o to c o l - r e q u i r e d  p r o c e d u r e s  h a v e  b e e n  r e d u c e d  f o r  o ng o ing  
su b j e c t s .  
F igu r e 1 :  S tudy  D e s ign 
 
4 . 2 .  M e a su r e s  T ak en  t o  A vo id  B i a s 
T h i s  i s  a n  o p e n -l a b e l  s tudy ;  n o  c omp a r i so n s  w i l l  b e  m a d e  b e tw e e n  su b j e c t s  o r  ag a in s t  h i s to r i c a l  
c o n t r o l s .   M e a su r em e n t s  o f  s a f e ty  a n d  e f f i c a cy  a r e  o b j e c t iv e  m e a su r em e n t s ,  a n d  o n ly  
c omp a r i so n s  to  p r e t r e a tm e n t  c o n d i t io n s  w i l l  b e  m a d e .   S a f e ty  w i l l  b e  o b j e c t iv e ly  a s s e s s e d  u s ing  NC I  CTCAE  v 4 . 0 3  (NC I 2 0 0 9 )  g u id e l in e s ;  r e sp o n s e  w i ll  b e  a s s e s s e d  by  a n  IRC  u s in g  th e  
L ug a n o  cl a s s i f i c a t io n  ( Ch e so n  e t  a l  2 0 1 4) .  
4 . 3 .  Numb e r  o f  Sub j e c t s 
4 . 3 . 1 .  P lann ed  Numb e r  o f  Sub j e c t s  and  S i t es  
T h e  s tu dy  w i l l  e n r o l l  1 0 0  to 1 2 0  su b j e c t s  a c r o s s  a pp r o x im a t e ly  8 0  s i t e s .  
4 . 3 . 2 .  R ep la c em en t  o f  Sub j e c t s 
N o  su b j e c t s  w i l l  b e  r e p l a c e d  a t  a ny  t im e  d u r ing  th i s  s tu dy . 
4 . 4 .  Du r a t i on  o f  T r e a tm en t  and  Sub j e c t  P a r t i c ip a t i on 
A f t e r  s ig n ing  th e  ICF ,  s c r e e n ing  a s s e s sm e n t s  m ay  b e  c omp l e t e d  o v e r  a  p e r io d  o f  u p  to  2 8  d ay s .   
E a c h  su b j e c t  en r o l l e d  in  th e  s tu dy  m ay  c o n t in u e  to  r e c e iv e  s tu dy  t r e a tm e n t  in  c o n t in u o u s  2 1 - d ay  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  26 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
in t e r v a l s .   I f  th e  su b j e c t  d i s c o n t in u e s  INCB 0 5 0 4 6 5 ,  th e  t r e a tm e n t  p e r io d  w i l l  e n d,  a n d  th e  su b j e c t  
w i l l  e n t e r  th e  3 0 - d ay  s a f e ty  f o l low - u p  p e r io d  a f t e r  w h i c h  th e  su b j e c t  w i l l  e n t e r  th e  su r v iv a l  
f o l low - u p  p e r io d  ( s e e  S e c t io n 6 . 4 ) .   S tu dy  p a r t i c ip a t io n ,  e x c lu d in g  su r v iv a l  f o l low - u p ,  i s  
e xp e c t e d  to  a v e r ag e  a p p ro x im a t e l y  1 1  mo n th s  p e r  su b j e c t .   Su r v iv a l  f o l low - u p  m ay  a v e r ag e  a p p r o x im a t e ly  1 2  mo n th s .  
4 . 5 .  O v e r a l l  S tud y  Du r a t ion 
T h e  s tu dy  b eg in s  w h e n  th e  f i r s t  su b j e c t  s ig n s  th e  ICF .   I t  i s  e s t im a t e d  th a t  th e  s tu dy  w i l l  t a k e  a p p r o x im a t e ly  1 . 5  y e a r s to  a c c r u e  1 2 0  su b j e c t s  a nd  th a t  th e  s tu dy  w i l l  b e  c lo s e d  n o  l a t e r  th a n  2  y e a r s  a f t e r  th e  f i r s t  d o s e  o f  IN CB 0 5 0 4 6 5  i s  a dm in i s t e r e d  to  th e  l a s t  su b j e c t  e n r o l l e d .  
4 . 6 .  S tud y  T e rm in a t i on 
T h e  i n v e s t ig a to r  r e t a in s  th e  r ig h t  to  t e rm in a t e  s tu d y  p a r t i c ip a t io n  a t  a ny  t im e ,  a c c o r d ing  to  th e  
t e rm s  sp e c i f i e d  in  th e  s tudy  c o n t r a c t .   T h e  in v e s t ig a to r  i s  to  n o t i fy  th e  in s t i t u t io n a l  r e v i ew  b o a r d  
( IRB ) / in d e p e n d e n t  e th i c s  c omm i t t e e  ( IEC )  in  w r i t in g  o f  th e  s tu dy ' s  c omp l e t io n  o r  e a r ly  t e rm in a t io n ,  s e n d  a  c o py  o f  th e  n o t i f i c a t io n  to  th e  sp o n so r  o r  sp o n so r ' s  d e s ig n e e ,  a n d  r e t a in  
1  c o py  f o r  th e  s i t e  s tu dy  r e g u l a to ry  f i l e .  
T h e  sp o n so r  m ay  t e rm in a t e  th e  s tu dy  e l e c t iv e ly o r  d o  so  i f  r e q u i r e d  by  a  r eg u l a to ry  ag e n cy  o r  
u p o n  a d v i c e  f r om  th e  IDMC .   I f  th e  s tu dy  i s  t e rm in a t e d  p r em a tu r e ly ,  th e n  th e  sp o n so r  w i l l  n o t i fy  
th e  in v e s t ig a to r s ,  th e  IRB s  a n d  IEC s ,  a n d  r eg u l a to ry  b o d i e s  o f  th e  d e c i s io n  an d  r e a so n  f o r  
t e rm in a t io n  o f  th e  s tu dy .   T h e  IDMC  w i l l  r e c omm e n d  t e rm in a t io n  o f  th e  s tu dy  i f  w a r r a nt e d ,  a s  d e s c r ib e d  in  th e  IDMC  ch a r t e r .  
U p o n  s tu dy  c lo su r e ,  su b j e c t s  w h o  a r e  s t i l l  r e c e iv ing  s tu dy  t r e a tm e n t  w i l l  h a v e  th e  o p t io n  to  
t r a n s i t io n  to  S tu dy  INCB  5 0 4 6 5 - 2 1 4 ,  in  w h i c h  th ey  m ay  c o n t in u e  to  r e c e iv e  s tu dy  t r e a tm e n t .  
5 .  TREATMENT 
5 . 1 .  T r e a tm en t  A s s i gnm en t 
5 . 1 . 1 .  Sub j e c t  Numb e r ing  and  T r e a tm en t  A s s ignm en t 
S tu dy  s i t e s  w i l l  e n t e r  su b j e c t  d emog r a p h i c  a n d  b a s e l in e  d a t a  in to  th e  in t e r a c t iv e  w e b  r e sp o n s e  
sy s t em  ( IW RS)  to  r e c e iv e  a  su b j e c t  n umb e r  a n d  t r e a tm e n t  a l lo c a t io n .  
A l l  su b j e c t  n umb e r s  w i l l  b e  6  d ig i t s ;  th e  f i r s t  3  d ig i t s  w i l l  b e  th e  s i t e  n umb e r ,  a n d  th e  l a s t  3  d ig i t s  
w i l l  b e  th e  su b j e c t' s  n umb e r .   T h i s  su b j e c t  n umb e r  w i l l  b e  m a in t a in e d  th r o u g h o u t  th e  s tu dy  a n d  w i l l  n o t  b e  r e a s s ig n e d .   Su b j e c t s  w h o  w i th d r aw  c on s e n t  o r  d i s c o n t in u e  f r om  th e  s tu dy  a f t e r  b e ing  
a s s ig n e d  a  su b j e c t  n umb e r  w i l l  r e t a in  th e i r  in i t i a l  n umb e r .  
S i t e  s t a f f  w i l l  c o n t a c t  th e  IWRS  to  a l lo c a t e  th e  sub j e c t  to  t r e a tm e n t  a s s ig nm e n t  a n d  o b t a in  th e  
in i t i a l  s tu dy  d r ug  a s s ig nm e n t .   T h e  in v e s t ig a to r  o r  d e s ig n e e  w i l l  s e l e c t  th e  a s s ig n e d  b o t t l e s  o f  
s tu dy  d r ug  f r om  th e i r  s to c k  th a t  c o r r e sp o n d  to  th e  n umb e r  p r o v id e d  by  th e  IWRS  a n d  d i sp e n s e  
th e  s tu dy  d r ug  to  th e  su b j e c t .   A l l  su b s e q u e n t  d i sp e n s in g  o f  s tu dy  d r ug  sh ou ld  f o l low  th i s  p r o c e s s .   R e f e r  to  th e  IWRS  m a n u a l  f o r  d e t a i l e d  in f o rm a t io n .  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  27 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
I f  a  su b j e c t  i s  m i s t a k e n ly  g iv e n  a  b o t t l e  o f  s tu dy  d r u g  th a t  i s  n o t  th e  b o t t l e  a s s ig n e d  by  th e  IWRS ,  
th e  IW RS  h e lp  d e sk  mu s t  b e  n o t i f i e d  imm e d i a t e ly .   T h e  r e a so n  f o r  th e  m i s a l lo c a t io n  o f  th e  s tu dy  
d r u g  mu s t  b e  d o c um e n t ed  by  th e  s tu dy  s i t e  a n d  r ep o r t e d  to  th e  IRB / IEC .  
F o r  su b j e c t s  w h o  s ig n e d  a n  ICF  b u t  a r e  n o t  a l lo c a t e d  s tu dy  d r ug  a n d  f o r  su b j e c t s  w h o  a r e  
a l lo c a t e d  s tu dy  d r ug  b u t  w e r e  n o t  t r e a t e d ,  r e f e r  to  th e  e l e c t r o n i c  c a s e  r e p o r t  f o r m  (eCRF )  
Comp l e t io n  G u id e l in e s  f o r  in s t r u c t io n  o n  w h i c h  eCRF s  to  c omp l e t e .  
5 . 1 . 2 .  R andom i z a t ion  and  B l ind ing 
N o t  a p p l i c a b l e .  
5 . 2 .  INCB 0 50 4 65  
5 . 2 . 1 .  D e s c r ip t ion  and  Adm in i s t r a t ion T h e  d o s e  a n d  r eg im e n  o f  INCB 0 5 0 4 6 5  i s  20  mg  QD f o r  8  w e e k s  f o l low e d  by  2 0  mg  o n c e  
w e e k ly .   INCB 0 5 0 4 6 5  w i l l  b e  t a k e n  o r a l ly  w i th  w a t e r  in  a  f a s t e d  s t a t e  e x c ep t  o n  mo r n in g s  o f    
c l in i c  v i s i t s  ( s e e  T a b l e 1 1 ) .   Su b j e c t s  sh o u ld  r e f r a in  f r om  f o o d  c o n sump t io n  f o r  2  h o u r s  b e f o r e  a n d  1  h o u r  a f t e r  a dm in i s t r a t io n  o f  INCB 0 5 0 4 6 5 .   T h e  d o s ag e  s t r e ng th s  a n d  f o rm  a r e  5  mg  a n d  2 0  
mg  t a b l e t s ( s e e  T a b l e 1 ) .   
Tab l e  1 :  D e s c r ip t ion  and  Adm in i s t r a t ion 
C om p o u n d  n am e INCB 0 5 0 4 6 5  
D o s ag e  S t r e n g th s  5  m g  an d  2 0  m g  
F o rm T ab l e t 
A c t iv e  com p o u n d   INCB 0 5 0 4 6 5   
R o u t e  o f  adm in i s t r a t io n  O r a l 
D o s e  an d  R eg im en 2 0  m g  QD fo r  8  w e ek s  fo l l ow ed  b y  2 0  m g  o n c e  w e ek ly  
I n s t ru c t i o n s  INCB 0 5 0 4 6 5  w i l l  b e  t ak en  o r a l ly  w i th  w a t e r  in  a  f a s t e d  s t a t e ex c e p t  o n  
m o rn in g s  o f   c l in i c  v i s i t s  ( s e e  T ab l e 1 1 ) .   S u b j e c t s  s h o u ld  r e f r a in  
f rom  fo o d  co n sum p t io n  fo r  2  h o u r s  b e fo r e  an d  1  h o u r  a f t e r  adm in i s t r a t io n  o f  INCB 0 5 0 4 6 5 .  
5 . 2 . 2 .  Supp ly ,  P a cka g ing ,  and  Lab e l ing 
INCB 0 5 0 4 6 5  w i l l  b e  p r ov id e d  a s  5 -mg  a n d  2 0 -mg  t a b l e t s p a c k ag e d  in  h ig h - d e n s i ty  p o ly e thy l e n e  
b o t t l e s.   N o  p r e p a r a t io n  i s  r e q u i r e d .  
A l l  I n cy t e  in v e s t ig a t io n a l  p r o d u c t  l a b e l s  w i l l  b e  in  th e  lo c a l  l a ng u ag e  a n d  w i l l  c omp ly  w i th  th e  
l e g a l  r e q u i r em e n t s  o f  e a ch  c o u n t ry .  
P n e um o c y s t i s  j i ro v e c i i p n e umo n i a  p r o p hy l a x i s  i s  r e q u i r e d  a s  c o a dm in i s t r a t io n  w i th  
INCB 0 5 0 4 6 5 ;  th e  p r o p hy l a c t i c  ag e n t s  w i l l  b e  p r o v id e d  by  I n cy t e .   I n cy t e  w i l l  d e t e rm in e  th e  mo s t  a p p r o p r i a t e  m a n n e r  in  wh i c h  to  su p p ly  a  p r o p hy l a c t i c  ag e n t  p e r  c o u n t ry  b a s e d  o n  r eg u l a to ry  
c o n s id e r a t io n s .   F u r th e r  d e t a i l s  a r e  a v a i l a b l e  in  th e  s tu dy  p h a rm a cy  m a n u a l .  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  28 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
5 . 2 . 3 .  S t o r a g e  
B o t t l e s  o f INCB 0 5 0 4 6 5  t a b l e t s  sh o u ld  b e  s to r e d  a t  amb i e n t  c o n d i t io n s  ( 1 5 °C - 3 0 °C  o r  
5 9 °F - 8 6 °F ) .  
5 . 2 . 4 .  In s t ru c t ion  t o  Sub j e c t s  fo r  Hand l ing  INCB0 5 0 4 6 5  
T h e  su b j e c t  mu s t  b e  in s t r u c t e d  in  th e  h a n d l ing  o f  s tu dy  d r ug  a s  f o l low s :  
•  T o  s to r e  s tu dy  d r ug  a t  r oom  t emp e r a tu r e .  
•  T o  r emo v e  f r om  th e  s tu d y  d r ug  b o t t l e  o n ly  th e  n umb e r  o f  t a b l e t s  n e e d e d  a t  th e  t im e  o f  
a dm in i s t r a t io n .  
•  N o t  to  r emo v e  d o s e s  in  ad v a n c e  o f  th e  n e x t  s c h e du l e d  a dm in i s t r a t io n .  •  T o  m a k e  e v e ry  e f f o r t  to  t a k e  d o s e s  o n  s c h e d u l e .  •  T o  r e p o r t  a ny  m i s s e d  d o s e s .  •  T o  k e e p  INCB 0 5 0 4 6 5  in  a  s a f e  p l a c e  a n d  o u t  o f  r e a c h  o f  c h i ld r e n .  
•  T o  b r in g  a l l  u s e d  a n d  u nu s e d  s tu dy  d r ug  k i t s  to  th e  s i t e  a t  e a c h  v i s i t.  
5 . 3 .  T r e a tm en t  C omp l i an c e 
Comp l i a n c e  w i th  a l l  s tu d y - r e l a t e d  t r e a tm e n t s  sh o u ld  b e  emp h a s i z e d  to  th e  su b j e c t  by  th e  s i t e  
p e r so n n e l ,  a n d  a p p r o p r i a t e  s t e p s  sh o u ld  b e  t a k e n  to  o p t im i z e  c omp l i a n c e  d u r in g  th e  s tu dy .   
Comp l i a n c e  w i th  INCB 04 0 4 6 5  w i l l  b e  c a l c u l a t e d  by  th e  sp o n so r  b a s e d  o n  th e  d r ug  
a c c o u n t a b i l i ty  d o c um e n t e d  by  th e  s i t e  s t a f f  a n d  mo n i to r e d  by  th e  sp o n so r /d e s ig n e e  ( t a b l e t  c o u n t s ) .   Su b j e c t s  w i l l  b e  in s t r u c t e d  to  b r in g  a l l  s tu dy d r ug s w i th  th em  to  th e  s tu dy  v i s i t s  f o r  s i t e  
p e r so n n e l  to  c o n d u c t  t a b l e t  c o u n t s  to  a s s e s s  s tu dy  d r u g  a c c o u n t a b i l i ty .   T h e  d r u g  a c c o u n t a b i l i ty  
d o c um e n t a t io n  w i l l  b e  u s e d  by  th e  sp o n so r  to  c a l cu l a t e  t r e a tm e n t  c omp l i a n c e .  
5 . 4 .  T r e a tm en t  In t e r rup t ion s  and  Ad ju s tm en t s  
5 . 4 . 1 .  C r i t e r ia  and  P r o c edu r e s  fo r  D o s e  In t e r rup t ion s  and  R edu c t ion s o f  INCB0 5 0 4 6 5  
T r e a tm e n t  w i th  INCB 0 50 4 6 5  m ay  b e  in t e r r u p t e d  f o r  u p  to  1 4  d ay s  to  a l low  f o r  r e so lu t io n  o f  
to x i c i ty .   Su b j e c t s  m ay  r e sum e  t r e a tm e n t  i f  n o  m e d i c a l  c o n d i t io n  o r  o th e r  c i r c um s t a n c e  e x i s t s  
th a t ,  in  th e  o p in io n  o f  th e  in v e s t ig a to r ,  w o u ld  m a k e  th e  su b j e c t  u n su i t a b l e  fo r  f u r th e r  p a r t i c ip a t io n  in  th e  s tu dy .   T h e  t r e a t ing  in v e s t ig a to r  sh o u ld  c o n t a c t  th e  sp o n so r  to  d i s c u s s  th e  
c a s e  o f  a ny  su b j e c t  w h o s e  t r e a tm e n t  h a s  b e e n  in t e r r u p t e d  f o r  mo r e  th a n  1 4  d ay s  b e f o r e  r e s t a r t in g  
t r e a tm e n t  w i th  INCB 0 5 04 6 5 .  
B e c a u s e  su b j e c t s  m ay  e n t e r  th e  s tu dy  w i th  e x t e n s i v e  p r e t r e a tm e n t  a n d /o r  s ev e r e  b o n e  m a r r ow  
in f i l t r a t io n  by  th e  p r im a ry  d i s e a s e ,  g u id e l in e s  f o r  d o s e  in t e r r u p t io n  f o r  h em a to lo g i c  AEs  ( s e e  
T a b l e 2 )  a r e  p r o v id e d .   Th e  s t a r t in g  d o s e  a n d  d o s e  r e d u c t io n  l e v e l s  o f  INCB 0 5 0 4 6 5  a r e  p r o v id e d  ( s e e  T a b l e 3 ) .   I n d iv id u a l  d e c i s io n s  r eg a r d in g  d o s e  in t e r r u p t io n  a n d  r e d u c t io n  sh o u ld  b e  m a d e  
u s in g  c l in i c a l  ju dgm e n t  an d  in  c o n su l t a t io n  w i th  th e  sp o n so r ' s  m e d i c a l  mo n i to r ,  t a k in g  in to  
a c c o u n t  r e l a t e d n e s s  o f  th e  AE  to  th e  s tu dy  d r ug  a nd  th e  su b j e c t ' s  u n d e r ly ing  c o n d i t io n .   A d v e r s e  e v e n t s  th a t  h a v e  a  c l e a r  a l t e r n a t iv e  e xp l a n a t io n  o r  t r a n s i e n t  (≤  7 2  h o u r s )  a bn o rm a l  l a b o r a to ry  
v a lu e s  w i th o u t  a s so c i a t e d  c l in i c a l ly  s ig n i f i c a n t  s ig n s  o r  symp tom s  m ay  b e  ex emp t  f r om  
d o s e - r e d u c t io n  g u id e l in e s .  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  29 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
Tab l e  2 :  Gu id e l in e s  fo r  In t e r rup t ion  and  R e s t a r t ing  S tudy  D rug  
ADVERSE  EVENT ACT ION  TAKEN 
Ch em i s t ry 
•  AST  an d / o r  ALT  i s  G r ad e  3  
(>  5 .0 ×  ULN ) . 
No t e :   In  s u b j e c t s  w i th  l i v e r  
m e t a s t a s i s−r e l a t ed  e l ev a t i on s  a t  b a s e l i n e ,  
con t a c t  s pon s o r  t o  d i s cu s s  c l in i c a l  
m an ag em en t  an d  po s s i b l e  do s e  r edu c t i on s . S t ep  1 :  In t e r ru p t  INCB0504 6 5  an d  m on i t o r  w e ek ly  u n t i l  t h e  
t ox i c i ty  h a s  r e s o l v ed  t o  ≤  G r ad e  1 .  
S t ep  2 :  R e s t a r t  INCB05046 5  a t  n ex t  l ow e r do s e w i th  m ed i c a l  
m on i t o r  app rov a l.   Mon i t o r  a s  c l i n i c a l ly  in d i c a t ed .  
H em a to l ogy 
•  G r ad e  3  ANC  (<  1 .0 ×  1 09/ L ) . 
•  P l a t e l e t  cou n t  i s  G r ad e  2  (50  t o  
<  75 ×  1 09/L )  f o r  s u b j e c t s  w ho  en ro l l ed  
w i th  p l a t e l e t s  > 100 ×  1 09/L .  
•  P l a t e l e t  cou n t  i s  G r ad e  3  (< 50  ×  109/L )  f o r  
s u b j e c t s  w h o  en ro l l ed  w i th  p l a t e l e t s  
≤  100  ×  109/L .  S t ep  1 :  In t e r ru p t  INCB0504 6 5  u p  t o  14  d ay s  u n t i l  th e  t ox i c i ty  h a s  r e s o l v ed  t o  ≤  G r ad e  1  o r  p r e t h e r apy  b a s e l in e .   F o r  G r ad e  3  ANC ,  
m on i t o r  a t  l e a s t  w e ek ly . 
S t ep  2 :  R e s t a r t  INCB05046 5  a t  s am e  do s e ;  m on i t o r  a s  c l in i c a l ly  
i n d i c a t ed .  
•  G r ad e  4  ANC  (<  0 .5 ×  1 0
9/ L ) . 
•  G r ad e 3  o r  G r ad e  4  ANC  w i th  an  o r a l  
t em p e r a t u r e  o f  a t  l e a s t  38 .5 °C  OR  w i th  ≥  G r ad e  3  i n f e c t i on . 
•  P l a t e l e t  cou n t  i s  G r ad e  4  (< 25  ×  10
9/ L ) . S t ep  1 :  In t e r ru p t  INCB0504 6 5  u p  t o  14  d ay s  u n t i l  th e  t ox i c i ty  h a s  
r e s o l v ed  ≤  G r ad e  1 .   (F o r  G r a d e  4  ANC ,  m on i t o r  ANC  a t  l e a s t  
w e ek ly . ) 
S t ep  2 :  R e s t a r t INCB05046 5  a t  s am e  do s e .   I f  a s s e s s ed  a s  r e l a t ed  
t o  INCB050 465 ,  r e s t a r t  a t  n ex t  l ow e r  do s e .   Mon i t o r  a s  c l i n i c a l ly  i n d i c a t ed .  
O th e r  tox i c i t i e s 
•  D i a r rh e a / co l i t i s  (G r ad e  1 ) S t ep  1 :   T r e a t  w i th  an t im o t i l i ty  ag en t s  ( eg ,  4  m g  l op e r am i d e  
f o l l ow ed  by  2  m g  ev e ry  4  h ou r s  o r  a f t e r  ev e ry  un f o rm ed  s t oo l )  an d  
i n i t i a t e  s u ppo r t i v e  c a r e  ( s e e  S e c t i on 5 .4 .2) .   I f  n o t  im p rov ed  a f t e r  
48 h ou r s ,  t r e a t  p e r  g u i d an c e f o r  G r ad e  ≥  2 .  
•  D i a r rh e a / co l i t i s  (G r ad e  ≥ 2 )  S t ep 1 :  In t e r ru p t  INCB0504 6 5 .   P e r f o rm  w o rk - u p  f o r  i n f e c t i on  
( i n c l u d in g  CMV ,  C .  d i f f i c i l e,  e t c ) .   In i t i a t e  o r  con t i n u e  s u ppo r t i v e  c a r e  ( s e e  S e c t i on 5 .4 .2) .   C on s i d e r  co l on o s copy w i th  b i op sy f o r  G r ad e ≥  3 . 
S t ep  2 :  I f  i n f e c t i on  i s  ru l ed  ou t ,  s t a r t  o r a l  s t e ro i d s ,  o r  con s i d e r  IV  
s t e ro i d s  i f  su b j e c t  i s  b e i n g  g iv en  IV  f lu i d s .   I f  n o  im p rov em en t  w i th  
o r a l  s t e ro i d s ,  sw i t ch  t o  IV  s t e ro i d s . 
Wh en  d i a r rh e a  r e s o l v e s  t o  G r ad e  ≤ 1 ,  con t i n u e  s u ppo r t i v e  c a r e  an d  
t ap e r  s t e ro i d s  ov e r  4  w e ek s .   Wh en  t ap e r  i s  com p l e t e  an d  d i a r rh e a  i s  G r ad e  ≤  1 ,  r e s t a r t  INCB0 50 465  a t  n ex t  l ow e r  do s e  w i t h  app rov a l  o f  t h e  m ed i c a l  m on i t o r . 
I f  G r ad e  ≥  2  d i a r rh e a  r eo c cu r s ,  p e rm an en t ly  d i s con t in u e  
INCB0504 65 .   
•  Pn eum on i t i s  (G r ad e  1 )  S t ep  1 :   In t e r ru p t  INCB0504 6 5  u n t i l  th e  t ox i c i ty  h a s  r e s o lv ed .    
S t ep  2 :  R e s t a r t  INCB05046 5  a t  n ex t  l ow e r  do s e .   Mon i t o r  a s  c l i n i c a l ly  in d i c a t ed .  
•  Pn eum on i t i s (G r ad e   ≥  2 )  P e rm an en t ly  d i s con t in u e  INCB050 465 . 
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  30 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
Tab l e  2 :  Gu id e l in e s  fo r  In t e r rup t ion  and  R e s t a r t ing  S tudy  D rug  (C on t inu ed )  
ADVERSE  EVENT ACT ION  TAKEN 
•  S k in  t ox i c i ty  ( eg ,  r a s h ,  p ru r i tus ,  e t c ,  u n l e s s  
o t h e rw i s e  s p e c i f i ed)  (G r ad e  2 - 3 )  S t ep  1 :   In t e r ru p t  INCB0504 6 5  u n t i l  th e  t ox i c i ty  h a s  r e s o lv ed  t o  
≤  G r ad e  1 . 
S t ep  2 : R e s t a r t  INCB050465  a t  s am e  do s e .   I f  a s s e s s ed  a s  r e l a t ed  
t o  INCB050 465 ,  r e s t a r t  a t  n ex t  l ow e r  do s e .  
•  Ex f o l i a t i v e  d e rm a t i t i s  (G r ad e  1 ) S t ep  1 :   In t e r ru p t  INCB0504 6 5  u n t i l  th e  t ox i c i ty  h a s  r e s o lv ed .  
S t ep  2 :  R e s t a r t  INCB05046 5  a t  n ex t  l ow e r  do s e .   Mon i t o r  a s  
c l i n i c a l ly  in d i c a t ed .  
•  Ex f o l i a t i v e  d e rm a t i t i s  (≥ G r ad e  2 ) P e rm an en t ly  d i s con t in u e  INCB050 465 . 
•  In t e s t in a l  p e r f o r a t i on  ( any  g r ad e )  P e rm an en t ly  d i s con t in u e  INCB050 465 . 
•  Pn eumo c y s t i s  j i r o v e c i pn eum on i a i n f e c t i on  In t e r ru p t  INCB050465 .   P e rm an en t ly  d i s con t in u e  INCB050 465  i f  Pn eumo c y st i s  j i r o v e c i  pn eum on i a i n f e c t i on  i s  con f i rm ed .  
•  CMV  in f e c t i on S u b j e c t s  w i t h  CMV  v i r em i a  w i t h ou t  a s s o c i a t ed  c l in i c a l  s ign s  o f  CMV  in f e c t i on  sh ou l d  b e  c a r e f u l ly  m on i t o r ed .   C on s i d e r  i n t e r ru p t in g  INCB05046 5  f o r  s u b j e c t s  w i t h  CMV  v i r em i a  and  c l i n i c a l  s i gn s  o f  i n f e c t i on  un t i l  t h e  i n f e c t i on  h a s  r e s o l v ed .   R e s t a r t  INCB0504 65  r e du c ed  by  1  do s e  l ev e l  i f  app rov ed  by  th e  m ed i c a l  
m on i t o r . 
•  V a r i c e l l a  zo s t e r  i n f e c t i on In t e r ru p t  INCB050465 .   R e s t a r t  INCB0504 65  on ly  by  app rov a l  o f  
t h e  m ed i c a l  m on i t o r .  
•  Any  G r ad e  1  o r  G r ad e 2  t ox i c i ty  un l e s s  
o t h e rw i s e  s p e c i f i ed.  C on t inu e  s tu dy  t r e a tm en t  an d  t r e a t  t h e  t ox i c i ty ;  m on i t o r  a s  c l i n i c a l ly  in d i c a t ed .  
•  Any  G r ad e  3  t ox i c i ty ,  i f  c l i n i c a l ly  
s i gn i f i c an t  an d  n o t  m an ag e ab l e  by  s u ppo r t i v e  c a r e  un l e s s  o t h e rw i s e  s p e c i f i ed .  S t ep  1 :  In t e r ru p t  INCB0504 6 5  u p  t o  14  d ay s  u n t i l  th e  t ox i c i ty  h a s  r e s o l v ed  t o  ≤  G r ad e  1 .  
S t ep  2 :  R e s t a r t  INCB05046 5  a t  s am e  do s e .   I f  a s s e s s ed  a s  r e l a t ed  
t o  INCB050 465 ,  r e s t a r t  a t  n ex t  l ow e r  do s e .   I f  i n t e r ru p t ed  f o r  >  14 d ay s ,  con t a c t  th e  m ed i c a l  m on i t o r  f o r  app rov a l  t o  r e s t a r t  
INCB 0504 65.   M on i t o r  a s  c l i n i c a l ly  in d i c a t ed.  
•  Any  r e cu r r en t  G r ad e  3  t ox i c i ty  a f t e r  2 do s e  
r edu c t i on s .  D i s con t inu e  s tu dy  d rug  adm in i s t r a t i on  an d  f o l l ow- u p  p e r  P r o t o co l .   Ex c ep t i on s  r equ i r e  app rov a l  o f  s pon s o r . 
•  Any  o th e r  G r ad e  4  t ox i c i ty . D i s con t inu e  s tu dy  d rug  adm in i s t r a t i on  an d  f o l l ow - u p  p e r  P r o t o co l .   
Ex c ep t i on s  r equ i r e  app rov a l  o f  s pon s o r . 
CMV  =  c y tom eg a lov i r u s ;  IV  =  i n t r a v e nou s ;  PCR  =  po lym e r a s e  c h a in  r e a c t ion .  
Tab l e  3 :  D o s e  L e v e l s  fo r  INCB0 5 0 4 6 5  
T im ep o in t D o s e   
S t ar t i n g  d o s e  2 0  m g  o n c e  d a i ly  fo r  8  w e e k s  
W e ek  9 ,  D ay  1 2 0  m g  o n c e  w e ek ly  
F i r s t  d o s e  r ed u c t i o n  1 0  m g  o n c e  w e ek ly  
S e co n d  d o s e  r ed u c t io n 5  m g  o n c e  w e ek ly  
N o t e  th a t  th e  f i r s t  d o s e  r ed u c t io n  i s  a p p l i c a b l e  f o r  su b j e c t  r e c e iv in g  e i th e r  20  mg  QD o r  2 0  mg  
o n c e  w e e k ly .  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  31 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
5 . 4 . 2 .  Suppo r t iv e  C a r e  Gu id e l in e s  fo r D ia r rh e a /C o l i t i s 
Su b j e c t s  sh o u ld  b e  in f o rm e d  to  imm e d i a t e ly  r e p o r t  to  th e  in v e s t ig a to r  a ny  e v e n t  o f  d i a r r h e a .   
Su b j e c t s  sh o u ld  r e c e iv e  ap p r o p r i a t e  su p p o r t iv e  c a r e  m e a su r e s  a s  d e em e d  n e c e s s a ry  by  th e  
in v e s t ig a to r .   F o r  a ny  G r a d e  ≥  1  d i a r r h e a ,  su b j e c t s  sh o u ld  b e  a d v i s e d  to  d r in k  l ib e r a l  q u a n t i t i e s  o f  
c l e a r  f lu id s .   I f  su f f i c i e n t  o r a l  f lu id  in t a k e  i s  n o t  f e a s ib l e ,  f lu id  a n d  e l e c t r o ly t e s  sh o u ld  b e  su b s t i tu t e d  v i a  IV  in f u s ion .   Su b j e c t s  sh o u ld  t ry  to  e a t :  5  to  6  sm a l l  m e a l s  p e r  d ay ;  low - f a t ,  
h ig h - p r o t e in  f o o d s ;  a n d  co o k e d  in s t e a d  o f  r aw  v eg e t a b l e s .   Su b j e c t s  m ay  sup p l em e n t  th e i r  d i e t  
w i th  b a n a n a s ,  r i c e ,  a p p l e s a u c e ,  a n d  to a s t  to  r e d u c e  th e  n umb e r  o f  b ow e l  mo v em e n t s ,  a n d  m ay  a l so  t ry  c r a c k e r s ,  g e l a t in ,  n o o d l e s ,  o r  o a tm e a l .   Sub j e c t s  sh o u ld  a v o id  f r i e d ,  f a t ty ,  g r e a sy ,  o r  sp i cy  
f o o d s ;  m i lk ,  m i lk  p r o d u c t s ,  a n d  a c id i c  d r in k s ;  h ig h - f ib e r  f o o d s  a n d  f o o d s  th a t  c a u s e  g a s ;  a n d  
a l c o h o l ,  c a f f e in e ,  a n d  h e rb a l  su p p l em e n t s  ( Co u t r e  e t  a l  2 0 1 5 ) .  
F o r  e a c h  o c c u r r e n c e ,  a t t emp t s  sh o u ld  b e  m a d e  to  r u l e  o u t  o th e r  c a u s e s ,  su ch  a s  m e t a s t a t i c  d i s e a s e  
o r  b a c t e r i a l  o r  v i r a l  in f e c t io n  ( in c lu d in g  CMV ),  w h i c h  m ig h t  r e q u i r e  a d d i t io n a l  su p p o r t iv e  c a r e .  
I t  m ay  b e  n e c e s s a ry  to  p e r f o rm  c o n d i t io n a l  p r o c e du r e s  su c h  a s  c o lo n o s c o py  w i th  b io p sy  a s  p a r t  
o f  e v a lu a t io n  o f  th e  e v e n t .   N o t e  th a t  s e v e r a l  c o u r s e s  o f  s t e r o id  t a p e r in g  m ay  b e  n e c e s s a ry  a s  
symp tom s  m ay  w o r s e n  wh e n  th e  s t e r o id  d o s e  i s  d e c r e a s e d .  
Su b j e c t s  sh o u ld  b e  c a r e fu l ly  mo n i to r e d  f o r  s ig n s  a n d  symp tom s  o f  e n t e r o co l i t i s  ( su c h  a s  d i a r r h e a ,  
a b d om in a l  p a in  o r  c r amp in g ,  b lo o d  o r  mu c u s  in  s to o l ,  w i th  o r  w i th o u t  f e v e r )  a n d  o f  b ow e l  
p e r f o r a t io n  ( su c h  a s  p e r i to n e a l  s ig n s  a n d  i l e u s ) .  
5 . 4 . 3 .  D e f in i t ion fo r  Immun e - R e la t ed  Adv e r s e  Ev en t s 
A d v e r s e  e v e n t s  o f  a  p o t en t i a l  immu n o lo g i c  e t io lo gy ,  o r  immu n e - r e l a t e d  AE s  ( i rAE s ) ,  m ay  b e  
d e f in e d  a s  a n  AE  c o n s i s t e n t  w i th  a n  immu n e  p h e nom e n o n  a s so c i a t e d  w i th  s tu dy  d r ug  e xp o su r e  
a f t e r  a l l  o th e r  e t io lo g i e s  h a v e  b e e n  e l im in a t e d .   Immu n e - r e l a t e d  AE s  m ay  b e  e xp e c t e d  b a s e d  o n  
p r e v io u s  e xp e r i e n c e  w i th  INCB 0 5 0 4 6 5  a n d  o th e r  d r u g s  ( eg ,  id e l a l i s ib )  th a t  in h ib i t  P I 3K δ .   Sp e c i a l  a t t e n t io n  sh o u ld  b e  p a id  to  AE s  th a t  m ay  b e  su g g e s t iv e  o f  p o t e n t i a l  i rAE s .   B a s e d  o n  
em e rg ing  d a t a  f r om  th e  on g o ing  S tu dy  INCB  5 0 46 5 - 1 0 1 ,  mo s t  i rAE s  o c c u r  a f t e r  th e  f i r s t  
9  w e e k s  o f  s tu dy  d r ug  a dm in i s t r a t io n .   H ow e v e r ,  an  i rAE  c o u ld  o c c u r  a t  a ny  t im e .   Su sp e c t e d  i rAE s  sh o u ld  b e  d i s c u s s ed  w i th  th e  m e d i c a l  mo n i to r  w h e n  p o s s ib l e .  
Su b j e c t s  sh o u ld  r e c e iv e  ap p r o p r i a t e  su p p o r t iv e  c a r e  m e a su r e s  a s  d e em e d  n e c e s s a ry  by  th e  
t r e a t in g  in v e s t ig a to r .   Su g g e s t e d  su p p o r t iv e  c a r e  m e a su r e s  f o r  th e  m a n ag em e n t  o f  d r ug - r e l a t e d  AE s  w i th  p o t e n t i a l  immu n o lo g i c  e t io logy  a r e  o u t l in e d  in  T a b l e 2  a n d  S e c t io n 5 . 4 . 2 .   F o r  e a c h  
AE ,  a t t emp t s  sh o u ld  b e  m a d e  to  r u l e  o u t  o th e r  c au s e s ,  in c lu d in g  b u t  n o t  l im i t e d  to  m e t a s t a t i c  
d i s e a s e  o r  b a c t e r i a l  o r  v i r a l  in f e c t io n ,  w h i c h  m ig h t  r e q u i r e  sp e c i f i c  su p p o r t iv e  c a r e .  
5 . 5 .  S tud y  T r e a tm en t  D i s c on t inu a t i on 
T h e  d e c i s io n  to  d i s c o n t in u e  s tu dy  t r e a tm e n t  w i l l  n o t  c o n s t i tu t e  s tu dy  c omp l e t io n .   I n  th e  e v e n t  
th a t  s tu dy  t r e a tm e n t  i s  d i s c o n t in u e d ,  th e  t r e a tm e n t  p h a s e  w i l l  b e  c o n s id e r e d  c omp l e t e ,  a n d  th e  
f o l low - u p  p h a s e s  w i l l  b eg in.  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  32 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
5 . 5 . 1 .  C r i t e r ia  fo r  S tudy  T r e a tm en t D i s c on t inua t ion  
Su b j e c t s  mu s t p e rm a n e n t ly  d i s c o n t in u e  s tu dy  t r e a tm e n t  f o r  a ny  1  th e  f o l low in g :  
•  T h e  su b j e c t  h a s  e xp e r i e n c e d  a n  u n a c c e p t a b l e  to x i c i ty d e f in e d  a s  f o l low s :  
− O c c u r r e n c e  o f  a n  AE  th a t  i s  r e l a t e d  to  t r e a tm e n t  w i th  th e  s tu dy  d r ug  th a t,  in  th e  
ju d gm e n t  o f  th e  in v e s t ig a to r  o r  th e  sp o n so r ' s  m e d i c a l  mo n i to r ,  c omp r om i s e s  th e  
su b j e c t ' s  a b i l i ty  to  c o n t inu e  s tu dy - sp e c i f i c  p r o c e du r e s  o r  i s  c o n s id e r e d  to  no t  b e  in  
th e  su b j e c t ' s  b e s t  in t e r e s t .  
− P e r s i s t e n t  AE  r e q u i r ing  a  d e l ay  o f  th e r a py  f o r  mo r e  th a n  2  w e e k s  ( 1 4  d ay s )  u n l e s s  
a  g r e a t e r  d e l ay  h a s  b e e n  a p p r o v e d  by  th e  sp o n so r .   
•  T h e  su b j e c t  i s  u n a b l e  to  to l e r a t e  INCB 0 5 0 4 6 5 .  
•  T h e  su b j e c t  h a s  a n  o b j e c t iv e  r a d iog r a p h i c  tumo r  r e sp o n s e  o f  PD/PMD .  
•  F u r th e r  p a r t i c ip a t io n  w o u ld  b e  in ju r io u s  to  th e  su b j e c t 's  h e a l th  o r  w e l l - b e ing ,  in  th e  
in v e s t ig a to r ' s  m e d i c a l  ju d gm e n t .  
•  T h e  su b j e c t  b e c om e s  p r eg n a n t .  
•  I n f o rm e d  c o n s e n t  i s  w i th d r aw n .   N o t e :   I n f o rm e d  co n s e n t  w i th d r aw n  m e a n s  th a t  th e  
su b j e c t  c a n  n o  lo ng e r  r e c e iv e  s tu dy  t r e a tm e n t  and  c a n  n o  lo ng e r  b e  f o l low ed .    
•  T h e  s tu dy  i s  t e rm in a t e d  by  th e  sp o n so r .  •  T h e  s tu dy  i s  t e rm in a t e d  by  th e  lo c a l  h e a l th  a u th o r i ty ,  IRB ,  o r  IEC .  
A  su b j e c t m a y  b e  d i s c o n t in u e d  f r om s tu dy  t r e a tm en t  in  th e  f o l low in g  s i tu a t io n s :   
•  I f  a  su b j e c t  i s  f o u n d  n o t  to  h a v e  m e t  e l ig ib i l i ty  c r i t e r i a ,  th e n  th e  m e d i c a l  mon i to r  a n d  
in v e s t ig a to r  w i l l  c o l l a b o r a t e  to  d e t e rm in e  w h e th e r  th e  su b j e c t  sh o u ld  b e  w i th d r aw n  
f r om  th e  s tu dy .   (N o t e :   N o t  a p p l i c a b l e  in  C a n a d a . ) 
•  I f  a  su b j e c t  i s  n o n c omp l i a n t  w i th  s tu dy  p r o c e d u r e s  o r  s tu dy  d r ug  a dm in i s t r a t io n  in  th e  
in v e s t ig a to r ' s  o p in io n ,  th e n  th e  sp o n so r  sh o u ld  b e  c o n su l t e d  f o r  in s t r u c t io n  o n  h a n d l in g  th e  su b j e c t .  
5 . 5 . 2 .  P r o c edu r e s fo r  S tudy  T r e a tm en t  D i s c on t inua t ion  
I f  a  sub j e c t  d i s c on t inu e s  s tudy  t r e a tm en t ,  th en  th e  fo l low ing  shou ld  o c cu r :  
•  T h e  r e a so n ( s )  f o r  d i s c o n t in u a t io n  mu s t  b e  d o c um e n t e d  in  th e  su b j e c t ' s  m e d i c a l  r e c o r d  
a n d  in  th e  e CRF . 
•  Th e  e n d - o f - t r e a tm e n t  ( EOT)  v i s i t  sh o u ld  b e  p e r f o rm e d .  
•  I f  th e  EOT  v i s i t  c o in c id e s  w i th  a  r eg u l a r  s tu dy  v i s i t ,  th e n  th e  EOT  e v a lu a t io n s  w i l l  
su p e r s e d e  th o s e  o f  th a t  s ch e d u l e d  v i s i t ,  a n d  th e  d a t a  w i l l b e  e n t e r e d  in  th e  EOT  v i s i t  
in  th e  e CRF.  
•  T h e  d a t e  o f  th e  EOT  v i s i t  sh o u ld  b e  r e c o r d e d  in  th e  IW RS . 
•  Su bj e c t s  mu s t  b e  f o l low e d  f o r  s a f e ty  f o r  n o  l e s s  th a n  3 0  d ay s  a f t e r  th e  EOT  v i s i t  o r  
u n t i l  s tu dy  d r ug – r e l a t e d  to x i c i t i e s  r e so lv e ,  r e tu r n  to  b a s e l in e ,  o r  a r e  d e em e d  
i r r e v e r s ib l e ,  w h i c h e v e r  i s  lo n g e s t .  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  33 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
I f  a  su b j e c t  a c t iv e ly  w i thd r aw s  f r om  s tu dy  t r e a tm e n t ,  th e n  th e  su b j e c t  w i l l  c o n t in u e  in  th e  s a f e ty  
a n d  su r v iv a l  f o l low - u p  p e r io d s  o f  th e  s tu dy .   T h e  s tu dy  mo n i to r  o r  sp o n so r  mu s t  b e  n o t i f i e d  i f  a  su b j e c t  a c t iv e ly  w i th d r aw s  f r om  s tu dy  t r e a tm e n t  o r  w i th d r aw s  th e  in f o rm ed  c o n s e n t .   I f  a  su b j e c t  
w i th d r aw s  in f o rm e d  c o ns e n t ,  th e n  th e  su b j e c t  w i l l  h a v e  c omp l e t e d  th e  s tu dy ,  a n d  n o  a d d i t io n a l  d a t a  c o l l e c t io n  sh o u ld  o c c u r .  
5 . 6 .  C on c om i t an t  M ed i c a t i on s 
A l l  c o n c om i t a n t  m e d i c a t io n s  a n d  t r e a tm e n t s  mu s t  b e  r e c o r d e d  in  th e  e CRF .   A ny  p r io r  m e d i c a t io n  r e c e iv e d  u p  to  3 0  d ay s  b e f o r e  th e  d a t e  o f  s tu dy  d r ug  a dm in i s t r a t io n  (D ay  1 )  w i l l  b e  r e c o r d e d  in  th e  e CRF .   Co n c om i t a n t  t r e a tm e n t s  a nd /o r  p r o c e d u r e s  th a t  a r e  r e q u i r e d  to  m a n ag e  a  
su b j e c t ' s  m e d i c a l  c o n d i t io n  d u r in g  th e  s tu dy  w i l l  a l so  b e  r e c o r d e d  in  th e  e CRF . 
5 . 6 . 1 .  Pn eumo c y s t i s  J i ro v e c i i P r ophy la x i s   
A l l  su b j e c t s  a r e  r e q u i r e d  to  r e c e iv e  a  s t a n d a r d  P JP  p r o p hy l a x i s  r eg im e n  d e t e rm in e d  by  th e  
in v e s t ig a to r .   E x amp l e s  o f  s t a n d a r d  P JP  p r o p hy l a x i s  th e r a p i e s  f o r  th i s  p o p u l a t io n  in c lu d e  
t r im e th o p r im - su l f am e th o x a zo l e ,  a to v a q u o n e ,  d a p so n e  w i th  o r  w i th o u t  py r im e th am in e ,  a n d  
p e n t am id in e  ( NCCN 2 0 1 6 ) .   D u e  to  r e p o r t s  o f  c r o s s- s e n s i t iv i ty  b e tw e e n  su l f o n am id e s  a n d  d a p so n e ,  a l l  su b j e c t s  w h o  h a v e  a  k n ow n  o r  su sp e c t e d  a l l e rgy  to  su l f o n am id e s  mu s t  r e c e iv e  e i th e r  
in h a l e d  p e n t am id in e  o r  a to v a q u o n e  f o r  P JP  p r o p hy l a x i s .   P r o p hy l a x i s  sh o u l d  b e  g iv e n  w h i l e  
su b j e c t s  a r e  r e c e iv in g  s tudy  t r e a tm e n t  a n d  sh o u ld  c o n t in u e  f o r  2  to  6  mo n th s  a f t e r  th e  l a s t  d o s e  o f  s tu dy  t r e a tm e n t .  
5 . 6 . 2 .  Suppo r t iv e  C a r e  M e a su r e s 
Su p p o r t iv e  c a r e  sh o u ld  b e  a dm in i s t e r e d  to  su b j e c t s  a s  p e r  th e  in s t i tu t io n a l  p o l i cy  a t  th e  s i t e  f o r  
th e  s t a n d a r d  th e r a py  th a t  th e  su b j e c t  w i l l  r e c e iv e .   A d d i t io n a l  in f o rm a t io n  m ay  b e  a v a i l a b l e  in  th e  a p p r o p r i a t e  p a c k ag e  in s e r t s .   T h i s  in c lu d e s  th e  u s e  o f  p r o p hy l a c t i c  g r ow th  f a c to r s,  w h i c h  sh o u ld  
b e  b a s e d  o n  Am e r i c a n  So c i e ty  o f  C l in i c a l  O n c o log y  g u id e l in e s  f o r  th e  u s e  o f  w h i t e  b lo o d  c e l l  
g r ow th  f a c to r s  ( Sm i th e t  a l  2 0 0 6 )  a n d  th e  in v e s t ig a to r ' s  c l in i c a l  ju dgm e n t .  
5 . 6 . 3 .  R e s t r i c t ed  M ed i c a t ion s 
•  U s e  o f  sy s t em i c  c o r t i c o s t e r o id  d o s e s  ≤  1 0  mg /d ay  p r e d n i so n e  ( o r  e q u iv a l e n t )  i s  
p e rm i t t e d  b u t  d i s c o u r ag ed  f r om  th e  s c r e e n ing  v i s i t  th r o u g h  th e  EOT  v i s i t .  
•  U s e  o f  w e a k  o r  mo d e r a t e  in d u c e r s  o r  in h ib i to r s  o f  CYP3A 4  (A p p e n d ix  B)  i s  
d i s c o u r ag e d ,  a n d  in v e s t ig a to r s  sh o u ld  s e e k  o th e r  op t io n s  w h e r e  p o s s ib l e .  
•  P - g ly c o p r o t e in  su b s t r a t e s  o f  c l in i c a l  r e l e v a n c e  sh ou ld  b e  u s e d  w i th  c a u t io n  (i e ,  
a l i sk i r e n ,  amb r i s e n t a n ,  co l c h i c in e ,  d a b ig a t r a n  e t ex i l a t e ,  d ig o x in ,  e v e r o l im u s ,  
f e xo f e n a d in e ,  im a t in ib ,  l a p a t in ib ,  m a r a v i r o c ,  n i lo t in ib ,  p o s a c o n a zo l e ,  r a n o l a z in e ,  
s a x a g l ip t in ,  s i r o l imu s ,  s i t a g l ip t in ,  t a l in o lo l ,  to lv a p t a n ,  to p o t e c a n ) .  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  34 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
5 . 6 . 4 .  P r oh ib i t ed  M ed i c a t ion s and  Th e r ap i e s  
•  U s e  o f  p o t e n t  in d u c e r s  a nd  in h ib i to r s  o f  CYP3A 4  a r e  p r o h ib i t e d  (A p p e n d ix  B) .   
B a s e d  on  th e  low  o v e r a l l  b io a v a i l a b i l i ty  o f  to p i c a l  k e to c o n a zo l e ,  th e r e  a r e  no  
r e s t r i c t io n s  o n  to p i c a l  k e to c o n a zo l e .  
•  U s e  o f  a ny  a n t i c a n c e r  m ed i c a t io n s  o th e r  th a n  th e  s tu dy  m e d i c a t io n  a s  d e s c r ib e d  ( s e e  
S e c t io n 3 . 2 )  th r o u g h  th e  3 0 - d ay  f o l low - u p  i s  p r o h ib i t e d .  
•  U s e  o f  sy s t em i c  c o r t i c o s t e r o id  d o s e s  >  1 0  mg /d ay  p r e d n i so n e  ( o r  e q u iv a l e n t )  i s  n o t  
p e rm i t t e d  f r om  th e  s c r e en in g  v i s i t  th r o u g h  th e  EOT  v i s i t .  
•  R a d i a t io n  th e r a py.  
6 .  STUDY  ASSESSMENTS 
S e e th e  s c h e d u l e  o f  a s s e s sm e n t s  ( Ta b l e  4 )  a n d  s c h e d u l e  o f  l a b o r a to ry  a s s e s sm e n t s  ( T a b l e 5 )  f o r  th e  t im in g  o f  a l l  a s s e s sm e n t s .   A l l  a s s e s sm e n t s  m a n d a t e d  th r o ug h o u t  th e  s tu dy  mu s t  b e  p e r f o rm e d  o n  a  c a l e n d a r  s c h e d u l e ;  d e l ay s  in  t r e a tm e n t  a dm in i s t r a t io n  w i l l  n o t  d e l ay  p e r f o rm a n c e  
o f  a s s e s sm e n t s .   A  t a b l e  o f  c l in i c a l  l a b o r a to ry  a n a ly t e s  to  b e  a s s e s s e d  (T a b l e 8 )  i s  p r o v id e d .   T h e  
o r d e r  o f  a s s e s sm e n t s  i s  su g g e s t e d  by  th e  o r d e r  l i s te d  w i th in  th e  S c h e d u l e  o f  A s s e s sm e n t s.   S e e  S e c t io ns  6  a n d  7  f o r  in s t ru c t io n s  o n  e a c h  a s s e s sm en t .   F u r th e r  d e t a i l s  o f  s tu dy  p r o c e d u r e s  a n d  
a s s e s sm e n t s  c a n  b e  f o u nd  in  t h e  s tu dy  r e f e r e n c e  m a n u a l .  
N o t e :   Upon  imp l em en ta t ion  o f  P r o t o c o l  Am endm en t  4,  on ly  s tudy  a s s e s sm en t s  ind i c a t ed  in  
Tab l e  6 and  Tab l e  7 w i l l  b e  p e r fo rm ed . 
 
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  35 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
Tab l e  4 :  S ch edu l e  o f A s s e s sm en t s 
N o t e :   Upon  imp l em en ta t ion o f  P r o t o c o l  Am endm en t  4 ,  on ly  th e  s ch edu l e s  o f  a s s e s sm en t s  in  Tab l e  6 and  Tab l e 7  shou ld  b e  
fo l lo w ed . 
P ro c edu r e S e c t i on S c r e enin g  T r ea tm en t 
EOT S a f e ty  
Fo l l ow- Up D i s ea s e  
Fo l l ow- Up Su rv i va l  
Fo l l ow- Up 
Day 
- 28  t o  - 1  Day  1 Day  15  
(±  3  Da y s ) E v e ry  
3  W e ek s 
(±  3  Da y s ) E v e ry 
12 W e ek s  
(±  3  Da y s ) EOT  + 
30- 3 5  Day s   E v e ry  
12 W e ek s  
(±  1 We ek )  
In f o rm ed  c on s en t 7 .1  X         
C on t a c t  IWRS 7 .2  X X  X  X    
In c l u s i on  &  e x c lu s i on  c r i t e r i a  3 .1  
3 .2  X  X         
D em og r aphy  an d  med i c a l  hi s to ry  7 .3 .1  X         
P r i o r /c on com i t an t  med i c a t i on s  7 .3 .1 . 1  X X X X  X X   
C om p r eh en s iv e phy s i c a l  ex am   7 .4 .2  Xa     X    
D i s e a s e- s p e c i f i c  phy s i c a l  e x am 7 .4 .2 . 1   X X X   X   
V i t a l  s ig n s  7 .4 .3  X X X X  X X   
12- l e ad  ECG 7 .4 .4  X X X  X X X   
ECOG  s t a tu s  7 .5 .6  X X  X  X X   
AE  a s s e s sm en t 7 .4 .1  X X X X  X X   
FDG- PET /CT  s c an  7 .5 .1  
7 .5 .2  X  Ev e ry  9  w e ek s  ( ±  1  w e ek)  th rou gh  W e ek  27 ,  
t h en  ev e ry  18  w e ek s  ( ±  1  w e ek)  t h e r e a f t e r .b     
Bon e  m a r row  ex am 7 .5 .3  Xc         
S t u dy  drug  di s p en s in g  5 .1   X  Xd      
S t u dy  drug  a c coun t ab i l i ty  5 .3   X  X  X    INCB0504 65  adm i n i s t r a t i on  5 .2 .1   X X X      
D i s e a s e  f o l l ow- u p 6 .4 .2         Xe  
S u rv i v a l  f o l l ow- u p 6 .4 .3          Xf 
FDG  =  f luo r od e ox y g lu c o s e ;  PET  =  po s i t r on  em i s s ion  t om og r a phy . 
a H e ig h t r e qu i r e d  a t  s c r e e n ing  on ly .  
b I f  th e  PET - CT  i s  o f  d i a g no s t i c  q u a l i ty ,  th e n  a  s e p a r a t e  CT  do e s  no t  n e e d  to  b e  p e r f o rm e d .   I f  CT  i s  no t  a v a i l a b l e ,  i s  no t  p r a c t i c a b l e ,  o r  i s  c on t r a in d i c a t e d ,  t h e n  an  MR I  m ay  b e  
s ub s t i t u t e d .   Ev e r y  e f f o r t  m u s t  b e  m a d e  to  u s e  t h e  s am e  m od a l i ty  f o r  d i s e a s e  a s s e s sm e n t  th r o ug ho u t  t h e  s tudy  f o r  e a c h  ind iv id u a l  s u b j e c t . 
c R e qu i r e d  a t  b a s e l in e  e x c e p t  f o r  r e a s on s  p rov id e d  i n  S e c t i on 7 . 5 .3 .   A l s o  r e qu i r e d  i f  n e e d e d  t o  c o n f i rm  CR /CMR .  
d S tudy  d r ug  w i l l  b e  d i s p e n s e d  a t  W e ek s  1 ,  4 ,  7 ,  a n d  10 ,  a nd  e v e ry  12  w e e k s  th e r e af t e r .  
e O n ly  f o r  s ub j e c t s  w ho  d i s c o n t i nu e  s tudy  t r e a tm e n t  f o r  r e a s on s  o th e r  th a n  d i s e a s e  p r og r e s s ion . 
f M a y  b e  c ondu c t e d  by  phon e  o r  em a i l . 
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  36 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
Tab l e  5 :  S ch edu l e  o f  Labo r a t o r y  A s s e s sm en t s 
N o t e :   Upon  imp l em en ta t ion o f  P r o t o c o l  Am endm en t  4 ,  on ly  th e  s ch edu l e s  o f  a s s e s sm en t s  in  Tab l e  6 and  Tab l e 7  shou ld  b e  
fo l low ed .  
L ab o ra to ry  T e s t s S e c t i on S c r e en in g T r ea tm en t 
EOT S a f e ty  
Fo l l ow- Up 
Day 
- 28  t o  - 1  Day  1 Day  15 
(±  3  Da y s )  E v e ry  3 W e ek s 
(±  3  Da y s )  O th e r EOT  + 
30- 3 5  Day s  
S e rum  c h em i s t r i e s 7 .4 .5 . 1  X Xa X X  X X 
H em a t o l ogy 7 .4 .5 . 1  X Xa X X  X X 
S e ro l ogy 7 .4 .5 . 3  X    Xb   
S e rum  pr eg n an cy   7 .4 .5 . 2  Xc     X  
U r i n e  p r eg n an cy   7 .4 .5 . 2     Xd    
H IV  t e s t in g 7 .4 .5 . 4  Xe       
a D ay  1  t e s t s  m ay  b e  om i t t e d  i f  th e  s c r e e n ing  t e s t s  o c c u r r e d  in  th e  p r e c e d ing  7  d a y s .   I f  n e e d e d ,  D a y  1  b lo od  d r aw s  s hou ld  b e  p e r f o rm e d  b e f o r e  do s e  a dm in i s t r a t ion . 
b S am p l e s  f o r  CMV  DNA  a n a ly s i s  on ly  w i l l  b e  c o l l e c t e d  e v e ry  3  w e e k s  f o r  10  w e e k s  (D ay  1  o f  W e ek s  4 ,  7 ,  a n d  1 0 )  a n d  t h e n  e v e r y  12  w e e k s  th e r e a f t e r . 
c O n ly  f o r  f em a l e  s ub j e c t s  o f  c h i ld b e a r ing  po t e n t i a l ;  n e g a t iv e  p r e g n an c y  t e s t  m u s t  b e  ob t a in e d  w i th in  14  d a y s  b e f o r e  a dm in i s t r a t ion  o f  s tudy  d r ug .  
d O n ly  f o r  f em a l e s  o f  c h i ldb e a r ing  po t e n t i a l . 
e O p t io n a l  f o r  s ub j e c t s  e n r o l l e d  in  t h e  U n i t e d  S t a t e s . 
 
  
  
  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  37 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
Tab l e  6 :  S ch edu l e  o f  A s s e s smen t s  fo r  Ong o ing  Sub j e c t s  in  A l l  C oho r t s  Upon  Imp l em en t a t ion  o f  P r o t o co l  Am endm en t  4  
P r o c edu r e S e c t ion A t  L e a s t  E v e r y  12 W e ek s  
in  C l in i ca EOT Fo l low- Up 
N o t e s EOT  +  30- 35  D a y s 
P r i o r / c o n c om i t a n t  m e d i c a t ion s 7 .3 .1 . 1 X  X  X  R e v i ew  to  e n s u r e  n o  p r oh i b i t e d  m e d i c a t ion s  a r e  
b e ing  u s e d .   P r ov id e  d a t a  t o  s p on s o r  in  r e g a r d  to  SAE s  on ly . 
S tudy  d r ug  d i s p e n s i ng 
5 .1 X     
S tudy  d r ug  a c cou n t a b i l i ty  5 .3 X  X    
D i s t r ibu t e  r em ind e r s 7 .8 .2  X  X    
L a bo r a to r y  t e s t s T ab l e 7   X  X  X  P e r f o rm e d  a t  e a c h  s i t e  a s  p e r  s t a nd a r d  o f  c a r e  a nd  m on i to r e d  p e r  inv e s t ig a to r  d i s c r e t ion . 
AE s /SAE s 
7 .4 .1 X  X  X  AE s  th a t  l e a d  to  t h e  d i s c o n t i nu a t i on  o f  s tudy  
t r e a tm e n t  a nd  a l l  SAE s  m u s t  b e  r e c o r d e d  i n  th e  
CRF s ,  r e g a r d l e s s  o f  th e  c a u s a l  r e l a t ion s h i p . 
FDG- PET /CT  s c a n 7 .5 .1  
7 .5 .2    P e r f o rm e d  p e r  s t a nd a r d- o f - c a r e  gu id e l i n e s .  
a I n f o rm a t ion  r e l a t e d  t o  c o n c om i t a n t  m e d i c a t ion s  a nd  a dv e r s e  e v e n t s  m ay  a l s o  b e  c o l l e c t e d  b e tw e e n  th e  r e qu i r e d  c l i n i c  v i s i t s  ( e g ,  by  phon e  o r  em a i l ) .  
Tab l e  7 :  S ch edu l e  o f  Labo r a t o r y  A s s e s sm en t s  fo r  Ong o ing  Sub j e c t s  in  A l l  C oho r t s  Upon  Imp l em en t a t ion o f  P r o t o c o l  
Am endm en t 4  
L o c a l  L abo r a to r y  T e s t s S e c t ion At  L e a s t  E v e r y  12  W e ek s  
in  C l in i c EOT Fo l low- Up 
D e t a i l s EOT  + 30- 35  D a y s 
S e r um  c h em i s t r i e s N /A X  X  X  P e r f o rm e d  a t  e a c h  s i t e  a s  p e r  s t a nd a r d  o f  c a r e  a nd  
m on i to re d  p e r  inv e s t ig a to r  d i s c r e t ion.  
Hem a to logy  N /A X  X  X  P e r f o rm e d  a t  e a c h  s i t e  a s  p e r  s t a nd a r d  o f  c a r e  a nd  m on i to re d  p e r  inv e s t ig a to r  d i s c r e t ion.  
 
 
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  38 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
Tab l e  8 :  Labo r a t o r y  T e s t s :   R equ i r ed  Ana ly t e s ( N o t  App l i c ab l e  A f t e r  Imp l em en t a t ion  
o f  P r o t o c o l  Am endm ent  4 )  
S e rum  Ch em i s t r i e s H em a to l ogy S e ro l ogy O th e r 
A l bum i n 
A lk a l in e  Ph o s ph a t a s e 
ALT 
AST 
B i c a rbon a t e 
B l ood  u r e a  n i t rog en  
C -r e a c t iv e  p ro t e i n  
C a l c ium 
C h l o r i d e 
C r e a t i n in e 
G l u co s e 
L a c t a t e  d ehy d rog en a s e 
Ph o s ph a t e  
Po t a s s i um  
S od i um  To t a l  b i l i ru b i n 
D i r e c t  b i l i ru bi n
a 
In d i r e c t  b i l i ru b i na 
To t a l  s e rum  pro t e i n  
To t a l  c h o l e s t e ro l  H em og l ob in H em a t o c r i t 
P l a t e l e t  cou n t  ( ab s o l u t e ) 
R ed  bl ood  c e l l  c ou n t  
Wh i t e  bl ood  c e l l  c ou n t  
D i f f e r en t i a l  c e l l  coun t :  
B a s oph i l s %  
Eo s i n oph i l s %  
Lym ph o cy t e s  ( ab s o l u t e ) 
Mon o cy t e s 
N eu t roph i l s  ( ab s o l u t e ) 
 HB sAg An t i- HB sAg 
An t i- HB  co r e  IgG HCV  an t i body 
HCV- RNA 
HBV- DNA CMV  DNA 
H IV  an t i body  
( imm un o a s s ay )
b P r egn ancy  T e s t  
F em a l e  s u b j e c t s  o f  
ch i l db e a r i ng  po t en t i a l  r equ i r e  s e rum  p r eg n an cy  an d  u r i n e  
p r eg n an cy  t e s t s  ( s e e  
T ab l e 5 ) .  
N o t e :   A dd i t i on a l  l a bo r a t o r y  t e s t s  m ay  b e  r e qu i r e d ,  a s  a g r e e d  by  inv e s t ig a to r  a nd  s p on s o r ,  b a s ed  o n  em e r g ing  s a f e ty  d a t a . 
a O n ly  r e qu i r e d  i f  to t a l  b i l i r u b i n  i s  >  ULN . 
b O p t io n a l  f o r  s ub j e c t s  e n r o l l e d  in  t h e  U n i t e d  S t a t e s .  
6 . 1 .  S c r e en in g 
Sc r e e n ing  i s  th e  in t e r v a l  b e tw e e n  s ig n ing  th e  ICF  a n d  th e  d a t e  th a t  th e  s tu dy  t r e a tm e n t  i s  f i r s t  
a dm in i s t e r e d  (D ay  1 ) .   S c r e e n ing  m ay  n o t  e x c e e d  2 8  d ay s .   A s s e s sme n t s  th a t  a r e  r e q u i r e d  to  
d emo n s t r a t e  e l ig ib i l i ty  m ay  b e  p e r f o rm e d  o v e r  th e  c o u r s e  o f  1  o r  mo r e  d ay s  d u r in g  th e  s c r e e n in g  
p r o c e s s.   C e n t r a l  l a b o r a to ry  r e su l t s  f o r  s e r um  c h em i s t ry ,  h em a to logy ,  s e r o lo gy ,  a n d  s e r um  p r eg n a n cy  w i l l  b e  u s e d  to  d e t e rm in e  e l ig ib i l i ty .   
P r o c e d u r e s c o n d u c t e d  a s  p a r t  o f  th e  su b j e c t ' s  r o u t in e  c l in i c a l  m a n ag em e n t  ( e g ,  im ag in g  s tu dy )  
a n d  o b t a in e d  b e f o r e  s ig n in g  o f  in f o rm e d  c o n s e n t  m ay  b e  u s e d  f o r  s c r e e n ing  o r  b a s e l in e  p u r p o s e s ,  p r o v id e d  th a t  th e  p r o c e du r e  m e e t s  th e  P ro to c o l - d e f in e d  c r i t e r i a  a n d  h a s  b e e n  p e r f o rm e d  in  th e  
s c r e e n ing  in t e r v a l .   A l l  in f o rm a t io n  a s so c i a t e d  w i th  e l ig ib i l i ty  r e q u i r em e n t s  mu s t  b e  e n t e r e d  in to  
th e  a p p r o p r i a t e  e CRF  p ag e s . 
R e su l t s  f r om  th e  s c r e e n ing  v i s i t  e v a lu a t io n s  w i l l  b e  r e v i ew e d  by  th e  in v e s t ig a to r  to  c o n f i rm  
su b j e c t  e l ig ib i l i ty  b e f o r e  e n r o l lm e n t  o r  th e  a dm in i s t r a t io n  o f  s tu dy  d r ug .   T e s t s  w i th  r e su l t s  th a t  
f a i l  e l ig ib i l i ty  r e q u i r em en t s  m ay  b e  r e p e a t e d  d u r in g  s c r e e n ing  i f  th e  i n v e s t ig a to r  b e l i e v e s  th e  r e su l t s  to  b e  in  e r r o r .   F o r  s c r e e n ing  a s s e s sm e n t s  th a t  a r e  r e p e a t e d ,  th e  mo s t  r e c e n t  a v a i l a b l e  
r e su l t  b e f o r e  a dm in i s t r a t io n  o f  s tu dy  d r ug  w i l l  b e  u s e d  to  d e t e rm in e  su b j e c t  e l ig ib i l i ty .   
A d d i t io n a l ly ,  a  su b j e c t  wh o  f a i l s  s c r e e n in g  m ay  r ep e a t  th e  s c r e e n ing  p r o c e s s  1  t im e  i f  th e  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  39 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
in v e s t ig a to r  b e l i e v e s th e r e  h a s  b e e n  a  c h a ng e  in  e l ig ib i l i ty  s t a tu s  ( eg ,  a f t e r  r e c o v e ry  f r om  a n  
in f e c t io n ) .   Su c h  su b j e c t s  w i l l  b e  a s s ig n e d  a  n ew  su b j e c t  ID  n umb e r .  
6 . 2 .  T r e a tm en t 
T h e  t r e a tm e n t  p e r io d  b eg in s  o n  th e  d ay  th a t  th e  sub j e c t  r e c e iv e s  th e  f i r s t  d o s e  o f  s tu dy  d r ug  ( D ay 1 ) .   T h i s  d ay  mu s t  b e  n o  mo r e  th a n  2 8  d ay s  a f t e r  th e  su b j e c t  h a s  s ig n e d  th e  ICF .   D a t e s  f o r  su b s e q u e n t  s tu dy  v i s i t s  w i l l  b e  d e t e rm in e d  b a s e d  on  th i s  d ay  a n d  sh o u ld  o c cu r  w i th in  th e  v i s i t  
w in d ow s  o u t l in e d  in  th e  s c h e d u l e  o f  a s s e s sm e n t s  (s e e  Ta b l e  4 )  u n l e s s  d e l ay ed  f o r  s a f e ty  r e a so n s .   
Su b j e c t s  m ay  r e c e iv e  t r e a tm e n t  u n t i l  d i s e a se  p r og r e s s io n ,  d e a th ,  u n a c c e p t ab l e  to x i c i ty ,  o r  c o n s e n t  w i th d r aw a l . 
6 . 3 .  End  o f  T r e a tm en t  
T h e r e  i s  n o  p r e d e f in e d  EOT.   I f  a  su b j e c t  p e rm a n en t ly  d i s c o n t in u e s  s tu dy  t r e a tm e n t ,  th e n  th e  
EOT  v i s i t  sh o u ld  b e  c o n d u c t e d .   T h e  su b j e c t  sh o u ld  b e  e n c o u r ag e d  to  r e tu r n  f o r  th e  s a f e ty  
f o l low - u p  v i s i t .  
6 . 4 .  F o l low- Up 
6 . 4 . 1 .  Sa f e t y  F o l low -Up 
T h e  s a f e ty  f o l low - u p  p e r io d  i s  th e  in t e r v a l  b e tw e en  th e  EOT  v i s i t  a n d  th e  s c h e d u l e d  f o l low - u p  
v i s i t ,  w h i c h  sh o u ld  o c c u r  3 0  to  3 5  d ay s  a f t e r  th e  EOT  v i s i t  ( o r  a f t e r  th e  l a s t  d o s e  o f  s tu dy  d r ug  i f  
th e  E OT  v i s i t  w a s  n o t  p e r f o rm e d ) .   A d v e r s e  e v e n t s  a n d  SAE s  mu s t  b e  r e p o r t e d  u p  u n t i l  a t  l e a s t  3 0  d ay s  a f t e r  th e  l a s t  d o s e  o f  s tu dy  d r ug ,  th e  d a t e  o f  th e  f o l low - u p  v i s i t ,  o r  u n t i l  to x i c i t i e s  
r e so lv e ,  r e tu r n  to  b a s e l in e ,  o r  a r e  d e em e d  i r r e v e r s ib l e ,  w h i c h e v e r  i s  lo n g e r .   R e a so n a b l e  e f f o r t  
sh o u ld  b e  m a d e  to  h a v e  th e  su b j e c t  r e tu r n  f o r  th e  fo l low - u p  v i s i t  a n d  r e p o r t  a ny  AE s  th a t  m ay  o c c u r  d u r ing  th i s  p h a s e .  
I f  a  su b j e c t  i s  s c h e d u l e d  to  b e g in  a  n ew  a n t i c a n c e r  th e r a py  b e f o r e  th e  e n d  o f  th e  s a f e ty  f o l low - u p  
p e r io d ,  th e n  th e  s a f e ty  f o l low - u p  v i s i t  sh o u ld  b e  p e r f o rm e d  b e f o r e  n ew  a n t i c a n c e r  th e r a py  i s  s t a r t e d .   O n c e  n ew  a n t i c an c e r  th e r a py  h a s  b e e n  in i t i a t e d ,  th e  su b j e c t  w i l l  mo v e  in to  th e  su r v iv a l  
f o l low - u p  p e r io d .  
6 . 4 . 2 .  D i s e a s e  S t a tu s F o l low - Up 
Su b j e c t s  w h o  d i s c o n t in u e  s tu dy  t r e a tm e n t  f o r  a  r e a so n  o th e r  th a n  d i s e a s e  p ro g r e s s io n  w i l l  
c o n t in u e  to  b e  f o l low e d  fo r  d i s e a s e  a s s e s sm e n t s  b y  r a d io lo g i c  im ag ing  p e r  th e  s c h e d u l e  o f  
a s s e s sm e n t s  ( s e e  Ta b l e  4 ) .   E v e ry  e f f o r t  sh o u ld  b e  m a d e  to  c o l l e c t  in f o rm a t io n  r e g a r d ing  d i s e a s e  
s t a tu s  u n t i l  a ny  1  o f  th e  fo l low in g  o c c u r s :  
•  T h e  s t a r t  o f  n ew  a n t in e o p l a s t i c  th e r a py . 
•  D i s e a s e  p r og r e s s io n.  •  D e a th.  •  T h e  e n d  o f  th e  s tu dy .  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  40 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
6 . 4 . 3 .  Su r v iv a l  F o l low -Up 
O n c e  a  su b j e c t  h a s  r e c e iv e d  th e  l a s t  d o s e  o f  s tu dy  d r u g ,  c o n f i rm e d  d i s e a s e  p r o g r e s s io n ,  o r  s t a r te d  
a  n ew  a n t i c a n c e r  th e r a py ,  th e  su b j e c t  mo v e s  in to  th e  su r v iv a l  f o l low - u p  p e r io d .   T h e  s i t e  w i l l  u s e  
c o n t in u in g  su b j e c t  r e c o r d s  to  su p p ly  d a t a  o n  su b s eq u e n t  t r e a tm e n t  r eg im e n s ,  tumo r  a s s e s sm e n t s  
( i f  d i s c o n t in u e d  t r e a tm e n t  f o r  a  r e a so n  o th e r  th a n  p r o g r e s s io n ) ,  a n d  OS in  th e  e CRF . 
F o r  su b j e c t s  w h o  d o  n o t  in t e n d  to  r e tu r n  to  th e  s tu dy  in v e s t ig a to r  f o r  th e i r  on g o ing  c a r e ,  
f o l low - u p  sh o u ld  b e  m a in t a in e d  to  a s s e s s  f o r  su r v iv a l  s t a tu s  u n t i l  d e a th ,  w i th d r aw a l  o f  c o n s e n t ,  
o r  th e  e n d  o f  th e  s tu dy ,  wh i c h e v e r  o c c u r s  f i r s t .  
6 . 5 .  End  o f  S tud y 
T h e  s tu dy  w i l l  c o n t in u e  up  to  2  y e a r s a f t e r  th e  f i r s t  d o s e  o f  s tu dy  t r e a tm e n t  i s  a dm in i s t e r e d  to  th e  
l a s t  su b j e c t  e n r o l l e d ,  a t  wh i c h  p o in t  th e  s tu dy  w i l l  b e  c lo s e d .  
6 . 6 .  Un s ch edu l ed  V i s i t s 
U n s c h e d u l e d  v i s i t s  m ay  b e  h e ld  a t  a ny  t im e  a t  th e  in v e s t ig a to r ' s  d i s c r e t io n ,  a n d  a p p r o p r i a t e  
c l in i c a l  a n d  l a b o r a to ry  m e a su r em e n t s  p e r f o rm e d  b a s e d  o n  AE s  o r  o th e r  f ind in g s .  
7 .  CONDUCT  OF  STUDY  ASSESSMENTS  AND  PROCEDURES 
Su b j e c t s  o n g o ing  a f t e r  imp l em e n t a t io n  o f  P r o to c o l  Am e n dm e n t  4  w i l l  o n ly h a v e  a s s e s sm e n t s  
p e r f o rm e d  a s  in d i c a t e d  in  T a b l e 6  a n d  T a b l e 7  a n d  a t  a  f r e q u e n cy  d e t e rm in ed  by  th e  in v e s t ig a to r  
a s  g u id e d  by  th e  s t a n d a r d  o f  c a r e .   Un l e s s  no t ed  b e low ,  p r o c edu r e s  l i s t ed  in  th i s  s e c t ion  a r e  
no t  r equ i r ed  t o  b e  p e r fo rm ed  o r  c o l l e c t ed  i n  th e  CRF  a f t e r  imp l em en t a t ion  o f  
Am endm en t 4 .  
7 . 1 .  Adm in i s t r a t i on  o f  In f o rm ed  C on s en t  F o rm 
V a l id  in f o rm e d  c o n s e n t  mu s t  b e  o b t a in e d  f r om  th e  s tu dy  su b j e c t  b e f o r e  c on d u c t in g  a ny  
s tu dy - sp e c i f i c  p r o c e d u r e s  u s in g  a n  ICF  a p p r o v e d  by  th e  lo c a l  IRB / IEC  th a t  c o n t a in s  a l l  e l em e n t s  r e q u i r e d  by  ICH  E 6  a n d  d e s c r ib e s  th e  n a tu r e ,  s c op e ,  a n d  p o s s ib l e  c o n s e q u e n c e s  o f  th e  s tu dy  in  a  
f o rm  u n d e r s t a n d a b l e  to  th e  s tu dy  su b j e c t .   L o c a l  an d  in s t i tu t io n a l  g u id e l in e s  f o r  ICF  c o n t e n t  a n d  
a dm in i s t r a t io n  mu s t  b e  f o l low e d ;  th e  o r ig in a l  s ig n e d  ICF  mu s t  b e  r e t a in e d  by  th e  in v e s t ig a to r ,  a n d  a  c o py  o f  th e  s ig n e d  ICF  mu s t  b e  p r o v id e d  to  th e  s tu dy  su b j e c t .   T h e  in f o rm e d  c o n s en t  
p r o c e s s  f o r  e a c h  su b j e c t  mu s t  b e  d o c um e n t e d  in  w r i t in g  w i th in  th e su b j e c t  so u r c e  d o c um e n t a t io n .  
7 . 2 .  In t e r a c t i v e  R e sp on s e  T e chn o l og y  P r o c edu r e 
T h e  IW RS w i l l  b e  c o n t a c t e d  to  o b t a in  a  su b j e c t  ID  n umb e r  w h e n  a  su b j e c t  en t e r s  s c r e e n in g ,  u p o n  
d e t e rm in in g  th a t  th e  su b j e c t  i s  e l ig ib l e  f o r  s tu dy  en t ry  to  o b t a in  th e  t r e a tm en t  a s s ig nm e n t ,  
th r o u g h o u t  th e  s tu dy  a s  in d i c a t e d  to  u p d a t e  th e  s tudy  d r ug  su p p ly  ( s e e  Ta b l e  4 ) ,  a n d  a t  th e  EOT  
v i s i t.     
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  41 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
7 . 3 .  D em og r aph y  and  M ed i c a l  H i s t o r y 
7 . 3 . 1 .  D em o g r aph i c s  and  M ed i c a l  H i s t o r y 
D emo g r a p h i c  d a t a  a n d  a  c omp l e t e  m e d i c a l  a n d  m e d i c a t io n  h i s to ry ,  in c lu d in g  d a t e  o f  d i ag n o s i s  o f  
DLBCL ,  h i s to lo gy ,  cu r r en t  s t a g ing ,  s i t e s  o f  d i s e a s e ,  p r io r  su rg e ry ,  r a d i a t io n ,  a n d  o th e r  d e t a i l s  
r e l a t e d  to  th e  d i s e a s e  u n d e r  s tu dy  w i l l  b e  c o l l e c t e d .  
7 . 3 . 1 . 1 .  P r io r and  C on c om i t an t  M ed i c a t ion s  and  P r o c edu r e s 
P r io r a n d  c o n c om i t a n t  m e d i c a t io n s  a n d  p r o c e d u r e s  w i l l  b e  r e v i ew e d  to  d e t e rm in e  su b j e c t  
e l ig ib i l i ty .   A l l  c o n c om i t a n t  m e d i c a t io n s  a n d  m e a su r e s  mu s t  b e  r e c o r d e d  in  th e  e CRF,  a n d  a ny  
m e d i c a t io n  r e c e iv e d o r  p r o c e d u r e  p e r f o rm e d  w i th in  3 0  d ay s  b e f o r e  e n r o l lm e n t  a n d  u p  to  th e  e n d  
o f  s tu dy  w i l l  b e  r e c o r d e d  in  th e  e CRF .   T h e  m e d i c a t io n  r e c o r d  w i l l  b e  m a in t a in e d a f t e r  s ig n ing  th e  ICF  to  d o c um e n t  c o n c om i t a n t  m e d i c a t io n s ,  in c lu d in g  a ny  c h a ng e s  to  th e  d o s e  o r  r eg im e n .   
Co n c om i t a n t  m e d i c a t io n s  in c lu d e  a ny  p r e s c r ip t io n ,  o v e r - th e - c o u n t e r ,  o r  n a tu r a l /h e r b a l  
p r e p a r a t io n s  t a k e n  o r  a dm in i s t e r e d  d u r in g  th e  s tudy  p e r io d .   Co n c om i t a n t  t r e a tm e n t s a n d /o r  p r o c e d u r e s  th a t  a r e  r e q u i r e d  to  m a n ag e  a  su b j e c t ' s  m e d i c a l  c o n d i t io n  d u r in g  th e  s tu dy  w i l l  a l so  b e  
r e c o r d e d  in  th e  e CRF . 
U p o n  imp l em e n t a t io n  o f  Am e n dm e n t  4 ,  u s e  o f  c on c om i t a n t  m e d i c a t io n s  sh o u ld  b e  mo n i to r e d  to  
v e r i fy  th a t  su b j e c t s  a r e  no t  t a k in g  a ny  c o n c om i t a n t  m e d i c a t io n  p r o h ib i t e d  p e r  P r o to c o l  
( S e c t io n 5 . 6 . 4 ) .   A  co n c om it a n t  m e d i c a t io n s  i s  r e q u i r e d  to  b e  e n t e r e d  in  th e  SAE  f o rm i f  
c o n s id e r e d  a s so c i a t e d  w i th  a n  SAE  o r  th e  eCRF  i f  th e  c o n c om i t a n t  m e d i c a t io n  l e d  to  s tu dy  d r ug  d i s c o n t in u a t io n .  
7 . 4 .  S a f e t y  A s s e s sm en t s 
U p o n  imp l em e n t a t io n  o f  Am e n dm e n t  4 ,  o n ly  sa f e ty  a s s e s sm e n t s  ( in c lu d in g  l a b o r a to ry  a n a ly t e s )  
th a t  a r e  c o n s i s t e n t  w i th  s t a n d a r d  o f  c a r e  a n d  mo n i to r in g  sh o u ld  b e  p e r f o rm ed  p e r  th e  
in v e s t ig a to r ' s  d i s c r e t io n .   Su b j e c t s  mu s t  b e  t a k e n  o f f  s tu dy  t r e a tm e n t  i f ,  in  th e  o p in io n  o f  th e  in v e s t ig a to r ,  a n  u n a c c e p t a b l e  to x i c i ty  d e v e lo p s .  
7 . 4 . 1 .  Adv e r s e  Ev en t s 
A d v e r s e  e v e n t s  w i l l  b e  mo n i to r e d  f r om  th e  t im e  th e  su b j e c t  s ig n s  th e  ICF .   Su b j e c t s  w i l l  b e  
in s t r u c t e d  to  r e p o r t  a l l  AE s  d u r in g  th e  s tu dy  a n d  w i l l  b e  a s s e s s e d  f o r  th e  o c c u r r e n c e  o f  AE s  th r o u g h o u t  th e  s tu dy .   I n  o r d e r  to  a v o id  b i a s  in  e l i c i t in g  AE s ,  su b j e c t s  w i l l  b e  a sk e d  g e n e r a l ,  
n o n l e a d in g  q u e s t io n s  su c h  a s  " H ow  a r e  y o u  f e e l in g ?"   A l l  AE s  ( s e r io u s  a n d  n o n s e r io u s )  mu s t  b e  
r e c o r d e d  o n  th e  so u r c e  do c um e n t s  a n d  e CRF s r eg a r d l e s s  o f  th e  a s sump t io n  o f  a  c a u s a l  r e l a t io n sh ip  w i th  th e  s tu d y  d r ug .   T h e  d e f in i t io n ,  r e p o r t in g ,  a n d  r e c o r d ing  r e q u i r em e n t s  f o r  AE s  
a r e  d e s c r ib e d  in  S e c t io n 8 .  
U p o n  imp l em e n t a t io n  o f  Am e n dm e n t  4 ,  AE s  th a t  l e a d  to  th e  d i s c o n t in u a t io n  o f  s tu dy  t r e a tm e n t  
a n d  a l l  SAE s  mu s t  b e  r e co r d e d  in  th e  CRF s ,  r eg a rd l e s s  o f  th e  a s sump t io n  o f  a  c a u s a l  r e l a t io n sh ip  
w i th  th e  s tu dy  d r ug .  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  42 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
7 . 4 . 2 .  C omp r eh en s iv e  Phy s i c a l  Ex am ina t ion s  
C l in i c a l ly  n o t a b l e  a b n o rm a l i t i e s  th a t  a r e  c o n s id e r e d  c l in i c a l ly  s ig n i f i c a n t  in  th e  ju d gm e n t  o f  th e  
in v e s t ig a to r  a r e  to  b e  r e po r t e d  a s  AE s .  
Phy s i c a l  e x am in a t io n s  mu s t  b e  p e r f o rm e d  by  a  m ed i c a l ly  q u a l i f i e d  in d iv id u a l  su c h  a s  a  l i c e n s e d  
p hy s i c i a n ,  p hy s i c i a n' s  a s s i s t a n t ,  o r  a n  a d v a n c e d  r eg i s t e r e d  n u r s e  p r a c t i t io n e r ,  a s  lo c a l  l aw  p e rm i t s .  
T h e  c omp r e h e n s iv e  p hy s i c a l  e x am in a t io n  w i l l  in c l u d e  h e ig h t  ( a t  s c r e e n ing  o n ly )  a n d  th e  
f o l low in g  o rg a n  o r  b o dy  sy s t em  a s s e s sm e n t s :   sk in ;  h e a d ,  ey e s ,  e a r s ,  n o s e ,  a n d  th r o a t ;  thy ro id ;  lu n g s ;  c a r d io v a s c u l a r  sy s t em ;  a b d om e n  ( l iv e r ,  sp l e e n ) ;  e x t r em i t i e s ;  lymp h  no d e s ;  a n d  a  b r i e f  
n e u r o lo g i c a l  e x am in a t io n  ( eg ,  r e f l e x e s ,  s t r e ng th ,  Romb e r g ' s  t e s t ,  v ib r a t io n  s e n s e ,  a n d  g r o s s  
s e n so ry  p e r c e p t io n ) ;  a n d  b o dy  w e ig h t  (w i th in  1  lb  o r  0 . 5  k g ) .  
7 . 4 . 2 . 1 .  D i s e a s e-S p e c i f i c Phy s i ca l  Ex am ina t ion  
A  d i s e a s e- sp e c i f i c  p hy s i c a l  e x am in a t io n  w i l l  b e  a  symp tom - d i r e c t e d  e v a lu a t io n  a n d  w i l l  in c lu d e  
a s s e s sm e n t ( s )  o f  th e  b o dy  sy s t em s  o r  o rg a n s ,  a s  in d i c a t e d  by  su b j e c t  d i s e a s e  a n d  symp tom s ,  AE s ,  
o r  o th e r  f in d ing s  a s  d e t e rm in e d  by  th e  in v e s t ig a to r  o r  d e s ig n e e .   A  d i s e a s e- sp e c i f i c  p hy s i c a l  e x am in a t io n  mu s t  in c lu d e  a  m e a su r em e n t  o f  th e  su b j e c t ' s  b o dy  w e ig h t  (w i th in  1  lb  o r  0 . 5  k g ) ,  
a n d  a n  e v a lu a t io n  o f  a ny  AE s  o r  symp tom s  th a t  th e  su b j e c t  h a s  p r e v io u s ly  r e p o r t e d .  
7 . 4 . 3 .  V i t a l  S ign s 
V i t a l  s ig n  m e a su r em e n t s  ( b lo o d  p r e s su r e ,  p u l s e ,  r e sp i r a to ry  r a t e ,  a n d  b o dy  t emp e r a tu r e )  w i l l  b e  
t a k e n  w i th  th e  su b j e c t  in  th e  r e c umb e n t ,  s em i r e c umb e n t ,  o r  s i t t in g  p o s i t io n  a f t e r  5  m in u t e s  o f  
r e s t .   C l in i c a l ly  n o t a b l e  ab n o rm a l i t i e s  th a t  a r e  c o n s id e r e d  c l in i c a l ly  s ig n i f i c a n t  in  th e  ju d gm e n t  o f  
th e  in v e s t ig a to r  a r e  to  b e  r e p o r t e d  a s  AE s.  
7 . 4 . 4 .  Tw e lv e- l e ad  E l e c t r o c a rd io g r am s  
A l l  1 2 - l e a d  ECG s  w i l l  b e  p e r f o rm e d  w i th  th e  su b j e c t  in  a  r e c umb e n t  o r  s em i r e c umb e n t  p o s i t io n  
a f t e r  5  m in u t e s  o f  r e s t .   B a s e l in e  ECG s  w i l l  b e  o b t a in e d  d u r ing  s c r e e n ing  u s in g  a  s ing l e  
m e a su r em e n t ,  b u t  c a n  b e  d o n e  in  t r ip l i c a t e  i f  th e  s in g l e  QT c  m e a su r em e n t i s  >  4 5 0  m i l l i s e c o n d s  ( c o r r e c t e d  by  F r id e r i c i a;  s e e  S e c t io n 3 . 2 ) .   E l e c t r o c a r d iog r am s w i l l  a l so  b e  o b t a in e d  d u r in g  th e  
D ay  1  v i s i t  ( t r ip l i c a t e  m e a su r em e n t s )  b e f o r e  th e  su b j e c t  r e c e iv e s  th e  f i r s t  do s e  o f  s tu dy  d r ug .   
T r ip l i c a t e  ECG s  w i ll  b e  p e r f o rm e d  p r e d o s e  a n d  1 .5  h o u r s  (±  1 5  m in u t e s )  a f t e r  r e c e iv ing  INCB 0 5 0 4 6 5  o n  D ay  1 5 .   Wh e n  t r ip l i c a t e  ECG s  a r e  b e ing  o b t a in e d ,  in d iv id u a l  m e a su r em e n t s  
sh o u ld  b e  p e r f o rm e d  5  m in u t e s  (±  3  m in u t e s )  a p a r t .   A l l  1 2 - l e a d  ECG s  o b t a in e d  a t  su b s e q u e n t  
t im e p o in t s  ( s in g l e  m e a su r em e n t s )  w i l l  b e  c omp a r ed  w i th  th e  b a s e l in e  1 2 - l e a d  ECG s  a s  f o l low s :  
•  F o r  ECG  mo r p h o logy ,  a l l  p o s td o s e  ECG  r e c o r d ing s  w i l l  b e  c omp a r e d  w i th  D ay  1  
p r e d o s e  ECG s .  
•  F o r  th e  c a l c u l a t io n  o f  c h an g e s  in  c a r d i a c  in t e r v a l s  (eg ,  QT  in t e r v a l ) ,  th e  in t e r v a l s  
f r om  th e  s c r e e n ing  a n d  D ay  1  p r e d o s e  ( t r ip l i c a t e )  ECG s  w i l l  b e  c omp u t e d  a n d  
a v e r ag e d  a n d  u s e d  a s  th e  b a s e l in e  f o r  c omp a r i so n  o f  a l l  p o s td o s e  in t e r v a l s .  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  43 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
I f  a  s ing l e  m e a su r em e n t  d emo n s t r a t e s  a  QT c  in t e rv a l  >  5 0 0  m i l l i s e c o n d s,  2  mo r e  ECG s  sh o u ld  
b e  o b t a in e d  o v e r  a  b r i e f  p e r io d ,  a n d  th e  a v e r ag e d  QT c  in t e r v a l s  sh o u ld  b e  u s e d  to  d e t e rm in e  
w h e th e r th e  s tu dy  t r e a tm e n t  sh o u ld  b e  in t e r r u p t e d .  
Tw e lv e- l e a d  ECG s  w i l l  b e  a c q u i r e d  u s in g  a n  ECG  a n a ly s i s  sy s t em  w i th  a n a ly s i s  a n d  p r in t in g  
c a p a b i l i t i e s ,  a s  w e l l  a s  d ig i t a l  t r a n sm i s s io n  c a p a b i l i t i e s  to  a  c e n t r a l  c a p tu r e  mo d u l e  a t  th e  ECG  
l a b o r a to ry .   T h e  in v e s t ig a to r  a n d  r e s e a r c h  s t a f f  w i l l  r e c e iv e  a d e q u a t e  t r a in in g  by  a  q u a l i f i e d  
p e r so n  o n  th e  u s e  a n d  o p e r a t io n  o f  th e  a n a ly s i s  sy s t em .   T h e  su c c e s s f u l  d ig i t a l  su bm i s s io n  o f  a  1 2 - l e a d  ECG ,  m e e t ing  q u a l i ty  s t a n d a r d s ,  to  th e  c e n t r a l  ECG  l a b o r a to ry  by  th e  s i t e  mu s t  b e  
e n su r e d  b e f o r e  e n r o l lm e n t  o f  th e  f i r s t  su b j e c t .   T h e  s tu dy  m a n u a l  f o r  p r o c e du r e s  th a t  mu s t  b e  
f o l low e d  f o r  th e  r e c o r d in g  a n d  t r a n sm i s s io n  o f  ECG s  a n d  th e  o p e r a to r ' s  m an u a l  w i th  in s t r u c t io n s  f o r  o p e r a t in g  th e  d ig i t a l  c a p tu r e  mo d u l e  w i l l  b e  sh ip p e d  to  th e  s i t e  a lo n g  w i th  th e  d e v i c e .   T h e  
1 2 - l e a d  ECG s  w i l l  b e  in t e r p r e t e d  by  th e  in v e s t ig a to r  a t  th e  s i t e  a n d  w i l l  b e  u s e d  f o r  imm e d i a t e  
su b j e c t  m a n ag em e n t .   T h e  d e c i s io n  to  in c lu d e  o r  ex c lu d e  a  su b j e c t  o r  d i s c on t in u e  a  su b j e c t ' s  p a r t i c ip a t io n  in  th e  s tu dy  b a s e d  o n  a n  ECG  f l ag g e d  a s  " A b n o rm a l ,  C l in i c a l ly  S ig n i f i c a n t"  i s  th e  
r e sp o n s ib i l i ty  o f  th e  in v e s t ig a to r ,  in  c o n su l t a t io n  w i th  th e  sp o n so r ' s  m e d i c a l  mo n i to r ,  a s  
a p p r o p r i a t e .   Tw e lv e- l e ad  ECG s  th a t  a r e  id e n t i f i ed  by  th e  in v e s t ig a to r  a s  " A b n o rm a l ,  C l in i c a l ly  S ig n i f i c a n t"  w i l l  b e  s e n t  to  th e  sp o n so r ' s  m e d i c a l  mo n i to r  f o r  r e v i ew .   
T h e  o v e r a l l  ECG  in t e r p r e t a t io n  w i l l  b e  in d i c a t e d  b y  a  f l ag g ing  sy s t em  th a t  w i l l  h e lp  d i s t in g u i sh  
b e tw e e n  a  n o rm a l  ECG ,  ECG  a b n o rm a l i t i e s  w h e r e  n o  f u r th e r  in v e s t ig a t io n  i s  r e q u i r e d ,  a n d  ECG  a b n o rm a l i t i e s  w h e r e  s tu d y  e x c lu s io n ,  f u r th e r  c a r d io v a s c u l a r  in v e s t ig a t io n ,  an d /o r  p r omp t  a c t io n  
m ay  b e  n e c e s s a ry  d e p e n d in g  o n  th e  c l in i c a l  c o n t e x t .   A  su i t a b l e  f l ag  w i l l b e  in c lu d e d  in  th e  
" O v e r a l l  ECG  I n t e r p r e t a t io n"  s e c t io n  o f  th e  r e p o r t  w h e n  a n  ECG  i s  c o n s id e r e d  to  b e  t e c h n i c a l ly  u n a c c e p t a b l e  o r  u n in t e r p r e t a b l e .   I f  s e v e r a l  d i f f e r en t  a b n o rm a l i t i e s  e x i s t  c o r r e sp o n d in g  to  
d i f f e r e n t  l e v e l s  o f  f l ag g ing ,  th e n  th e  l a b e l  w i l l  r e f l e c t  th e  mo s t  s e v e r e  l e v e l .   F l ag g ing  by  th e  
c e n t r a l  e xp e r t  c a r d io log i s t  o f  th e s e  s ig n i f i c a n t  a b no rm a l i t i e s  sh o u ld  o n ly  b e  r eg a r d e d  a s  a  su g g e s t io n .   T h i s  s e r v i c e  i s  in t e n d e d  to  a s s i s t  th e  in v e s t ig a to r  in  h i s /h e r  in t e r p r e t a t io n  o f  th e  ECG  
a n d  d e c i s io n -m a k ing .   I t  i s  n o t  in t e n d e d  to  r e p l a c e  th e  in v e s t ig a to r ' s  e xp e r t  ju d gm e n t  a n d  
k n ow l e d g e  o f  th e  su b j e c t ' s  m e d i c a l  c o n d i t io n .  
7 . 4 . 5 .  Labo r a t o r y  A s s e s sm en t s  
B lo o d  d r aw s  f o r  l a b o r a to ry  a s s e s sm e n t s  w i l l  o c c u r  a t  s tu dy  v i s it s  in d i c a t e d  ( s e e  T a b l e 5 ) .   B lo o d  
d r aw s  w i l l  b e  c omp l e t e d  b e f o r e  th e  su b j e c t  r e c e iv e s  th e  d a i ly  d o s e  o f  INCB 0 5 0 4 6 5 .   Sp e c i f i c  
l a b o r a to ry  a s s e s sm e n t s  a r e  p r o v id e d  ( s e e  T a b l e 8 ) .    
A l l  l a b o r a to ry  a s s e s sm e n t s  w i l l  b e  p e r f orm e d  a t  a  c e n t r a l  l a b o r a to ry .   I f  a  lo c a l  l a b o r a to ry  
a s s e s sm e n t  i s  d e em e d  n e c e s s a ry  by  th e  in v e s t ig a to r  a n d  r e su l t s  in  a  c h a ng e  in  p a t i e n t  
m a n ag em e n t  ( eg ,  d o s e  mo d i f i c a t io n )  o r  a n  SAE ,  th e n  th e  a s s e s sm e n t  d a t a  an d  r e f e r e n c e  r a ng e s  mu s t  b e  r e c o r d e d  in  th e  su b j e c t' s  e CRF . 
U p o n  imp l em e n t a t io n  o f  Am e n dm e n t  4 ,  l a b o r a to ry  a s s e s sm e n t s  ( T a b l e 7 )  o n ly  n e e d  to  b e  
p e r f o rm e d  in  a c c o r d a n c e  w i th  s t a n d a r d  o f  c a r e  a t  e a c h  in v e s t ig a t io n a l  s i t e  an d  mo n i to r e d  a s  p e r  th e  in v e s t ig a to r ’ s  d i s c r e t io n .   L a b o r a to ry  r e su l t s  d o  n o t  n e e d  to  b e  r e p o r t e d  in  th e  CRF ,  b u t  a l l  
l a b o r a to ry  r e su l t s  c o r r e spo n d in g  w i th  a n  SAE  mu s t  b e  r e p o r t e d  o n  th e  SAE  f o rm .  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  44 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
7 . 4 . 5 . 1 .  Ch em i s t r y and  H em a t o lo g y  
A l l  c h em i s t ry a n d  h em a to lo gy  a s s e s sm e n t s  ( s e e  T a b l e 5  a n d  T a b l e 8 )  w i l l  b e  p e r f o rm e d  f r om  
b lo o d  s amp l e s  c o l l e c t e d  u s in g  in s t i tu t io n a l  b e s t  p r a c t i c e s . 
7 . 4 . 5 . 2 .  P r e gnan c y  T e s t ing 
A  s e r um  p r eg n a n cy  t e s t  w i l l  b e  p e r f o rm e d  a t  s c r e e n in g  a n d  EOT.   U r in e  p r e g n a n cy  t e s t  w i l l  b e  
p e r f o rm e d  p e r  T a b l e 5 ;  po s i t iv e  r e su l t s  mu s t  b e  c o n f i rm e d  w i th  a  s e r um  p r eg n a n cy  t e s t .   P r e g n a n cy  t e s t ing  w i l l  o n ly  b e  r e q u i r e d  f o r  w om e n  o f  c h i ld b e a r ing  p o t e n t i a l .  
7 . 4 . 5 . 3 .  S e r o lo g y  
S e r o lo gy  a s s e s sm e n t s  ( s e e  T a b l e 8 )  w i l l  b e  p e r f o rm e d  a t  a  c e n t r a l  l a b o r a to ry .  
7 . 4 . 5 . 4 .  H IV  S c r e en ing  T e s t 
Su b j e c t s  e n r o l l e d  o u t s id e  o f  th e  U n i t e d  S t a t e s  mu s t  h a v e  a n  H IV  immu n o a s s ay  t e s t  d u r in g  
s c r e e n ing  to  e n su r e  n eg a t iv e  H IV  s t a tu s  b e f o r e  D ay  1 .   T h i s  t e s t  i s  o p t io n a l  f o r  su b j e c t s  e n r o l l e d  
in  th e  U n i t e d  S t a t e s .  
7 . 5 .  E f f i c a c y  A s s e s sm en t s 
Su b j e c t s  w i l l  h a v e  a n o b j e c t iv e  a s s e s sm e n t  o f  d i s e a s e  s t a tu s  u s in g  PET  a n d  d i a g n o s t i c  q u a l i ty  CT  
s c a n  o r  MR I .  
7 . 5 . 1 .  FDG- PET  o r  C omb in ed  PET- CT 
Po s i t r o n  em i s s io n  tomo g r a p hy  u s in g  [18 F ]  f lu o r o d e o xy g lu c o s e  (FDG ) ,  o r  c omb in e d  PET - CT  i s  
r e q u i r e d  to  e v a lu a t e  d i s e a s e  b u r d e n  d u r ing  th e  s c r e e n ing  p h a s e .   I f  FDG - PET  a s s e s sm e n t  w a s  
p e r f o rm e d  a s  s t a n d a r d  o f  c a r e  b e f o r e  s ig n in g  o f  th e  ICF  b u t  w i th in  2 8  d ay s  o f  D ay  1 ,  th e  r e su l t s  
f r om  th a t  a s s e s sm e n t  m ay  b e  r e c o r d e d  in  th e  eCRF  in  l i e u  o f  a  s tu dy - sp e c i f i c  a s s e s sm e n t .    
S c h e d u l e d  a s s e s sm e n t s  sh o u ld  a lw ay s  b e  c a l c u l a t e d  f r om  th e  f i r s t  d o s e  o f  s tu dy  t r e a tm e n t .   
Im ag ing  sh o u ld  n o t  b e  d e l ay ed  f o r  d e l ay s  in  t r e a tm e n t .  
N o t e :   Su b j e c t s  w h o  d i s co n t in u e  s tu dy  t r e a tm e n t  fo r  a ny  r e a so n  o th e r  th a n  d i s e a s e  p r og r e s s io n  o r  
w i th d r aw a l  o f  c o n s e n t  w i l l  b e  f o l low e d  a c c o r d ing  to  th e  d i s e a s e  a s s e s sm e n t  s c h e d u l e  u n t i l  e i th e r  d i s e a s e  p r og r e s s io n ,  th e  s t a r t  o f  a  n ew  a n t i c a n c e r  th e r a py ,  o r  d e a th ,  w h i c h ev e r  o c c u r s  f i r s t . 
U p o n  imp l em e n t a t io n  o f  Am e n dm e n t  4 ,  FDG- PET  o r  c omb in e d  PET - CT a s s e s sm e n t s  a r e  o n ly  
r e q u i r e d  to  b e  p e r f o rm e d  a s  p e r  s t a n d a r d  o f  c a r e  g u id e l in e s  a n d  mo n i to r e d .   Su b j e c t s  mu s t  b e  t a k e n  o f f  s tu dy  i f ,  in  th e  o p in io n  o f  th e  in v e s t ig a to r ,  th e  d i s e a s e  h a s  p r og r e s s e d  a n d  th e  su b j e c t  i s  
n o  lo n g e r  h a v ing  c l in i c a l  b e n e f i t  f r om  th e  s tu dy  t r e a tm e n t .  
7 . 5 . 2 .  C ompu t ed  Tom o g raphy  S c an  o r  M a gn e t i c  R e sonan c e  Im a g ing 
Su b j e c t s  w i l l  u n d e r g o  a  d i a g n o s t i c - q u a l i ty  CT  o r  MR I to  e v a lu a t e  m e a su r ab l e  d i s e a s e  d u r ing  th e  
s c r e e n ing  p h a s e .   I f  CT /MR I  a s s e s sm e n t  w a s  p e r f o rm e d  a s  s t a n d a r d  o f  c a r e  b e f o r e  s ig n ing  o f  th e  
ICF  b u t  w i th in  2 8  d ay s  o f  D ay  1 , th e n  th e  r e su l t s  f r om  th a t  a s s e s sm e n t  mu s t  b e  r e c o r d e d  in  th e  
eCRF  i f  u s e d  in  l i e u  o f  a  s tu dy - sp e c i f i c  a s s e s sm e n t .    
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  45 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
T h e d i s e a s e  a s s e s sm e n t  s c h e d u l e  a lso  a p p l i e s  to  tho s e  su b j e c t s  w h o  d i s c o n t in u e  s tu dy  t r e a tm e n t  
f o r  r e a so n s  o th e r  th a n  d i s e a s e  p r og r e s s io n  u n t i l  d i s e a s e  p r og r e s s io n ,  s t a r t  o f  n ew  a n t i c a n c e r  
th e r a py ,  w i th d r aw a l  o f  co n s e n t ,  e n d  o f  th e  s tu dy ,  o r  d e a th ,  w h i c h e v e r  o c c u r s  f i r s t .   S c h e d u l e d  
a s s e s s m e n t s  sh o u ld  a lw ay s  b e  c a l c u l a t e d  f r om  th e  f i r s t  d o s e  o f  s tu dy  t r e a tm e n t .   Im ag ing  sh o u ld  n o t  b e  d e l ay e d  f o r  in t e r r up t io n  o f  s tu dy  t r e a tm e n t .  
U p o n  imp l em e n t a t io n  o f  Am e n dm e n t  4 ,  CT  o r  MR I a s s e s sm e n t s  a r e  o n ly  r e q u i r e d  to  b e  
p e r f o rm e d  a s  p e r  s t a n d a rd  o f  c a re  g u id e l in e s  a n d  mo n i to r e d .   Su b j e c t s  mu s t  b e  t a k e n  o f f  s tu dy  i f ,  in  th e  o p in io n  o f  th e  in v e s t ig a to r ,  th e  d i s e a s e  h a s  p r o g r e s s e d  a n d  th e  su b j e c t  i s  n o  lo n g e r  h a v in g  
c l in i c a l  b e n e f i t  f r om  th e  s tu dy  t r e a tm e n t .  
7 . 5 . 3 .  Bon e  M a r r ow  Ex am ina t ion  
B o n e  m a r r ow  e x am in a t io n  i s  r e q u i r e d  a s  a  b a s e l in e  a s s e s sm e n t  e x c e p t  in  th e  f o l low in g  
c i r c um s t a n c e s :  
•  Su b j e c t  h a d  a  b o n e  m a r r ow  e x am in a t io n  p e r f o rm ed  a s  p e r  s t a n d a r d  o f  c a r e  w i th in 
a p p r o x im a t e ly  6 0  d ay s  o f  th e  f i r s t  d o s e  o f  s tu dy  d ru g .  
•  Su b j e c t  h a d  a  b o n e  m a r r ow  e x am in a t io n  p e r f o rm ed  a f t e r  th e  l a s t  t r e a tm e n t  f o r  NHL 
a n d  th e  r e su l t s  sh ow e d  lymp h om a  in v o lv em e n t  o f  th e  b o n e  m a r r ow .  
•  B a s e l in e  PET  s c a n  sh ow s  th a t  th e  su b j e c t  d o e s  h av e  FDG - a v id  d i s e a s e  in  th e  b o n e  
m a r r ow  (PET  +  b o n e  m a r r ow ) . 
Su b s e q u e n t ly ,  b o n e  m a r row  b io p sy  w i l l  b e  p e r f o rm e d  o n ly  to  c o n f i rm  CR/CMR  o r  a s  c l in i c a l ly  
in d i c a t e d .   I f  th e  b o n e  m a r r ow  d o e s  n o t  h a v e  lymph om a  in v o lv em e n t  a t  b a s e l in e ,  a  r e p e a t  
m a r r ow  e x am in a t io n  i s  n o t  r e q u i r e d  to  c o n f i rm  in d i c a t io n  o f  CR/CMR  o n  im a g ing . 
A l l  b o n e  m a r r ow  e x am in a t io n s  sh o u ld  in c lu d e  a  u n i l a t e r a l  a sp i r a t io n  a n d  b io p sy ,  w h e n  f e a s ib l e .  
T h e  p a th o lo gy  r e p o r t  r e su l t  f r om  th e  b o n e  m a r r ow  e x am in a t io n  w i l l  b e  c a p tu r e d  in  th e  eCRF .    
7 . 5 . 4 .  Ind ep end en t  R e v i ew  C omm i t t e e  
A l l  im a g ing  (PET  a n d  CT  o r  MR I )  w i l l  b e  su bm i t t e d  to  th e  c e n t r a l  r a d io lo gy  v e n d o r  f o r  r e v i ew .   
Im ag ing  d a t a  a n d  a p p l i c ab l e  c l in i c a l  d a t a  w i l l  b e  r e v i ew e d  a n d  r e sp o n s e  a s s e s s e d  u s in g  th e  PET  
CT– b a s e d  r e sp o n s e  c r i t e r i a  o f  th e  L ug a n o  C l a s s i f i c a t io n  ( Ch e so n  e t  a l  2 0 1 4)  by  in d ep e n d e n t  r e v i ew e r s  a s  d e s c r ib e d  in  th e  Im a g in g  Ch a r t e r . 
7 . 5 . 5 .  R e spon s e  C r i t e r ia  –  Th e  Lug ano  C la s s i f i c a t ion  
S i t e s  w i l l  u s e  th e  PET- CT– b a s e d  r e sp o n s e  c r i t e r i a  o f  th e  L ug a n o  C l a s s i f i c a t io n  (Ch e so n  e t  a l  
2 0 1 4 )  to  a s s e s s  r e sp o n s e  to  t r e a tm e n t  lo c a l ly .   D e t a i l s  r eg a r d ing  r e sp o n s e  a s s e s sm e n t  p e r  th e  L ug a n o C l a s s i f i c a t io n  a r e  p r o v id e d  ( s e e  T a b l e 9 ) .   Po s i t r o n  em i s s io n  tomo g r a p hy  i s  r e q u i r e d  a n d  
th e r e f o r e  th e  c r i t e r i a  f o r  PET - b a s e d  r e sp o n s e  sh ou ld  b e  a p p l i e d  in  mo s t  c i r c um s t a n c e s .   
Comp u t e d  tomo g r a p hy/MR I – b a s e d  r e sp o n s e  c r i t e r i a  a r e  p r o v id e d  f o r  th o s e  su b j e c t s  w i th  PET  s c a n s  th a t  c a n n o t  b e  in t e rp r e t e d  o r  w h o  d o  n o t  h a v e  FDG - a v id  d i s e a s e .   R e sp o n s e  p e r  th e  
PET- CT  a n d  CT /MR I  c r i t e r i a  w i l l  b e  c o l l e c t e d  in  th e  eCRF . 
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  46 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
Tab l e  9 :   Lug ano  C la s s i f i c a t ion  f o r  R e spon s e  A s s e s sm en t  
S i t e PET- Ba s ed  R e sp on s e CT- Ba s ed  R e sp on s e 
 Comp l e t e  m e tab o l i c  r e sp on s e Comp l e t e  rad i o l og i c  r e sp on s e 
(a l l  o f  th e  f o l l ow in g )  
Lym ph  n od e s  an d  
ex t r a lym ph a t i c  s i t e s   S co r e  1 ,  2 ,  o r  3  w i t h  o r  w i t h ou t a  r e s i du a l  m a s s  on  5PSa T a rg e t  n od e s / n od a l  m a s s e s  mu s t  r eg r e s s  t o  ≤  1 .5  cm  i n  LD i 
Nonm e a s u r ed  l e s i on   No t  app l i c ab l e A b s en t 
O rg an  en l a rg em en t   No t  app l i c ab l e R eg r e s s  t o  n o rm a l 
N ew  l e s i on s   Non e Non e 
Bon e  m a r row   No  ev i d en c e  o f  FDG- av i d  d i s e a s e  i n  
m a r row No rm a l  by  m o rph o l ogy ;  i f  in d e t e rm in a t e ,  IHC  n eg a t iv e  
 Pa r t i a l  m e tab o l i c  r e sp on s e Pa r t i a l  r em i s s i on  (a l l  o f  th e  f o l l ow in g ) 
Lym ph  n od e s  an d  ex t r a lym ph a t i c  s i t e s   •  S co r e  4  o r  5
a w i th  r edu c ed  u p t ak e  
com p a r ed  w i th  b a s e l i n e  an d  r e s i du a l  m a s s ( e s )  o f  any  s i z e 
•  A t  in t e r im ,  t h e s e  f i n d in g s  su gg e s t  
r e s pon d i n g  d i s e a s e  
•  A t  EOT ,  t h e s e  f i n d ing s  sug g e s t  r e s i du a l  
d i s e a s e •  ≥  50%  d e c r e a s e  i n  SPD  o f  u p  t o  6  t a rg e t  
m e a su r ab l e  n od e s  an d  ex t r an od a l  s i t e s   
•  Wh en  a  l e s i on  i s  t oo  sm a l l  t o  m e a su r e  on  
CT ,  a s s i gn  5  mm  ×  5  mm  a s  th e  d e f au l t   
•  Wh en  n o  l ong e r  v i s i b l e ,  0  ×  0  mm 
F o r  a  n od e  >  5  mm  ×  5  mm  bu t  sm a l l e r  t h an  
n o rm a l ,  u s e  a c t u a l  m e as u r em en t  
Nonm e a s u r ed  l e s i on s   No t  app l i c ab l e   A b s en t / r eg r e s s ed ,  bu t  n o  i n c r e a s e 
O rg an  en l a rg em en t   No t  app l i c ab l e   S p l e en  m u s t  h av e  r eg r e s s ed  by  >  50%  i n  l en g t h  b ey on d  n o rm a l  
N ew  l e s i on s   Non e Non e 
Bon e  m a r row   R e s i du a l  u p t ak e  h igh e r  t h an  up t ak e  i n  
n o rm a l  m a r row  bu t  r edu c ed  com p a r ed  w i th  b a s e l i n e  (d i f fu s e  u p t ak e  com p a t i b l e  w i th  
r e a c t i v e  ch ang e s  f rom  ch em o th e r apy  
a l l ow ed ) .   I f  t h e r e  a r e  p e r s i s t en t  f o c a l  ch ang e s  in  th e  m a r row  i n  th e  con t ex t  o f  a  n od a l  r e s pon s e ,  con s i d e r  fu r t h e r  ev a l u a t i on  w i th  MR I  o r  b i ops y   No t  app l i c ab l e 
 No  m e tab o l i c  r e sp on s e S tab l e  d i s ea s e 
T a rg e t  n od e s / n od a l  m a s s e s ,  ex t r an od a l  l e s i on s   S co r e  o f  4  o r  5
a w i t h  n o  s ig n i f i c an t  ch ang e  
i n  FDG  u p t ak e  f rom  b a s e l in e  a t  i n t e r im  o r  EOT <  50%  d e c r e a s e  f rom  b a s e l in e  i n  SPD  o f  u p  t o  6  dom i n an t ,  m e a su r ab l e  n od e s  an d  ex t r an od a l  s i t e s ;  n o  c r i t e r i a  f o r  PD a r e  m e t  
Nonm e a s u r ed  l e s i on s   No t  app l i c ab l e No  i n c r e a s e  con s i s t en t  w i th  p rog r e s s i on 
O rg an  en l a rg em en t   No t  app l i c ab l e No  i n c r e a s e  con s i s t en t  w i th  p rog r e s s i on 
N ew  l e s i on s   Non e Non e 
Bon e  m a r row   No  ch ang e  f rom  b a s e l i n e No t  app l i c ab l e 
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  47 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
Tab l e  9 :   Lug ano  C la s s i f i c a t ion  f o r  R e spon s e  A s s e s sm en t  (C on t inu ed )  
S i t e PET- Ba s ed  R e sp on s e CT- Ba s ed  R e sp on s e 
 P rog r e s s i v e  m e tab o l i c  d i s ea s e P rog r e s s i v e  d i s ea s e 
( r equ i r e s  a t  l ea s t  1  o f  th e  fo l l ow in g )  
In d i v i du a l  t a rg e t  
n od e s / n od a l  l e s i on s   In d i v i du a l  t a rg e t  n od e s / n od a l  l e s i on s :   
•  S co r e  4  o r  5a w i th  an  i n c r e a s e  i n  
i n t en s i ty  o f  u p t ak e  f rom  b a s e l in e  an d / o r   
•  N ew  FDG- av i d  f o c i  con s i s t en t  w i th  
lym ph om a  a t  in t e r im  o r  EOT  a s s e s sm en t  
 
Ex t r an od a l  l e s i on s :   
•  N ew  FDG- av i d  f o c i  con s i s t en t  w i th  
lym ph om a  a t  in t e r im  o r  EOT a s s e s sm en t  
 
N ew  l e s i on s :   
•  N ew  FDG- av i d  f o c i  con s i s t en t  w i th  
lym ph om a  r a th e r  t h an  an o th e r  e t i o l ogy  
( eg ,  i n f e c t i on ,  in f l amm a t i on ) .   I f  u n c e r t a in  r eg a rd in g  e t i o l ogy  o f  n ew  
l e s i on s ,  b i op s y  o r  i n t e rv a l  s c an  m ay  b e  
con s i d e r ed  
 
Bon e  m a r row :   
•  N ew  o r  r e cu r r en t  FDG- av i d  f o c i  PPD  p rog r e s s i on :   •  An  in d i v i du a l  n od e / l e s i on  m u s t  b e  
abn o rm a l  w i th  a l l  o f  th e  f o l l ow ing :  
- LD i  >  1 .5  cm   
- In c r e a s e  by  ≥  50%  f rom  PPD  n ad i r   
- In c r e a s e  i n  LD i  o r  SD i  f rom  n ad i r :  
o 0 .5  cm  f o r  l e s i on s  ≤  2  cm   o 1 .0  cm  f o r  l e s i on s  >  2  cm   
•  In  t h e  s e t t i ng  o f  s p l en om eg a ly ,  t h e  s p l en i c  
l en g t h  m u s t  in c r e a s e  by  >  50%  o f  t h e  
ex t en t  o f  i t s  p r i o r  i n c r e a s e  b ey on d  b a s e l i n e  ( eg ,  a  15  cm  s p l e en  m u s t  in c r e a s e  t o  >  16  cm ) .   I f  n o  p r i o r  s p l en om eg a ly ,  m u s t  in c r e a s e  by  a t  l e a s t  2  cm  f rom  
b a s e l i n e 
•  N ew  o r  r e cu r r en t  s p l en om eg a ly 
•  N ew  o r  c l e a r  p rog r e s s i on  o f  p r e- ex i s t ing  
n onm e a su r ed  l e s i on s  
•  R eg row th  o f  any  p r ev i ou s ly  r e s o l v ed  
l e s i on s  
•  A  n ew  n od e  >  1 .5  cm  in  any  ax i s •  A  n ew  ex t r an od a l  s i t e  >  1 .0  cm  i n  any  
ax i s ;  i f  <  1 .0  cm  i n  any  ax i s ,  i t s  p r e s en c e  
m u s t  b e  un equ iv o c a l  an d  m u s t  b e  a t t r i bu t ab l e  t o  lym ph om a  
•  A s s e s s ab l e  d i s e a s e  o f  any  s i z e  
u n equ i v o c a l ly  a t t r i bu t abl e  t o  l ym ph om a  
•  N ew  o r  r e cu r r en t  inv o l v em en t  o f  t h e  bon e  
m a r row 
5PS  =  5- p o in t  s c a l e ;  LD i  =  long e s t  t r a n s v e r s e  d i am e t e r  o f  l e s ion ;  PPD  =  c r o s s - p r o du c t  o f  th e  lo ng e s t  t r a n s v e r s e  d i am e t e r  a nd  
p e r p e nd i c u l a r  d i am e t e r ;  SD i  =  s ho r t e s t  a x i s  p e r p e nd i c u l a r  t o  t h e  lo ng e s t  t r a n s v e r s e  d i am e t e r;  SPD  =  s um  o f  th e  p r od u c t  o f  th e  
p e r p e nd i c u l a r  d i am e t e r s  f o r  m u l t ip l e  l e s ion s .  
a PET  5- po in t  s c a l e :   1 ,  no  up t a k e  a bov e  b a c k g r ound ;  2 ,  u p t a k e  ≤  m ed i a s t inum ;  3 ,  u p t a k e  >  m e d i a s t inum  bu t  ≤  l iv e r ;  4 ,  up t a k e  
m od e r a t e ly  >  l iv e r ;  5 ,  u p t a k e  m a rk e d ly  h ig h e r  th a n  l iv e r  a nd / o r  n ew  l e s ion s ;  X ,  n ew  a r e a s  o f  up t a k e  un l ik e ly  to  b e  r e l a t e d  t o lym phom a .  
7 . 5 . 6 .  ECOG  P e r fo rm an c e  S ta tu s 
E a s t e r n  Co o p e r a t iv e  O n co lo gy  G r o u p  p e r f o rm a n c e  s t a tu s  ( O k e n e t  a l  1 9 8 2 ;  T a b l e 1 0 )  w i l l  b e  
a s s e s s e d  ( s e e  Ta b l e  4 ) .   P e r f o rm a n c e  s t a tu s  mu s t  b e a s s e s s e d  by  a  m e d i c a l ly - q u a l i f i e d  in d iv id u a l  
a n d  r e c o r d e d  in  th e  eCRF .  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  48 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
Tab l e  1 0 :   Ea s t e rn  C o op e r a t iv e  On c o lo g y  G r oup  P e r fo rm an c e  S c o r e s 
G rad e P e r fo rman c e  S ta tu s 
0  F u l ly  a c t iv e ,  ab l e  to  c a r ry  o n  a l l  p r ed i s e a s e  p e r f o rman c e  w i th o u t  r e s t r i c t i o n  
1  R e s t r i c t ed  in  p h y s i c a l ly  s t r e n u o u s  a c t iv i ty  b u t  am b u l a to ry  an d  ab l e  t o  c a r ry  o u t  w o r k  o f  a  
l ig h t  o r  s e d en t a ry  n a tu r e ,  e g ,  l ig h t  h o u s e  w o rk ,  o f f i c e  w o rk  
2  Am b u l a to ry  an d  c a p ab l e  o f  a l l  s e l f- c a r e  b u t  u n ab l e  to  c a r ry  o u t  an y  w o rk  a c t iv i t i e s .   U p  an d  
ab o u t  m o r e  th an  5 0%  o f  w a k in g  h o u r s  
3  C ap ab l e  o f  o n ly  l im i t ed  s e l f - c a r e ,  co n f in ed  to  b ed  o r  ch a i r  m o r e  th an  5 0%  o f  w ak i n g  h o u r s  
4  C om p l e t e ly  d i s ab l ed .   C an n o t  c a r ry  o n  an y  s e l f- c a r e .   T o t a l ly  co n f in e d  to  b ed  o r  ch a i r  5  D e ad 
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  49 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  50 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
7 . 8 .  O th e r  S tud y  P ro c edu r e s 
7 . 8 . 1 .  Adm in i s t r a t ion  o f  S tud y  D rug 
S e e  S e c t io n 5 . 2 . 1  f o r  c omp l e t e  d e t a i l s  r eg a r d in g  s tu dy  d r ug  a dm in i s t r a t ion .  
A f t e r  imp l em e n t a t io n  o f  Am e n dm e n t  4 ,  su b j e c t s  w i l l  b e  d i sp e n s e d  th e  a p p r o p r i a t e  amo u n t  o f  
m e d i c a t io n  to  s e l f- a dm in i s t e r  s tu dy  d r ug  a s  p e r  p ro to c o l  u n t i l  th e i r  n e x t  s c h e d u l e d  v i s i t  
( s c h e d u l e d  n o  mo r e  th a n  1 2  w e e k s  l a t e r ) .   Su b j e c t s  w i l l  c o n t in u e  to  s e l f - a dm in i s t e r  s tu dy  m e d i c a t io n,  a n d  c omp l i an c e  w i l l  c o n t in u e  to  b e  a s s e s s e d .  
7 . 8 . 2 .  D i s t r ibu t ion  o f Sub j e c t  R em ind e r  C a rd s 
Su b j e c t s  w i l l  b e  p r o v id e d  w i th  a  r em in d e r  c a r d  a t  e a c h  v i s i t .    
T h e  su b j e c t  r em in d e r  c a rd  w i l l  in d i c a t e  th e  d a t e / t im e  o f  th e  n e x t  v i s i t  a n d  w i l l  a l so  r em in d  th e  
su b j e c t s  o f  w h i c h  d ay s  th ey  sh o u ld  n o t  t a k e  th e i r  mo r n in g  d o s e  b e f o r e  c om in g  to  th e  c l in i c  ( s e e  
S e c t io n 7 . 6 ) .   T h e  r em in d e r  c a r d s  f o r  th e  D ay  1 5  v i s i t  w i l l  h a v e  a n  a r e a  o n  wh i c h  th e  d a t e  a n d  
t im e  o f  th e  l a s t  d o s e  t a k en  ( f r om  th e  p r e v io u s  d ay )  a n d  th e  t im e  o f  th e i r  l a s t  m e a l  b e f o r e  th e  v i s i t  sh o u ld  b e  r e c o r d e d .  
A f t e r  imp l em e n t a t io n  o f  Am e n dm e n t  4 ,  su b j e c t s  w i l l  r e c e iv e  r em in d e r  c a rd s  th a t  w i l l  in c lu d e  th e  
d a t e  a n d  t im e  o f  th e  n e x t  v i s i t  a n d  in s t r u c t io n s  f o r  s tu dy  d r ug  a dm in i s t r a t ion .  
7 . 8 . 3 .  D a t a  C o l l e c t ion  fo r  Su r v iv a l  F o l low -Up 
F o r  su b j e c t s  h a v in g  e n t e r e d  th e  su r v iv a l  f o l low - u p  p e r io d  o f  th e  s tu dy ,  th e  s i t e  w i l l  c o l l e c t  d a t a  
a s  d e s c r ib e d  ( s e e  S e c t io n  6 . 4 . 3 ) .  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  51 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
8 .  SAFETY  MON ITOR ING  AND  REPORT ING 
8 . 1 .  Ad v e r s e  E v en t s 
8 . 1 . 1 .  D e f in i t ion s 
F o r  th e  p u r p o s e s  o f  th i s  P r o to c o l ,  a n  a d v e r s e  e v en t  (AE )  is  d e f in e d  a s  a ny  u n tow a r d  m e d i c a l  
o c c u r re n c e  a s so c i a t e d  w i th  th e  u s e  o f  a  d r ug  in  h um a n s ,  w h e th e r  o r  n o t  c o n s id e r e d  d r ug  r e l a t e d ,  th a t  o c c u r s  a f t e r  a  su b j e c t  p r o v id e s  in f o rm e d  c o n s en t .   A b n o rm a l  l a b o r a to ry  v a lu e s  o r  t e s t  r e su l t s  
o c c u r r ing  a f t e r  in f o rm e d  c o n s e n t  c o n s t i tu t e  AE s  on ly  i f  th ey  in d u c e  c l in i c a l  s ig n s  o r  symp tom s ,  
a r e  c o n s id e r e d  c l in i c a l ly  m e a n in g f u l ,  r e q u i r e  th e r apy  ( eg ,  h em a to log i c  a b n o rm a l i ty  th a t  r eq u i r e s  t r a n s f u s io n ) ,  o r  r e q u i r e  ch a n g e s  in  th e  s tu dy  d r ug ( s ) .  
8 . 1 . 2 .  R epo r t ing 
Ad v e r s e  e v e n t s th a t  b eg in  o r  w o r s e n  a f t e r  in f o rm ed  c o n s e n t  sh o u ld  b e  r e c o rd e d  o n  th e  A d v e r s e  
E v e n t s  f o rm  o f  th e  e CRF .   Co n d i t io n s  th a t  w e r e  a l r e a dy  p r e s e n t  a t  th e  t im e  o f  in f o rm e d  c o n s e n t  sh o u ld  b e  r e c o r d e d  o n  th e  M e d i c a l  H i s to ry  f o rm  in  th e  e CRF .   Mo n i to r in g  f o r  th e  o c c u r r e n c e  o f  
n ew  AE s  sh o u ld  b e  c o n t in u e d  f o r  a t  l e a s t  3 0  d ay s  a f t e r  th e  l a s t  d o s e  o f  s tu dy  d r ug .   A d v e r s e  
e v e n t s  ( in c lu d ing  l a b o r a to ry  a b n o rm a l i t i e s  th a t  c on s t i tu t e  AE s )  sh o u ld  b e  d e s c r ib e d  u s in g  a  d i a g n o s i s  w h e n e v e r  p o s s ib l e  r a th e r  th a n  by  in d iv id u a l  u n d e r ly ing  s ig n s  a n d  symp tom s .   Wh e n  a  
c l e a r  d i ag n o s i s  c a n n o t  b e  id e n t i f i e d ,  e a c h  s ig n  o r  symp tom  sh o u ld  b e  r e p o r t e d  a s  a  s e p a r a t e  AE.  
T h e  t e rm  " d i s e a s e  p r og r e s s io n "  sh o u ld  b e  r e c o r d ed  a s  a n  AE /SAE  o n ly  i f  th e r e  a r e  n o  o th e r  
id e n t i f i a b l e  AE s /SAE s  a s so c i a t e d  w i th  th e  d i s e a s e  p r o g r e s s io n  a t  th e  t im e  o f  r e p o r t ing .   F o r  
e v e n t s  a s so c i a t e d  w i th  d i s e a s e  p r og r e s s io n ,  th e  r e l e v a n t  s ig n s  a n d  symp tom s  sh o u ld  b e  r e p o r t e d  
u s in g  a  d i ag n o s i s  w h e n ev e r  p o s s ib l e  r a th e r  th a n  in d iv id u a l  u n d e r ly ing  s ig n s  a n d  symp tom s .   Wh e n  a  c l e a r  d i ag n o s i s  c a n n o t  b e  id e n t i f i e d ,  e a c h  s ig n  o r  symp tom  sh o u ld  b e  r e p o r t e d  a s  a  
s e p a r a t e  AE .   I f  th e  e v e n t s  r e su l t in g  f r om  d i s e a s e  p r o g r e s s io n  m e e t  th e  c r i t e r i a  f o r  a n  SAE  ( eg ,  
r e su l t e d  in  h o sp i t a l i z a t io n ,  a  l i f e - th r e a t e n ing  e v e n t ,  o r  d e a th ) ,  th e  sp e c i f i c  ev e n t ( s )  sh o u ld  b e  r e p o r t e d  a s  a n  SAE ( s ) a s  d e s c r ib e d  in  S e c t io n 8 . 3 .2 .   I n  b o th  c a s e s  ( i e ,  AE s  o r  SAE s  r e l a t e d  to  
d i s e a s e  p r og r e s s io n ) ,  i t  sh o u ld  b e  in d i c a t e d  th a t  e a c h  e v e n t  ( r e p o r t e d  a s  a  d i a g n o s i s  o r  a s  s ig n s  
a n d  symp tom s )  i s  r e l a t e d  to  d i s e a s e  p r og r e s s io n  o n  th e  A d v e r s e  E v e n t s  f o rm  o f  th e  eCRF .  
T h e  s e v e r i ty  o f  AE s w i l l  b e  a s s e s s e d  u s ing  CTCAE  v4 . 0 3  G r a d e s  1  th r o ug h  4 .   T h e  CTCAE  
v 4 . 0 3  s e v e r i ty  o f  G r a d e  5  w i l l  n o t  b e  u s e d ;  AE s  r e su l t in g  in  d e a th w i l l  b e  g r a d e d  a c c o r d in g ly  
u s in g  G r a d e s  1  th r o ug h  4  a n d  h a v e  th e  o u tc om e  no t e d  a s  f a t a l .   I f  a n  e v e n t  i s  n o t  c l a s s i f i e d  by  CTCAE th e  s e v e r i ty  o f  th e  AE  w i l l  b e  g r a d e d  a c co r d in g  to  th e  s c a l e  b e low  to  e s t im a t e  th e  g r a d e  
o f  s e v e r i ty : 
G rad e 1  M i ld ;  a sym p tom a t i c  o r  m i l d  sym p tom s ;  c l in i c a l  o r  d i a g n o s t i c  o b s e rv a t io n s  o n ly ;  i n t e rven t io n  
n o t  i n d i c a t ed .  
G rad e  2 Mo d e r a t e ;  m in im a l ,  lo c a l ,  o r  n o n in v a s iv e  in t e rv en t io n  i n d i c a t ed ;  l im i t i n g  ag e- ap p ro p r i a t e  a c t iv i t i e s  o f  d a i ly  l iv in g .  
G rad e  3 S ev e r e  o r  m ed i c a lly  s ig n i f i c an t  b u t  n o t  imm ed i a t e ly  l i f e - th r e a t e n in g ;  h o sp i t a l i z a t i o n  o r  p ro lo n g a tio n  o f  h o sp i t a l i z a t io n  i n d i c a t ed ;  d i s ab l in g ;  l im i t in g  s e l f - c a r e  a c t iv i t i e s  o f  d a i ly  l iv in g .  
G rad e  4 L i f e- th r e a t e n in g  co n s eq u e n c e s ;  u rg en t  in t e rv en t io n  in d i c a t ed .  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  52 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
T h e  o c c u r r e n c e  o f  AE s sh o u ld  b e  so u g h t  by  n o n d i r e c t iv e  q u e s t io n ing  o f  th e  su b j e c t  d u r in g  th e  
s c r e e n ing  p r o c e s s  a f t e r  s ig n ing  th e  ICF  a n d  a t  e a ch  v i s i t  d u r in g  th e  s tu dy .   A d v e r s e  e v e n t s  m ay  
a l so  b e  d e t e c t e d  w h e n  th ey  a r e  v o lu n t e e r e d  by  th e  su b j e c t  d u r in g  th e  s c r e e n in g  p r o c e s s  o r  
b e tw e e n  v i s i t s ,  o r  th r o ug h  p hy s i c a l  e x am in a t io n ,  l a b o r a to ry  t e s t ,  o r  o th e r  a s s e s sm e n t s .   T o  th e  e x t e n t  p o s s ib l e ,  e a c h  AE sh o u ld  b e  e v a lu a t e d  to  d e t e rm in e :  
•  T h e  s e v e r i ty  g r a d e  (CTCAE  Gr a d e  1  to  4 ) .  
•  Wh e th e r  th e r e  i s  a t  l e a s t  a  r e a so n a b l e  p o s s ib i l i ty  th a t  th e  AE  i s  r e l a t e d  to  th e  s tu dy  
t r e a tm e n t :   su sp e c t e d  (y e s )  o r  n o t  su sp e c t e d  ( n o ) .  
•  T h e  st a r t  a n d  e n d  d a t e s ,  un l e s s  u n r e so lv e d  a t  f in a l  f o l low - u p .  •  T h e  ac t io n  t a k e n  w i th  r e g a r d  to  s tu dy  d r ug .  
•  T h e  e v e n t  ou t c om e  ( eg ,  no t  r e c o v e r e d /n o t  r e so lv e d ,  r e c o v e r e d / r e so lv e d ,  
r e c o v e r ing / r e so lv ing ,  r e co v e r e d / r e so lv e d  w i th  s e qu e l a e ,  f a t a l ,  u n k n ow n ) .  
•  T h e  se r io u s n e s s ,  a s  p e r  s e r io u s  a d v e r s e  e v e n t  ( SAE)  d e f in i t io n  p r o v id e d  in  
S e c t io n 8 . 3 . 1 .  
U n l ik e  r o u t in e  s a f e ty  a s s e s sm e n t s ,  SAE s  a r e  mo n i to r e d  c o n t in u o u s ly  a n d  h a v e  sp e c i a l  r e p o r t ing  
r e q u i r em e n t s  ( s e e  S e c t ion  8 . 3 . 2 ) .  
A l l  AE s sh o u ld  b e  t r e a t ed  a p p r o p r i a t e ly .   I f  a n  AE  i s  t r e a t e d  w i th  a  c o n c om i t a n t  m e d i c a t io n  o r  
n o n d r u g  th e r a py ,  th i s  a c t io n  sh o u ld  b e  r e c o r d e d  o n  A d v e r s e  Ev e n t f o rm  a n d  th e  t r e a tm e n t  sh o u ld  
b e  sp e c i f i e d  o n  th e  P r io r /Co n c om i t a n t  Me d i c a t io n s  o r  P r o c e d u r e s  a n d  N o n - D r ug  T h e r a py  f o rm  in  th e  e CRF.  
O n c e  a n  AE i s  d e t e c t e d ,  i t  sh o u ld  b e  f o l low e d  u n t i l  i t  h a s  r e so lv e d  o r  u n t i l  i t  i s  ju d g e d  to  b e  
p e rm a n e n t ; a s s e s sm e n t  sh o u ld  b e  m a d e  a t  e a c h  v i s i t  ( o r  mo r e  f r e q u e n t ly  i f  n e c e s s a ry )  o f  a ny  c h a ng e s  in  s e v e r i ty ,  th e  su sp e c t e d  r e l a t io n sh ip  to  th e  s tu dy  d r ug ,  th e  in t e r v en t io n s  r e q u i r e d  to  
t r e a t  th e  e v e n t ,  a n d  th e  ou t c om e .  
Wh e n  th e  s e v e r i ty  o f  a n  AE c h a ng e s  o v e r  t im e  f o r  a  r e p o r t in g  p e r io d  ( eg ,  b e tw e e n  v i s i t s ) ,  e a c h  
c h a ng e  in  s e v e r i ty  w i l l  b e  r e p o r t e d  a s  a s e p a r a t e  AE u n t i l  th e  e v e n t  r e so lv e s .   F o r  e x amp l e ,  
2  s e p a r a t e  AE s w i l l  b e  r ep o r t e d  i f  a  su b j e c t  h a s  G r a d e  1  d i a r r h e a ,  m e e t ing  th e  d e f in i t io n  o f  a n  
AE ,  th a t  l a s t s  f o r  3  d ay s  b e f o r e  w o r s e n ing  to  a  G r a d e  3  s e v e r i ty .   T h e  G r a d e  1  e v e n t  w i l l  b e  r e p o r t e d  a s  a n  AE w i th  a  s t a r t  d a t e  e q u a l  to  th e  d ay  th e  e v e n t  m e t  th e  G r a d e 1  AE d e f in i t io n  a n d  
a  s to p  d a t e  e q u a l  to  th e  d ay  th a t  th e  e v e n t  in c r e a s ed  in  s e v e r i ty  f r om  G r a d e  1  to  G r a d e  3 .   T h e  
G r a d e 3  e v e n t  w i l l  a l so  b e  r e p o r t e d  a s  a n  AE,  w i th  th e  s t a r t  d a t e  e q u a l  to  th e  d ay  th e  e v e n t  c h a ng e d  in  in t e n s i ty  f r om  G r a d e  1  to  G r a d e  3  a nd  a  s to p  d a t e  e q u a l  to  th e  d ay  th a t  th e  e v e n t  
e i th e r  c h a ng e d  s e v e r i ty  ag a in  o r  r e so lv e d .  
U p o n  imp l em e n t a t io n  o f  Am e n dm e n t  4 ,  AE s  l e a d in g  to  t r e a tm e n t  d i s c o n t in u a t io n  a n d  a l l  SAE s  
r eg a r d l e s s  o f  c a u s a l  r e l a t io n sh ip  mu s t  b e  r e p o r t e d  o n  th e  AE  f o rm  in  th e  e CRF . 
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  53 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
8 . 2 .  L ab o ra t o r y  T e s t  Abn o rm a l i t i e s 
L a b o r a to ry  a b n o rm a l i t i e s  th a t  c o n s t i tu t e  a n  AE in  th e i r  ow n  r ig h t  ( c o n s id e r ed  c l in i c a l ly  
m e a n in g f u l ,  in d u c e  c l in i c a l  s ig n s  o r  symp tom s ,  r eq u i r e  c o n c om i t a n t  th e r a py ,  o r  r e q u i r e  c h a ng e s  
in  s tu dy  d r ug )  sh o u ld  b e  r e c o r d e d  o n  th e  Ad v e r s e  E v e n t  f o rm  in  th e  e CRF .   Wh e n e v e r  p o s s ib l e ,  a  
d i a g n o s i s  r a th e r  th a n  a  symp tom  sh o u ld  b e  p r o v id e d  ( eg ,  " a n em i a "  in s t e a d  o f  " low  h emo g lo b in " ) .   L a b o r a to ry  a b n o rm a l i t i e s  th a t  m e e t  th e  c r i t e r i a  f o r  AE s sh o u ld  b e  f o l low e d  u n t i l  th ey  h a v e  
r e tu r n e d  to  n o rm a l  o r  a n  a d e q u a t e  e xp l a n a t io n  o f  th e  a b n o rm a l i ty  i s  f o u n d .   Wh e n  a n  a b n o rm a l  
l a b o r a to ry  t e s t  r e su l t  c o r r e sp o n d s  to  a  s ig n  o r  symp tom  o f  a  p r e v io u s ly  r e po r t e d  AE,  i t  i s  n o t  n e c e s s a ry  to  s e p a r a t e ly  r e c o r d  th e  l a b o r a to ry  t e s t  r e su l t  a s  a n  a d d i t io n a l  e v e n t .  
L a b o r a to ry  a b n o rm a l i t i e s th a t  d o  n o t  m e e t  th e  d e f in i t io n  o f  a n  AE sh o u ld  n o t  b e  r e p o r t e d  a s  AE s.   
A  Gr a d e  3  o r  4  ( s e v e r e )  AE d o e s  n o t  a u tom a t i c a l ly  in d i c a t e  a n  SAE  u n l e s s  i t  m e e t s  th e  d e f in i t io n  o f  s e r io u s ,  a s  d e f in e d  in  S e c t io n 8 . 3 . 1 .   A  d o s e  mo d i f i c a t io n f o r  th e  l a b o r a to ry  a b n o rm a l i ty  m ay  
b e  r e q u i r e d  ( s e e  S e c t io n 5 . 4 )  a n d  sh o u ld  n o t  c o n t r ib u t e  to  th e  d e s ig n a t io n  o f  a  l a b o r a to ry  t e s t  
a b n o rm a l i ty  a s  a n  SAE.  
8 . 3 .  S e r i ou s  Ad v e r s e  E v en t s 
8 . 3 . 1 .  D e f in i t ion s 
A n  SAE  i s  d e f in e d  a s  a n  e v e n t  th a t  m e e t s  a t  l e a s t  1  o f  th e  f o l low in g  c r i t e r i a :  
•  I s  f a t a l  o r  l i f e - th r e a t e n ing .  
•  R e q u i r e s  in p a t i e n t  h o sp i t a l i za t io n  o r  p r o lo n g a t io n  o f  e x i s t in g  h o sp i t a l i z a t io n ,  u n l e s s  
h o sp i t a l i z a t io n  i s  a  r e su l t  o f : 
− A  r o u t in e  t r e a tm e n t  o r  mo n i to r in g  o f  th e  s tu d i e d  in d i c a t io n  n o t  a s so c i a t e d  w i th  
a ny  d e t e r io r a t io n  in  c o n d i t io n .    
− A n  e l e c t iv e  su rg e ry  o r  p r e p l a n n e d  t r e a tm e n t  f o r  a  p r e - e x i s t in g  c o n d i t io n  th a t  i s  
u n r e l a t e d  to  th e  in d i c a t ion  u n d e r  s tu dy  a n d  h a s  n o t  w o r s e n e d  s in c e  s ig n ing  th e  
ICF .  
− A  t r e a tm e n t  o n  a n  em e rg e n cy  o u tp a t i e n t  b a s i s  f o r  a n  e v e n t  n o t  f u l f i l l in g  a ny  o f  th e  
d e f in i t io n s  o f  a  SAE  a n d  n o t  r e su l t in g  in  h o sp i t a l  adm i s s io n .  
− A ny  so c i a l  r e a so n s  a n d  r e sp i t e  c a r e ,  in  th e  a b s e n c e  o f  a ny  d e t e r io r a t io n  in  th e  
su b j e c t ' s  g e n e r a l  c o n d i t io n .  
•  R e su l t s  in  p e r s i s t e n t  o r  s ig n i f i c a n t  d i s a b i l i ty,  in c a p a c i ty ,  o r  a  su b s t a n t i a l  d i s r u p t io n  o f  
a  p e r so n ' s  a b i l i ty  to  c o n du c t  n o rm a l  l i f e  f u n c t io n s .  
•  Co n s t i tu t e s  a  c o n g e n i t a l  a n om a ly  o r  b i r th  d e f e c t.  
•  I s  c o n s id e r e d  to  b e  a n  imp o r t a n t  m e d i c a l  e v e n t  o r  a  m e d i c a l ly  s ig n i f i c a n t  ev e n t  th a t  
m ay  n o t  r e su l t  in  d e a th ,  b e  imm e d i a t e ly  l i f e - th r e a t e n in g ,  o r  r e q u i r e  h o sp i t a l i z a t io n  b u t  
m ay  b e  c o n s id e r e d  s e r io u s w h e n ,  b a s e d  o n  a p p r o p r i a t e  m e d i c a l  ju dgm e n t ,  th e  e v e n t  
m ay  j e o p a r d i z e  th e  su b j e c t  o r  m ay  r e q u i r e  m e d i c a l  o r  su r g i c a l  in t e r v e n t io n  to  p r e v e n t  1  o f  th e  o u t c om e s  l i s t e d  a b o v e .  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  54 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
8 . 3 . 2 .  R epo r t ing 
E v e ry  SAE ,  r eg a r d l e s s  o f  su sp e c t e d  c a u s a l i ty  ( eg ,  r e l a t io n sh ip  to  s tu dy  d r ug ( s)  o r  s tu dy  
p r o c e d u r e  o r  d i s e a s e  p r og r e s s io n ) ,  o c c u r r ing  a f t e r  th e  su b j e c t  h a s  s ig n e d  th e  ICF  th r o ug h  th e  l a s t  
s tu dy  v i s i t  ( o r  3 0  d ay s  a f t e r  th e  l a s t  d o s e  o f  s tu dy  d r u g ,  w h i c h e v e r  i s  l a t e r )  mu s t  b e  r e p o r t e d  to  
th e  sp o n so r  ( o r  d e s ig n e e )  w i th in  2 4  hou r s o f  l e a r n in g  o f  i t s  o c c u r r e n c e ,  u n l e s s  o th e rw i s e  sp e c i f i e d  by  th e  P r o to c o l .   A ny  SAE s  o c c u r r ing  mo r e  th a n  3 0  d ay s  a f t e r  th e  l a s t  d o s e  o f  s tu dy  
d r u g  sh o u ld  b e  r e p o r t e d  to  th e  sp o n so r  o r  i t s  d e s ig n e e  o n ly  i f  th e  in v e s t ig a to r  su sp e c t s  a  c a u s a l  
r e l a t io n sh ip  to  th e  s tu dy  d r u g .    
I n f o rm a t io n  a b o u t  a l l  SAE s  i s  c o l l e c t e d  a n d  r e c o rd e d  o n  th e  A d v e r s e  E v e n t  f o rm  o f  th e  eCRF .   
T h e  in v e s t ig a to r  mu s t  a s s e s s  a n d  r e c o r d  th e  c a u s a l  r e l a t io n sh ip  o f  e a c h  SAE  to  th e  s tu dy  
t r e a tm e n t .    
T h e  in v e s t ig a to r  mu s t  a l so  c omp l e t e  th e  I n cy t e  S e r io u s  A d v e r s e  E v e n t  R e p o r t  F o rm ,  in  E ng l i sh ,  
a n d  s e n d  th e  c omp l e t e d  an d  s ig n e d  f o rm  to  th e  sp o n so r  o r  d e s ig n e e  w i th in  2 4  h o u r s  o f  b e c om ing  
aw a r e  o f  th e  SAE .   T h e  in v e s t ig a to r  mu s t  p r o v id e  a  c a u s a l i ty  a s s e s sm e n t ,  th a t  i s ,  a s s e s s  w h e th e r  th e r e  i s  a t  l e a s t  a  r e a so n ab l e  p o s s ib i l i ty  th a t  th e  SAE  i s  r e l a t e d  to  th e  s tu dy  t r e a tm e n t :   su sp e c t e d  
(y e s )  o r  n o t  su sp e c t e d  ( no ) .   R e f e r  to  th e  I n cy t e  R e f e r e n c e  G u id e  f o r  Comp l e t in g  th e  S e r io u s  
A d v e r s e  E v e n t  R e p o r t  F o rm .  
T h e  c o n t a c t  in f o rm a t io n  o f  th e  sp o n so r ' s  s tu dy - sp e c i f i c  r e p r e s e n t a t iv e s  i s  l i s t e d  in  th e  
in v e s t ig a to r  m a n u a l  p r o v id e d  to  e a c h  s i t e .   T h e  o r ig in a l  c o py  o f  th e  SAE  R e p o r t  F o rm  a n d  th e  
c o n f i rm a t io n  sh e e t  mu s t  b e  k e p t  a t  th e  s tu dy  s i t e .  
I n v e s t ig a t io n a l  s i t e  p e r son n e l  mu s t  r e p o r t  a ny  n ew  in f o rm a t io n  r eg a r d in g  th e  SAE  w i th in  
2 4  h o u r s  o f  b e c om ing  aw a r e  o f  th e  in f o rm a t io n  in  th e  s am e  m a n n e r  th a t  th e  in i t i a l  SAE  R e p o r t  
F o rm  w a s  s e n t .   F o l low -u p  in f o rm a t io n  i s  r e c o r d ed  o n  a n  am e n d e d  o r  n ew  SAE  R e p o r t  F o rm ,  w i th  a n  in d i c a t io n  th a t  i t  i s  f o l low- u p  to  th e  p r e v iou s ly  r e p o r t e d  SAE  a n d  th e  d a t e  o f  th e  o r ig in a l  
r e p o r t .   T h e  f o l low - u p  r ep o r t  sh o u ld  in c lu d e  in f o rm a t io n  th a t  w a s  n o t  p r o v id e d  o n  th e  p r e v io u s  
SAE  R e p o r t  F o rm ,  su c h  a s  th e  o u t c om e  o f  th e  e v en t  ( e g ,  r e so lv e d  o r  o ng o in g ) ,  t r e a tm e n t  p r o v id e d ,  a c t io n  t a k e n  w i th  s tu dy  d r ug  b e c a u s e  o f  th e  SAE  ( eg ,  d o s e  r e d u c ed ,  in t e r r u p t e d ,  o r  
d i s c o n t in u e d ) ,  o r  su b j e c t  d i sp o s i t io n  ( e g ,  c o n t in u ed  o r  w i th d r ew  f r om  s tu dy  p a r t i c ip a t io n ) .   E a c h  
r e c u r r e n c e ,  c omp l i c a t io n ,  o r  p r og r e s s io n  o f  th e  o r ig in a l  e v e n t  sh o u ld  b e  r e po r t e d  a s  f o l low - u p  to  th a t  e v e n t ,  r eg a r d l e s s  o f  w h e n  i t  o c c u r s .  
I f  th e  SAE  i s  n o t  d o c um en t e d  in  th e  IB  f o r  th e  s tudy  d r ug  ( n ew  o c c u r r e n c e )  a n d  i s  th o u g h t  to  b e  
r e l a t e d  to  th e  sp o n so r ' s  s tu dy  d r ug ,  th e  sp o n so r  o r  i t s  d e s ig n e e  m ay  u rg e n t ly  r e q u i r e  f u r th e r  in f o rm a t io n  f r om  th e  i n v e s t ig a to r  f o r  r e p o r t ing  to  h e a l th  a u th o r i t i e s.   T h e  sp o n so r  o r  i t s  d e s ig n e e  
m ay  n e e d  to  i s su e  a n I n v e s t ig a to r  N o t i f i c a t io n  ( IN )  to  in f o rm  a l l  in v e s t ig a to r s  in v o lv e d  in  a ny  
s tu dy  w i th  th e  s am e  d r ug  th a t  th i s  SAE  h a s  b e e n  r e p o r t e d .   Su sp e c t e d  U n e xp e c t e d  S e r io u s  A d v e r s e  R e a c t io n s  (SUSAR s )  w i l l  b e  c o l l e c t e d  a nd  r e p o r t e d  to  th e  c omp e t en t  a u th o r i t i e s  a n d  
r e l e v a n t  e th i c s  c omm i t t e e s  in  a c c o r d a n c e  w i th  D i r e c t iv e  2 0 0 1 /2 0 /EC ,  o r  a s  p e r  n a t io n a l  
r eg u l a to ry  r e q u i r em e n t s  in  p a r t i c ip a t in g  c o u n t r i e s .  
U p o n  imp l em e n t a t io n  o f  Am e n dm e n t  4 ,  a l l  SAE s  r eg a r d l e s s  o f  c a u s a l  r e l a t io n sh ip  w i l l  b e  
r e p o r t e d  a s  d e s c r ib e d  a b ov e .  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  55 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
8 . 4 .  Ad v e r s e  E v en t s  o f  Sp e c i a l  In t e r e s t 
Sp e c i f i c  a d v e r s e  e v e n t s ,  o r  g r o u p s  o f  a d v e r s e  e v en t s ,  w i l l  b e  f o l low e d  a s  p a r t  o f  s t a n d a r d  s a f e ty  
mo n i to r in g  a c t iv i t i e s .   T h e s e  e v en t s  ( r eg a r d l e s s  o f  s e r io u sn e s s )  w i l l  b e  r e p o r t e d  p e r  th e  SAE  
r e p o r t ing  t im e l in e s  ( s e e  S e c t io n  8 . 3 . 2 ) .  
•  ALT  ≥  5  ×  ULN 
•  AST  ≥  5  ×  ULN •  Co l i t i s 
•  D i a r r h e a ≥  G r a d e  2   
•  R a sh ≥  G r a d e  2 •  I n t e s t in a l  p e r f o r a t io n  •  Pn e umo n i t i s  •  P n e um o c y s t i s j i ro v e c i i  in f e c t io n  •  CMV  in f e c t io n 
•  H e r p e s  s i mp l e x  v i r u s  in f e c t io n  
•  V a r i c e l l a  z o s t e r  v i r u s  in f e c t io n  •  E x f o l i a t iv e  d e rm a t i t i s 
8 . 5 .  P r e gn an cy  
P r e g n a n cy , in  a n d  o f  i t s e l f ,  i s  n o t  r eg a r d e d  a s  a n  AE u n l e s s  th e r e  i s  su sp i c io n  th a t  s tu dy  d r ug  m ay  
h a v e  in t e r f e r e d  w i th  th e  e f f e c t iv e n e s s  o f  a  c o n t r a c ep t iv e  m e d i c a t io n  o r  m e tho d .   Wh e n  a  p r eg n a n cy  h a s  b e e n  c o n f i rm e d  in  a  su b j e c t  d u r ing  m a t e r n a l  o r  p a t e r n a l  e xp o su r e  to  s tu dy  d r ug ,  
th e  f o l low in g  p r o c e d u r e s  sh o u ld  b e  f o l low e d  in  o rd e r  to  e n su r e  su b j e c t  s a f e ty :  
•  T h e  stu dy  d r ug  mu s t  b e  d i s c o n t in u e d  imm e d i a t e ly  ( f em a l e  su b j e c t s  o n ly ;  s e e  
S e c t io n 5 . 4  f o r  th e  m a x imum  p e rm i t t e d  d u r a t io n  o f  s tu dy  d r ug  in t e r r u p t io n ) .  
•  T h e  in v e s t ig a to r  mu s t  c omp l e t e  a n d  su bm i t  th e  I n cy t e  C l in i c a l  T r i a l  Pr eg n a n cy  f o rm 
to  th e  sp o n so r  o r  i t s  d e s ig n e e  w i th in  2 4  hou r s o f  l e a r n ing  o f  th e  p r eg n a n cy .  
D a t a  o n  f e t a l  o u t c om e  a nd  b r e a s t f e e d ing  a r e  c o l l e c t e d  f o r  r eg ul a to ry  r e p o r t in g  a n d  d r ug  s a f e ty  e v a lu a t io n .   F o l low - u p  sho u ld  b e  c o n d u c t e d  f o r  e a c h  p r eg n a n cy  to  d e t e rm in e  o u t c om e ,  in c lu d ing  
sp o n t a n e o u s  o r  v o lu n t a ry  t e rm in a t io n ,  d e t a i l s  o f  th e  b i r th ,  a n d  th e  p r e s e n c e  o r  a b s e n c e  o f  a ny  b i r th  d e f e c t s ,  c o ng e n i t a l  a b n o rm a l i t i e s ,  o r  m a t e r n a l  a n d /o r  n ew b o r n  c omp l i c a t io n s ,  by  f o l low ing  
u n t i l  th e  f i r s t  w e l l- b a by  v i s i t .   P r e g n a n cy  sh o u ld  b e  r e c o r d e d  o n  a  C l in i c a l  T r i a l  P r egn a n cy  f o rm  
a n d  r e p o r t e d  by  th e  in v e s t ig a to r  to  th e  sp o n so r  o r  i t s  d e s ig n e e .   P r eg n a n cy  fo l low - u p  in f o rm a t io n  sh o u ld  b e  r e c o r d e d  o n  th e  s am e  f o rm  a n d  sh o u ld  in c lu d e  a n  a s s e s sm e n t  o f  th e  p o s s ib l e  c a u s a l  
r e l a t io n sh ip  to  th e  sp o n so r ' s  s tu dy  d r ug  to  a ny  p r eg n a n cy  o u t c om e ,  a s  w e l l  a s  f o l low - u p  to  th e  
f i r s t  w e l l - b a by  v i s i t  o r  th e  d u r a t io n  sp e c i f i e d  in  lo c a l  r eg u l a t io n s ,  w h i c h e v e r  i s  l a t e r .   R e f e r  to  th e  I n cy t e  R e f e r e n c e  G u id e  fo r  Comp l e t in g  th e  C l in i c a l  T r i a l  P r eg n a n cy  F o rm .  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  56 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
Any  SAE  o c cu r r ing  du r ing  p r e gnan c y  mu s t  b e  r ec o rd ed  on  th e  SAE  r epo r t  fo rm  and  
subm i t t ed  t o  th e  spon so r  o r  d e s ign e e .  
8 . 6 .  W a rn in g s  and  P r e c au t ion s 
Sp e ci a l  w a r n ing s  o r  p r e c a u t io n s  f o r  th e  s tu dy  d r ug ,  d e r iv e d  f r om  s a f e ty  in fo rm a t io n  c o l l e c t e d  by  th e  sp o n so r  o r  i t s  d e s ig n e e ,  a r e  p r e s e n t e d  in  th e  I nv e s t ig a to r ' s  B r o c h u r e  ( INCB 0 5 0 4 6 5  IB ) .   A d d i t io n a l  s a f e ty  in f o rm a t io n  c o l l e c t e d b e tw e e n  IB  u p d a t e s  w i l l  b e  c ommu n i c a t e d  in  th e  f o rm  o f  
I n v e s t ig a to r  N o t i f i c a t io n s  ( IN s ) .   A ny  imp o r t a n t  n ew  s a f e ty  in f o rm a t io n  sh o u ld  b e  d i s c u s s e d  w i th  
th e  su b j e c t  d u r ing  th e  s tu dy ,  a s  n e c e s s a ry .   I f  n ew  s ig n i f i c a n t  r i sk s  a r e  id e n t i f i e d ,  th ey  w i l l  b e  a d d e d  to  th e  ICF .  
8 . 7 .  Ind ep end en t  D a t a  M on i t o r in g  C omm i t t e e  
A n  IDMC  w i l l  b e  f o rm e d a n d  w i l l  c o n s i s t  o f  q u a l i f i e d  in d iv id u a l s  w h o  a r e  no t  in v o lv e d  w i th  th e  
c o n d u c t  o f  th e  s tu dy .   T h e  e s t a b l i shm e n t ,  c omp o s i t io n ,  r o l e s ,  d u t i e s ,  a n d  r e sp o n s ib i l i t i e s  o f  th e  
IDMC  a r e  a d d r e s se d  in  th e  a p p r o v e d  IDMC  c h a r t e r .  
8 . 8 .  P r odu c t  C omp l a in t s 
T h e  sp o n so r  c o l l e c t s  p r od u c t  c omp l a in t s  o n  s tu dy  d r u g s  a n d  d r ug  d e l iv e ry  sy s t em s  u s e d  in  
c l in i c a l  s tu d i e s  in  o r d e r  to  e n su r e  th e  s a f e ty  o f  s tudy  p a r t i c ip a n t s ,  mo n i to r  q u a l i ty ,  a n d  f a c i l i t a t e  
p r o c e s s  a n d  p r o d u c t  imp ro v em e n t s .  
Al l  p r o d u c t  c omp l a in t s  a s so c i a t e d  w i th  m a t e r i a l  p a c k ag e d ,  l a b e l e d ,  a n d  r e l e a s e d  by  th e  sp o n so r  
o r  i t s  d e s ig n e e  w i l l  b e  r ep o r t e d to  th e  sp o n so r .   A l l  p r o d u c t  c omp l a in t s  a s so c i a t e d  w i th  o th e r  
s tu dy  m a t e r i a l  w i l l  b e  r e po r t e d  d i r e c t ly  to  th e  r e sp e c t iv e  m a n u f a c tu r e r .  
T h e  in v e s t ig a to r  o r  h i s /h e r  d e s ig n e e  i s  r e sp o n s ib l e  f o r  r e p o r t ing  a  c omp l e t e  d e s c r ip t io n  o f  th e  
p r o d u c t  c omp l a in t  v i a  em a i l  o r  o th e r  w r i t t e n  c ommu n i c a t io n  to  th e  sp o n so r  c o n t a c t  o r  r e sp e c t iv e  
m a n u f a c tu r e r  a s  n o t e d  in  th e  p ac k ag ing  in f o rm a t io n .   A ny  AE  a s so c i a t e d  w i th  a  p r o d u c t  c omp l a in t  sh o u ld  b e  r e p o r t e d  a s  d e s c r ib e d  in  S e c t io n 8 . 1 . 2  o f  th i s  P r o to c o l .  
I f  th e  i n v e s t ig a to r  i s  a sk ed  to  r e tu r n  th e  p r o d u c t  f o r  in v e s t ig a t io n ,  h e / sh e  w i ll  r e tu r n  a  c o py  o f  th e  
p r o d u c t  c omp l a in t  c ommu n i c a t io n  w i th  th e  p r o d u c t .  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  57 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
9 .  STAT IST ICS 
9 . 1 .  S tud y  P opu l a t ions  
T h e  f u l l  a n a ly s i s  s e t  in c lu d e s  a l l  su b j e c t s  e n r o l l e d  in th e  s tu dy  w h o  r e c e iv ed  a t  l e a s t  1  d o s e o f  
INCB 0 5 0 4 6 5 .   T h e  f u l l  an a ly s i s  s e t  w i l l  b e  u s e d  fo r  th e  summ a ry  o f  d emog r a p h i c s ,  b a s e l in e  c h a r a c t e r i s t i c s ,  su b j e c t  d i sp o s i t io n ,  a n d  a n a ly s e s  o f  a l l  e f f i c a cy  d a t a .  
T h e  p e r p r o to c o l  (PP )  p o p u l a t io n  in c lu d e s  a l l  s u b j e c t s  in  th e  f u l l  a n a ly s i s  s e t  w h o  w e r e 
su f f i c i e n t ly  c omp l i a n t  w i th  th e  P r o to c o l .   T h e  f o l low in g  p r o c e d u r e s  w i l l  b e  p e r f o rm e d  to  id e n t i fy  th o s e  su b j e c t s  w h o  a r e  to  b e  e x c lu d e d  f r om  th e  PP  p o p u l a t io n  b e f o r e  th e  d a t a b a s e  f r e e z e : 
•  C l in i c a l  r e v i ew  o f  P r o to co l  d e v i a t io n s /v io l a t io n s  
•  C l in i c a l  r e v i ew  o f  c o n c om i t a n t  m e d i c a t io n s  a s  de f in e d  in  S e c t io n 5 . 6  o f  th e  P r o to c o l  
•  C l in i c a l  r e v i ew  o f  th e  d o s e  a dm in i s t r a t io n  a n d  d r ug  a c c o u n t a b i l i ty  l i s t in g  
T h e  d e t e rm in a t io n  o f  su b j e c t s  b e in g  c o n s id e r e d  f o r  e x c lu s io n  f r om  th e  PP  p o p u l a t io n  by  th e  
c l in i c a l  t e am  w i l l  b e  p r e p a r e d  a n d  s ig n e d  b e f o r e  d a t a b a s e  f r e e z e .   
T h e  s a f e ty  p o p u l a t io n  in c lu d e s  a l l  su b j e c t s  e n r o l l ed  in  th e  s tu dy  w h o  r e c e iv e d  a t  l e a s t  1  d o s e o f  
INCB 0 5 0 4 6 5 .   T h i s  p o p u l a t io n  w i l l  b e  u s e d  f o r  a l l  s a f e ty  a n a ly s e s .   
9 . 2 .  S e l e c t i on  o f  S amp l e  S i z e 
T h e  s tu dy  w i l l  e n r o l l  1 0 0  su b j e c t s  in to  G r o u p  A .   I f  th e  t r u e  ORR  i s  0 . 5 0 ,  th e n  th e r e  i s  
a p p r o x im a t e ly  9 0%  p r o b a b i l i ty  o f  o b s e r v ing  th e  low e r  b o u n d  o f  th e  9 5%  C I  o f  th e  ORR  ≥  3 5 % . 
 
 
 
9 . 3 .  L e v e l  o f  S i gn i f i c an c e 
T h e r e  w i l l  no t  b e  a ny  s t a t i s t i c a l  c omp a r i so n  b e tw e e n  th e  2  g r o u p s .   W i th in  e a c h  g r o u p ,  2 - s id e d  
9 5%  C I s  w i l l  b e  r e p o r t e d  f o r  a l l  a n a ly s e s  w h e n  a pp r o p r i a t e .  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  58 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
9 . 4 .  S t a t i s t i c a l  An a l y s e s 
9 . 4 . 1 .  E f f i c a c y  Ana ly s e s  
9 . 4 . 1 . 1 .  P r im a r y  E f f i c a c y  Ana ly s e s 
O b j e c t iv e  r e sp o n s e  r a t e  i s  d e f in e d  a s  th e  p e r c e n t ag e  o f  su b j e c t s  w i th  a  CR/CMR  o r  PR/PMR  a s  
d e t e rm in e d  by  r e v i s e d  r e sp o n s e  c r i t e r i a  f o r  DLBCL ( Ch e so n  e t  a l  2 0 1 4) .  
T h e  ORR  a s  d e t e rm in e d  by  th e  IRC  a n d  i t s  9 5%  ex a c t  b in om i a l  C I s w i l l  b e  c a l c u l a t e d f o r  su b j e c t s  in  G r o u p  A .   T h i s  i s  c o n s id e r e d  th e  p r im a ry  e f f i c a cy  a n a ly s i s  o f  th e  s tu dy .   
T h e  ORR  a s  r e p o r t e d  by  th e  in v e s t ig a to r  a n d  i t s  9 5%  e x a c t  b in om i a l  C I s  w i l l  a l so  b e  c a l c u l a t e d  
f o r  su b j e c t s  in  G r o u p  A .  
R e sp o n s e  d a t a  w i l l  b e  a n a ly z e d  w h e n  a l l  su b j e c t s  h a v e  r e c e iv e d  a t  l e a s t  1  po s tb a s e l in e  d i s e a s e  
a s s e s sm e n t ,  o r  h a v e  p r og r e s s e d ,  w i th d r aw n  f r om  th e  s tu dy ,  o r  d i e d .   
9 . 4 . 1 . 2 .  S e c onda r y  E f f i c a c y  Ana ly s e s  
D u r a t io n  o f  r e sp o n s e  i s  d e f in e d  a s  th e  t im e  f r om  f i r s t  d o c um e n t e d  e v id e n c e  o f  CR/CMR  o r  
PR/PMR  u n t i l  d i s e a s e  p ro g r e s s io n  o r  d e a th  d u e  to  a ny  c a u s e  amo ng  su b j e c t s  w h o  a c h i e v e  a n  o v e r a l l  r e sp o n s e  ( i e ,  CR/CMR  o r  PR/PMR )  a s  d e t e rm in e d  by  r e v i s e d  r e sp on s e  c r i t e r i a  f o r  
lymp h om a s  ( Ch e so n  e t  a l  2 0 1 4) .   F o r  su b j e c t s  w h o  h a v e  n o t  p r og r e s s e d  a n d  a r e  s t i l l  a l iv e  a t  th e  
t im e  o f  t h e  a n a ly s i s ,  DOR  w i l l  b e  c e n so r e d  o n  th e  d ay  o f  l a s t  e v a lu a b l e  d i s e a s e  a s s e s sm e n t .   F o r  su b j e c t s  w h o  h a v e  d i s c o n t in u e d  s tu dy  o r  h a v e  s t a r t e d  o th e r  a n t i c a n c e r  t r e a tm e n t ,  DO R  w i l l  b e  
c e n so r e d  o n  th e  d ay  o f  l a s t  e v a lu a b l e  d i s e a s e  a s s e s sm e n t  d o c um e n t in g  a b s en c e  o f  PD/PMD  
b e f o r e  th e  d i s c o n t in u a t io n  o r  th e  s t a r t  o f  th e  n ew  an t i c a n c e r  t r e a tm e n t .  
P r o g r e s s io n - f r e e  su r v iv a l  i s  d e f in e d  a s  th e  t im e  f r om  th e  d a t e  o f  f i r s t  d o s e  o f  th e  s tu dy  d r ug  to  th e  
f i r s t  d o c um e n t e d  d i s e a s e  p r o g r e s s io n  a s  d e t e rm in ed  by  r e v i s e d  r e sp o n s e  c r i t e r i a  f o r  lymp h om a s  
( Ch e so n  e t  a l  2 0 1 4) ,  o r  d e a th  d u e  to  a ny  c a u s e ,  wh i c h e v e r  o c c u r s  f i r s t .   F o r  su b j e c t s  w h o  h a v e  n o t  p r o g r e s s e d  a n d  a r e  s t i l l  a l iv e  a t  th e  t im e  o f  th e  a n a ly s i s ,  PFS  w i l l  b e  c e n so r e d  o n  th e  d ay  o f  
l a s t  e v a l u a b l e  d i s e a s e  a s s e s sm e n t .   F o r  su b j e c t s  wh o  h a v e  d i s c o n t in u e d  s tudy  o r  h a v e  s t a r t e d  
o th e r  a n t i c a n c e r  t r e a tm e n t ,  PFS  w i l l  b e  c e n so r e d  on  th e  d ay  o f  l a s t  e v a lu a b l e  d i s e a s e  a s s e s sm e n t  d o c um e n t in g  a b s e n c e  o f  PD/PMD  b e f o r e  th e  d i s co n t in u a t io n  o r  th e  s t a r t  o f  th e  n ew  a n t i c a n c e r  
t r e a tm e n t .   F o r  su b j e c t s  w h o  h a v e  n o  b a s e l in e  o r  n o  p o s tb a s e l in e  d i s e a s e  a s s e s sm e n t ,  PFS  w i l l  b e  
c e n so r e d  w i th  c e n so r e d  du r a t io n  o f  1  d ay .  
T h e  K a p l a n- M e i e r  e s t im a t io n  o f  m e d i a n  DOR  a nd  PFS  a s  d et e rm in e d  by  th e  IRC  an d  i t s  
9 5%  C I s  w i l l  b e  pr o v id ed  f o r  su b j e c t s  in  G r o u p  A .  
T h e  K a p l a n- M e i e r  e s t im a t io n  o f  m e d i a n  DOR  a nd  PFS  a s  r e p o r t e d  by  th e  in v e s t ig a to r  a n d  i t s  
9 5%  C I s  w i l l  a l so  b e  p r ov id e d  f o r  su b j e c t s  in  G r ou p  A .  
O v e r a l l  su r v iv a l  i s  d e f in ed  a s  th e  t im e  f r om  th e  d a t e  o f  f i r s t  d o s e  o f  s tu dy  d ru g  to  d e a th  d u e  to  
a ny  c a u s e .   F o r  su b j e c t s  w h o  a r e  s t i l l  a l iv e  a t  th e  t im e  o f  th e  a n a ly s i s ,  OS  w i l l  b e  c e n so r e d  o n  th e  d a t e  th e  su b j e c t s  i s  l a s t  kn ow n  to  b e  a l iv e .   T h e  K a p l a n - M e i e r  e s t im a t io n  o f  m e d i a n  OS  a n d  i t s  
9 5%  C I s  w i l l  b e  p r o v id ed  f o r  su b j e c t s  in  G r o u p  A .  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  59 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
9 . 4 . 2 .  Sa f et y  Ana ly s e s  
9 . 4 . 2 . 1 .  Adv e r s e  Ev en t s 
A  t r e a tm e n t- em e rg e n t  a dv e r s e  e v e n t  (TEAE )  i s  a ny  AE  e i th e r  r e p o r t e d  f o r  th e  f i r s t  t im e  o r  
w o r s e n ing  o f  a  p r e- e x i s t i n g  e v e n t  a f t e r  f i r s t  d o s e  o f  s tu dy  d r ug .   A n a ly s i s  o f  AE s  w i l l  b e  l im i t e d  
to  TEAE s ,  b u t  d a t a  l i s t in g s  w i l l  in c lu d e  a l l  AE s  r eg a r d l e s s  o f  th e i r  t im in g  to  s tu dy  d r ug  
a dm in i s t r a t io n .   A d v e r s e  e v e n t s  w i l l  b e  t a b u l a t e d  by  th e  M edDRA  p r e f e r r e d  t e rm  a n d  sy s t em  o r g a n  c l a s s .   S e v e r i ty  o f  AE s  w i l l  b e  b a s e d  o n  th e  NC I  CTCAE  v 4 . 0 3  u s ing  G r a d e s  1  th r o ug h  4 .  
T h e  su b s e t  o f  AE s  c o n s id e r e d  by  th e  in v e s t ig a to r  to  h a v e  a  r e l a t io n sh ip  to  s tu dy  d r ug  w i l l  b e  
c o n s id e r e d  to  b e  t r e a tm en t - r e l a t e d  AE s .   I f  th e  in v e s t ig a to r  d o e s  n o t  sp e c i fy  th e  r e l a t io n sh ip  o f  th e  AE  to  s tu dy  d r ug ,  th en  th e  AE  w i l l  be  c o n s id e r e d  t r e a tm e n t - r e l a t e d .   T h e  in c id e n c e  o f  AE s  
a n d  t r e a tm e n t - r e l a t e d  AE s  w i l l  b e  t a b u l a t e d .  
A n  o v e r a l l  summ a ry  o f  AE s  w i l l  in c lu d e  n umb e r  (% )  o f  su bj e c t s  r e p o r t ing  a ny  TEAE s ,  a ny  
SAE s ,  a ny  G r a d e  3  o r  4  TEAE s ,  a ny  t r e a tm e n t- r e l a t e d  TEAE s ,  a ny  f a t a l  T EAE , a n d  a ny  TEAE s  
l e a d in g  to  t r e a tm e n t  in t e r r u p t io n /d o s e  r e d u c t io n /d i s c o n t in u a t io n .  
N umb e r  (% )  o f  su b j e c t s  r e p o r t in g  a ny  TEAE s ,  a ny  SAE s ,  a ny  G r a d e  3  o r  4  TEAE s ,  a ny  
t r e a tm e n t - r e l a t e d  TEAE s ,  a ny  t r e a tm e n t - r e l a t e d  SAE s ,  a ny  t r e a tm e n t - r e l a t e d  G r a d e  3  o r  4  
TEAE s ,  a ny  f a t a l  TEAE ,  a n d  a ny  TEAE s  l e a d ing  to  t r e a tm e n t  in t e r r u p t io n /d o s e  
r e d u c t io n /d i s c o n t in u a t io n  w i l l  b e  t a b u l a t e d  by  sy s t em  o r g a n  c l a s s  a n d  p r e f e r r e d  t e rm .  
9 . 4 . 2 . 2 .  C l in i c a l  Labo r a t o r y  T e s t s  
L a b o r a to ry  d a t a  w i l l  b e  c l a s s i f i e d  in to  Gr a d e s  1  th r o u g h  4  u s ing  CTCAE  v4 . 0 3  w h e n  a p p l i c a b l e .   
T h e  f o l low in g  summ a r i e s  w i l l  b e  p r o d u c e d  f o r  th e  l a b o r a to ry  d a t a :  
•  D e s c r ip t iv e  s t a t i s t i c s  o f  th e  v a lu e  a n d  c h a ng e  f r om  b a s e l in e  a t  e a c h  a s s e s sm e n t  t im e  
w i l l  b e  p r o v id e d .  
•  F o r  l a b o r a to ry  p a r am e t e r s  th a t  h a v e  CTC  g r a d ing ,  sh i f t  t a b l e s  w i l l  b e  p r o v id e d  
sh ow in g  c h a ng e  in  CTC  g r a d e  f r om  b a s e l in e  to  th e  w o r s t  g r a d e  p o s tb a s e l in e .  
•  F o r  l a b o r a to ry  p a r am e t e r s  w h e r e  CTC  g r a d e s  a r e  n o t  d e f in e d ,  sh i f t  t a b l e s  f r om  
b a s e l in e  to  th e  w o r s t  p o s tb a s e l in e  v a lu e  w i l l  b e  p ro d u c e d  u s ing  th e  low /n o rm a l /h ig h  c l a s s i f i c a t io n s  b a s e d  o n  l a b o r a to ry  r e f e r e n c e  r a ng e s .  
C a t e g o r i c a l  l a b o r a to ry  d a t a  w i l l  b e  t a b u l a t e d  by  v i s i t  a t  b a s e l in e  a n d  p o s tb a s e l in e  v i s i t s  w h e n  
n e c e s s a ry .
 
9 . 4 . 2 . 3 .  V i t a l  S ign s 
D e s c r ip t iv e  s t a t i s t i c s  a n d  m e a n  c h a ng e  f r om  b a s e l in e  w i l l b e  summ a r i z e d  f o r  v i t a l  s i g n s  ( w e ig h t ,  
b lo o d  p r e s su r e ,  p u l s e ,  r e sp i r a to ry  r a t e ,  a n d  b o dy  t emp e r a tu r e )  a t  e a c h  a s s e s sm e n t  t im e .   V i t a l  s ig n  r e su l t s  w i l l  b e  r e v i ew e d  f o r  c l in i c a l ly  n o t a b l e  a b n o rm a l i t i e s  ( s e e  T a b l e 1 2 ) ,  a n d  su b j e c t s  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  60 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
e xh ib i t in g  c l in i c a l ly  n o t ab l e  v i t a l  s ig n  a b n o rm a l i t i e s  w i l l  b e  l i s t e d .   A  v a lu e  w i l l  a l so  b e  
c o n s id e r e d  a n  " a l e r t "  v a lu e  i f  i t  i s  o u t s id e  th e  e s t a b l i sh e d  r a ng e  a n d  sh ow s  a  >  2 5%  ch a ng e  f r om  
b a s e l in e .   T h e  a b n o rm a l  v a lu e s  f o r  su b j e c t s  e xh ib i t in g  a l e r t  v i t a l  s ig n  a b n o r m a l i t i e s  w i l l  b e  l i s t e d 
Tab l e  1 2 :  C r i t e r ia  fo r  C l in i c a l ly  N o t ab l e  V i t a l  S ign  Abn o rm a l i t i e s 
Pa ram e t e r H i gh  Th r e sh o ld L ow  Th r e sh o ld 
Sy s t o l i c  b l ood  p r e s s u r e >  155  mmHg <  85  mmHg 
D i a s t o l i c  b l ood  p r e s s u r e >  100  mmHg <  40 mmHg 
Pu l s e >  100  bpm <  45  b pm  
T em p e r a t u r e >  38 ºC <  35 ºC 
R e s p i r a t o ry  r a t e >  24 /m in <  12/m in  
9 . 4 . 2 . 4 .  E l e c t r o c a rd io g r am s 
D e s c r ip t iv e  s t a t i s t i c s  a n d  m e a n  c h a ng e  f r om  b a s e l in e  w i l l b e  summ a r i z e d  f o r  th e  ECG  p a r am e t e r 
a t  e a c h  a s s e s sm e n t  t im e .   A v e r ag e  o f  a l l  v a lu e s  b e f o r e  th e  f i r s t  d o s e  o f  s tu dy  d r ug  w i l l  b e  u s e d  a s  th e  b a s e l in e  v a lu e .   C r i t e r i a  f o r  c l in i c a l ly  n o t a b l e  ECG  a b n o rm a l i t i e s  a r e  d e f in e d  ( s e e  T a b l e 1 3 ) .   
T h e  a b n o rm a l  v a lu e s  f o r  su b j e c t s  e xh ib i t in g  c l in i c a l ly  n o t a b l e  ECG  a b n o rm a l i t i e s  w i l l  b e  l i s t e d
.   
A l e r t  ECG  v a lu e s  a r e  d e f in e d  a s  a n  a b so lu t e  v a lu e  o u t s id e  th e  d e f in e d  r a ng e  a n d  a b so lu t e  
p e r c e n t ag e  c h a ng e  >  2 5%  ( 3 0%  f o r  QRS )  in t e r v a l .   T h e  a b n o rm a l  v a lu e s  fo r  su b j e c t s  e xh ib i t in g  
a l e r t  ECG  a b n o rm a l i t i e s  w i l l  b e  l i s t e d .   O u t l i e r s  o f  QT ,  QT cB ,  a n d  QT cF ,  d e f in e d  a s  a b so lu t e  
v a lu e s  >  4 5 0  m i l l i s e c o n d s  o r  c h a ng e  f r om  b a s e l in e  >  3 0  m i l l i s e c o n d s ,  w i l l  a l so  b e  l i s t e d .    
Tab l e  1 3 :  C r i t e r ia  fo r  C l in i c a l ly  N o t ab l e  E l e c t r o c a rd io g r am Abno rm a l i t i e s  
Pa ram e t e r H i gh  Th r e sh o ld L ow  Th r e sh o ld 
QT cF >  460  m se c  <  295  m se c  
PR >  220  m se c  <  75  m se c  
QRS >  120  m se c  <  50  m se c  
QT >  500  m se c  <  300  m se c  
RR >  1330  m se c  <  600  m se c  
QT cF  =  F r id e r i c i a c o r r e c t ion .  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  61 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
9 . 5 .  An a l y s e s  f o r  th e  Ind ep end en t  D a t a  M on i t o r in g  C omm i t t e e 
P r e p l a n n e d  a n a ly s e s  o f  s a f e ty  w i l l  b e  p r o v id e d  to  th e  IDMC  a s  sp e c i f i e d  in  th e  IDMC  c h a r t e r .   I n  
a d d i t io n ,  th e  IDMC  w i l l  m a k e  r e c omm e n d a t io n s  to  th e  sp o n so r  a t  th e  p l a nn e d  in t e r im  f u t i l i ty  a n a ly s i s  in  G r o u p  A  ( s e e  S e c t io n 9 . 6 ) .   T h e  p r o c e s s  by  w h i c h  th e  IDMC  w i l l  m a k e  
r e c omm e n d a t io n s  a n d  d e c i s io n s  w i l l  b e  d o c um e n t e d  in  th e  IDMC  c h a r t e r .  
9 . 6 .  In t e r im  An a ly s i s  
A n  in t e r im  f u t i l i ty  a n a ly s i s  i s  p l a n n e d  w h e n  th e  f i r s t  4 0  su b j e c t s  in  G r o u p  A  h a v e  b e e n  t r e a t e d  
a n d  h a v e  b e e n  e v a lu a t e d  f o r  r e sp o n s e  o r  h a v e  p e rm a n e n t ly  d i s c o n t in u e d  s tu dy  t r e a tm e n t  b e c a u s e  o f  d i s e a s e  p r og r e s s io n ,  w i th d r aw a l  o f  c o n s e n t ,  o r  d e a th .   G r o u p  A  o f  th e  s tu dy  w i l l  b e  t e rm in a t e d  
f o r  f u t i l i ty  i f  ≤  1 3  o f  th e  4 0  su b j e c t s  h a v e  r e sp o n d e d  ( i e ,  CR /CMR  o r  PR /PMR )  b a s e d  o n  
a s s e s sm e n t s  p r o v id e d  by  th e  IRC ;  o th e rw i s e  th e  s tu dy  w i l l  c o n t in u e .   T h e  fu t i l i ty  b o u n d a ry  i s  d e t e rm in e d  u s ing  a  sp e n d in g  f u n c t io n  o f  HSD ( - 4 ) .   A  t im e ly  a s s es sm e n t  o f  r e sp o n s e  w i l l  b e  
p e r f o rm e d  to  a v o id  th e  r i sk  o f  o v e r e n r o l lm e n t .  
 
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  62 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
10 .  ETH ICAL  CONS IDERAT IONS  AND  ADM IN ISTRAT IVE  
PROCEDURES 
10 . 1 .  In v e s t i ga t o r  R e sp on s ib i l i t i e s  
T h i s  s tu dy  w i l l  b e  p e r f o rm e d  in  a c c o r d a n c e  w i th  e th i c a l  p r in c ip l e s  th a t  o r ig in a t e  in  th e  
D e c l a r a t io n  o f  H e l s in k i  an d  c o n d u c t e d  in  a d h e r e n c e  to  th e  s tu dy  P r o to c o l ;  GCP s  a s  d e f in e d  in  T i t l e 2 1  o f  th e  US  CFR  P a r t s  1 1 ,  5 0 ,  5 4 ,  5 6 ,  a n d  31 2 ;  ICH  E 6  GCP  c o n so l id a t e d  g u id e l in e s ;  a n d  
lo c a l  r eg u l a to ry  r e q u i r em e n t s  a s  a p p l i c a b l e  to  th e  s tu dy  lo c a t io n s .  
T h e  in v e s t ig a to r  w i l l  b e  r e sp o n s ib l e  f o r :  
•  P e rm i t t in g  s tu dy- r e l a t e d  mo n i to r in g ,  sp o n so r  a u d i t s ,  IRB / IEC  r e v i ew ,  a n d  r e g u l a to ry  
in sp e c t io n s  by  p r o v id ing  d i r e c t  a c c e s s  to  so u r c e  d a t a  a n d  o th e r  r e l e v a n t  c l in i c a l  s tu dy  
d o c um e n t s .  
− Mo n i to r in g :   Q u a l i f i e d  r ep r e s e n t a t iv e s  o f  th e  sp o n so r  o r  i t s  d e s ig n e e ,  s tu dy  
mo n i to r s ,  w i l l  mo n i to r  th e  s tu dy  a c c o r d in g  to  a  p r e d e t e rm in e d  p l a n .   T h e  
in v e s t ig a to r  mu s t  a l low  th e  s tu dy  mo n i to r s  to  r e v i ew  a ny  s tu dy  m a t e r i a l s  an d  su b j e c t  r e c o r d s  a t  e a c h  mo n i to r in g  v i s i t .  
− A u d i t in g :   Q u a l i f i e d  r e p r e s e n t a t iv e s  o f  th e  sp o n so r  o r  i t s  d e s ig n e e  m ay  a u d i t  th e  
c l in i c a l  s tu dy  s i t e  a n d  s tudy  d a t a  to  e v a lu a t e  c omp l i a n c e  w i th  th e  P r o to c o l ,  
a p p l i c a b l e  lo c a l  c l in i c a l  s tu dy  r eg u l a t io n s ,  a n d  o v e r a l l  s tu dy  c o n d u c t .   T h e  
in v e s t ig a to r  mu s t  a l low  th e  a u d i to r s  to  r e v i ew  o r ig in a l  so u r c e  r e c o r d s  a n d  s tu dy  d o c um e n t a t io n  f o r  a l l  sub j e c t s .  
− R e g u l a to ry  in sp e c t io n :   R e g u l a to ry  a u th o r i t i e s  m ay  c o n d u c t  a n  in sp e c t io n  o f  th e  
s tu dy  a n d  th e  s i t e  a t  a ny  t im e  d u r in g  th e  d e v e lo pm e n t  o f  a n  in v e s t ig a t io n a l  p r o d u c t .   T h e  in v e s t ig a to r  a n d  s t a f f  a r e  e xp e c t e d  to  c o o p e r a t e  w i th  th e  in sp e c to r s  a n d  a l low  a c c e s s  to  a l l  sou r c e  d o c um e n t s  su p p o r t in g  th e  eCRF s  a n d  o th e r  
s tu dy - r e l a t e d  d o c um e n t s .   T h e  in v e s t ig a to r  mu s t  imm e d i a t e ly  n o t i fy  th e  spo n so r  
w h e n  c o n t a c t e d  by  a ny  r eg u l a to ry  a u th o r i ty  f o r  th e  p u r p o s e s  o f  c o n d u c t in g  a n  in sp e c t io n .  
•  O b t a in in g  in f o rm e d  c o n s e n t  a n d  e n su r ing  th a t  th e  s tu dy  su b j e c t s '  q u e s t io n s  h a v e  b e e n  
a n sw e r e d  a n d  th e  su b j e c t s  f u l ly  u n d e r s t a n d  s tu dy  p r o c e d u r e s :  
− I n f o rm e d  c o n s e n t  mu s t  b e  o b t a in e d  b e f o r e  a ny  s tu dy - r e l a t e d  p r o c e d u r e s  a r e  
c o n d u c t e d ,  u n l e s s  o th e rw i s e  sp e c i f i e d  by  th e  P r o to c o l .  
− I n f o rm e d  c o n s e n t  mu s t  b e  o b t a in e d  u s in g  th e  IRB / IEC - a p p r o v e d  v e r s io n  in  a  
l a n g u ag e  th a t  i s  n a t iv e  a nd  u n d e r s t a n d a b l e  to  th e  su b j e c t .   A  t emp l a t e  w i l l  b e  
p r o v id e d  by  th e  sp o n so r  o r  i t s  d e s ig n e e .   T h e  sp o n so r  o r  i t s  d e s ig n e e  mu s t  r e v i ew  a n d  a c k n ow l e dg e  th e  s i t e - sp e c i f i c  c h a ng e s  to  th e  ICF  t emp l a t e .   T h e  ICF  mu s t  
in c lu d e  a  s t a t em e n t  th a t  th e  sp o n so r  o r  i t s  d e s ig n e e  a n d  r eg u l a to ry  a u th o r i t i e s  h a v e  
d i r e c t  a c c e s s  to  su b j e c t  r e c o r d s . 
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  63 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
•  O b t a in in g  a p p r o v a l  f r om  th e  IRB / IEC  b e f o r e  th e  s t a r t  o f  th e  s tu dy  a n d  f o r  any  
c h a ng e s  to  th e  c l in i c a l  s tu dy  P r o to c o l ,  imp o r t a n t  P r o to c o l  d e v i a t io n s ,  r o u t in e  u p d a t e s ,  
a n d  s a f e ty  in f o rm a t io n  in  a c c o r d a n c e  w i th  in s t i tu t i o n a l  r e q u i r em e n t s  a n d  lo c a l  l aw .  
− T h e  in v e s t ig a to r  i s  r e sp on s ib l e  f o r  e n su r ing  th a t  th e  s a f e ty  r e p o r t s  p r o v id ed  by  th e  
sp o n so r  a r e  r e v i ew e d  a n d  p r o c e s s e d  in  a c c o r d a n c e  w i th  r e g u l a to ry  r e q u i r em e n t s  
a n d  w i th  th e  p o l i c i e s  a n d  p r o c e d u r e s  e s t a b l i sh e d  by  th e  IRB / IEC . 
•  A d h e r ing  to  th e  P r o to c o l  a s  d e s c r ib e d  in  th i s  d o c um e n t  a n d  ag r e e ing  th a t  ch a n g e s  to  
th e  P r o to c o l  p r o c e d u r e s ,  w i th  th e  e x c e p t io n  o f  m e d i c a l  em e rg e n c i e s ,  mu s t  b e  
d i s c u s s e d  a n d  a p p r o v e d ,  f i r s t ,  by  th e  sp o n so r  o r  i t s  d e s ig n e e  a n d ,  s e c o n d ,  by  th e  IRB / IEC .   E a c h  in v e s t ig a to r  i s  r e sp o n s ib l e  f o r  e n ro l l in g  su b j e c t s  w h o  h a v e  m e t  th e  
sp e c i f i e d  e l ig ib i l i ty  c r i t e r i a .  
•  R e t a in in g  r e c o r d s  in  a c c o r d a n c e  w i th  a l l  lo c a l ,  n a t io n a l ,  a n d  r eg u l a to ry  l aw s ,  b u t  f o r  a  
m in imum  p e r io d  o f  a t  l e a s t  2 y e a r s  a f t e r  th e  l a s t  m a r k e t ing  a p p l i c a t io n  a p p ro v a l  in  a n  
ICH  r eg io n  a n d  u n t i l  th e r e  a r e  n o  p e n d ing  o r  c o n t emp l a t e d  m a r k e t ing  a p p l i c a t io n s  in  
a n  ICH  r eg io n ,  o r  i f  n o t  ap p r o v e d ,  2  y e a r s  a f t e r  th e  t e rm in a t io n  o f  th e  t e s t  a r t i c l e  f o r  
in v e s t ig a t io n  to  e n su r e  th e  a v a i l a b i l i ty  o f  s tu dy  d o c um e n t a t io n  sh o u ld  i t  b e c om e  n e c e s s a ry  f o r  th e  sp o n so r  o r  a  r eg u l a to ry  a u th o r i ty  to  r e v i ew .  
− T h e  in v e s t ig a to r  mu s t  n o t  d e s t r oy  a ny  r e c o r d s  a s so c i a t e d  w i th  th e  s tu dy  w i th o u t  
r e c e iv ing  a p p r o v a l  f r om  th e  sp o n so r .   T h e  in v e s t ig a to r  mu s t  n o t i fy  th e  sp o n so r  o r  
i t s  d e s ig n e e  in  th e  e v e n t  o f  a c c id e n t a l  lo s s  o r  d e s t ru c t io n  o f  a ny  s tu dy  r e c o rd s .   I f  
th e  in v e s t ig a to r  l e a v e s  th e  in s t i tu t io n  w h e r e  th e  s tu dy  w a s  c o n d u c t e d ,  th e  sp o n so r  o r  i t s  d e s ig n e e  mu s t  b e  co n t a c t e d  to  a r r a ng e  a l t e r n a t iv e  r e c o r d  s to r ag e  o p t io n s .  
− A l l  eCRF  d a t a  e n t e r e d  by  th e  s i t e  ( in c lu d in g  a u d i t  t r a i l ) ,  a s  w e l l  a s  c omp u t e r  
h a r dw a r e  a n d  so f tw a r e  ( fo r  a c c e s s in g  th e  d a t a ) ,  w i l l  b e  m a in t a in e d  o r  m a d e  a v a i l a b l e  a t  th e  s i t e  in  c omp l i a n c e  w i th  a p p l i c a b l e  r e c o r d  r e t e n t io n  r eg u l a t io n s .   T h e  sp o n so r  w i l l  r e t a in  th e  o r ig in a l  eCRF  d a t a  a nd  a u d i t  t r a i l . 
10 . 2 .  A c coun t ab i l i t y ,  H and l in g ,  and  D i sp o sa l  o f  S tud y  D ru g 
T h e  in v e s t ig a to r  i s  r e sp on s ib l e  f o r  d r ug  a c c o u n t a b i l i ty  a t  th e  s tu dy  s i t e ;  h ow e v e r ,  som e  o f  th e  d r u g  a c c o u n t a b i l i ty  d u t i e s  m ay  b e  a s s ig n e d  to  a n  ap p r o p r i a t e  p h a rm a c i s t  o r  o th e r  d e s ig n e e .   I n v e n to ry  a n d  a c c o u n t a b i l i ty  r e c o r d s  mu s t  b e  m a in t a in e d  a n d  r e a d i ly  a v a i l ab l e  f o r  in sp e c t io n  by  
th e  s tu dy  mo n i to r  a n d  a r e  o p e n  to  in sp e c t io n  a t  a ny  t im e  by  a ny  a p p l i c a b l e  r eg u l a to ry  a u th o r i t i e s .   
T h e  in v e s t ig a to r  o r  d e s ig n e e  mu s t  m a in t a in  r e c o r d s  th a t  d o c um e n t :  
•  D e l iv e ry  o f  s tu dy  d r ug  to  th e  s tu dy  s i t e . 
•  I n v e n to ry  o f  s tu dy  d r ug  a t  th e  s i t e .  •  Su b j e c t  u s e  o f  th e  s tu dy  d r u g  in c lu d ing  p i l l  o r  u n i t  c o u n t s  f r om  e a c h  su p p ly  
d i sp e n s e d .  
•  R e tu r n  o f  s tu dy  d r ug  to  th e  in v e s tig a to r  o r  d e s ig n e e  by  su b j e c t s .  
T h e  in v e s t ig a t io n a l  p r o du c t  mu s t  b e  u s e d  o n ly  in  a c c o r d a n c e  w i th  th e  P r o to c o l .   T h e  in v e s t ig a to r  
w i l l  a l so  m a in t a in  r e c o r d s  a d e q u a t e ly  d o c um e n t in g  th a t  th e  su b j e c t s  w e r e  p r o v id e d  th e  sp e c i f i e d  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  64 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
s tu dy  d r ug .   T h e s e  r e c o r d s  sh o u ld  in c lu d e  d a t e s ,  q u a n t i t i e s ,  a n d  a ny  a v a i l a b l e  b a t c h  o r  s e r i a l  
n umb e r s  o r  u n iq u e  c o d e  n umb e r s  a s s ig n e d  to  th e  in v e s t ig a t io n a l  p r o d u c t  a nd  s tu dy  su b j e c t s .  
Comp l e t e d  a c c o u n t a b i l i ty  r e c o r d s  w i l l  b e  a r c h iv ed  by  th e  s i t e .   T h e  in v e s t ig a to r  o r  d e s ig n e e  w i l l  
b e  e xp e c t e d  to  c o l l e c t  a nd  r e t a in  a l l  u s e d ,  u n u s e d ,  a n d  p a r t i a l ly  u s e d  c o n t a in e r s  o f  s tu dy  d r ug  u n t i l  v e r i f i e d  by  th e  s tu d y  mo n i to r  ( u n l e s s  o th e rw i s e  a g r e e d  to  by  th e  sp o n so r ) .   A t  th e  
c o n c lu s io n  o f  th e  s tu dy ,  th e  in v e s t ig a to r  o r  d e s ig n e e  w i l l  o v e r s e e  sh ipm e n t  o f  a ny  r em a in in g  
s tu dy  d r ug  b a c k  to  th e  spo n so r  o r  i t s  d e s ig n e e  f o r  d e s t r u c t io n  a c c o r d ing  to  in s t i tu t io n a l  s t a n d a r d  o p e r a t ing  p r o c e d u r e s .   I f  lo c a l  p r o c e d u r e s  m a n d a t e  o n - s i t e  d e s t r u c t io n  o f  inv e s t ig a t io n a l  su p p ly ,  
th e  s i t e  sh o u ld  (w h e r e  lo c a l  p r o c e d u r e s  a l low )  m a in t a in  th e  in v e s t ig a t io n a l  su p p ly  u n t i l  th e  s tu dy  
mo n i to r  in sp e c t s  th e  a c c ou n t a b i l i ty  r e c o r d s  in  o r d e r  to  e v a lu a t e  c omp l i a n c e  a n d  a c c u r a cy  o f  a c c o u n t a b i l i ty  by  th e  in v e s t ig a t iv e  s i t e .   A t  s i t e s  wh e r e  th e  s tu dy  d r ug  i s  d e s t r oy e d  b e f o r e  
mo n i to r  in sp e c t io n ,  th e  mo n i to r s  r e ly  o n  d o c um en t a t io n  o f  d e s t r u c t io n  p e r  th e  s i t e  SOP .  
10 . 3 .  D a t a  M an a g em en t 
D a t a  m a n ag em e n t  w i l l  b e  p e r f o rm e d  in  a  v a l id a t ed  d a t a b a s e  v i a  a n  E l e c t r on i c  D a t a  C a p tu r e  
(EDC )  sy s t em .   A l l  d a t a  e n t ry ,  v e r i f i c a t io n ,  a n d  v a l id a t io n  w i l l  b e  p e r f o rm e d  in  a c c o r d a n c e  w i th  
th e  c u r r e n t  s t a n d a r d  o p e r a t in g  p r o c e d u r e s  o f  th e  D a t a  M a n ag em e n t  D e p a r tm e n t  a t  th e  sp o n so r  o r  
i t s  d e s ig n e e .   T h e  d a t a b a s e  w i l l  b e  a u th o r i z e d  f o r  lo c k  o n c e  a l l  d e f in e d  p r o c e d u r e s  a r e  c omp l e t e d .  
T h e  in v e s t ig a to r  w i l l  b e  p r o v id e d  w i th  a cc e s s  to  an  EDC  sy s t em  so  th a t  a n  eCRF  c a n  b e  
c omp l e t e d  f o r  e a c h  su b j e c t .   E n t r i e s  m a d e  in  th e  eCRF  mu s t  b e  v e r i f i a b l e  ag a in s t  so u r c e  
d o c um e n t s ;  i f  u p d a t e s  to  th e  d a t a b a s e  a r e  n o t  p o s s ib l e ,  a ny  d i s c r e p a n c i e s  sho u ld  b e  e xp l a in e d  a n d  d o c um e n t e d .   T h e  in v e s t ig a to r  w i l l  b e  r e sp o n s ib l e  f o r  r e v i ew in g  a l l  d a t a  a n d  eCRF  e n t r i e s ,  
a n d  w i l l  s ig n  a n d  d a t e  th e  d e s ig n a t e d  f o rm s  in  e a ch  su b j e c t ' s  eCRF ,  v e r i fy in g  th a t  th e  
in f o rm a t io n  i s  t r u e  a n d  co r r e c t .   T h e  in v e s t ig a to r  i s  r e sp o n s ib l e  f o r  th e  r e v i ew  a n d  a p p r o v a l  o f  a l l  q u e ry  r e sp o n s e s .  
P r o to c o l  d e v i a t io n s  w i l l  b e  id e n t i f i e d  a n d  r e c o r d ed  in  th e  P r o to c o l  D e v i a t io n  f o rm  o f  th e  eCRF .   
T h e  s tu dy  mo n i to r  w i l l  r e f e r e n c e  th e  Mo n i to r ing  P l a n  in  o r d e r  to  e n su r e  th a t  e a c h  i s su e  id e n t i f i e d  i s  a p p r o p r i a t e ly  d o c um e n t e d ,  r e p o r t e d ,  a n d  r e so lv ed  in  a  t im e ly  m a n n e r  in  a c c o r d a n c e  w i th  th e  
p l a n ' s  r e q u i r em e n t s .  
10 . 4 .  D a t a  P r iv a c y  and  C on f id en t ia l i t y  o f  S tud y  R e c o rd s 
T h e  in v e s t ig a to r  a n d  th e  sp o n so r  o r  i t s  d e s ig n e e  mu s t  a d h e r e  to  a p p l i c a b l e  d a t a  p r iv a cy  l aw s  a n d  
r eg u l a t io n s .   T h e  in v e s t ig a to r  a n d  th e  sp o n so r  o r  i t s  d e s ig n e e  a r e  r e sp o n s ib l e  f o r  e n su r in g  th a t  s e n s i t iv e  in f o rm a t io n  i s  h a n d l e d  in  a c c o r d a n c e  w i th  lo c a l  r e q u i r em e n t s  ( eg ,  H IPAA ) .   
A p p r o p r i a t e  c o n s e n t  a n d  a u th o r i z a t io n s  f o r  u s e  a nd  d i s c lo su r e  a n d /o r  t r a n s f e r  ( i f  a p p l i c a b l e )  o f  
p r o t e c t e d  in f o rm a t io n  mu s t  b e  o b t a in e d .  
Su b j e c t  n am e s  w i l l  n o t  b e  su p p l i e d  to  th e  sp o n so r  o r  i t s  d e s ig n e e ,  i f  a p p l i c ab l e .   O n ly  th e  su b j e c t  
n umb e r  a n d  su b j e c t ' s  in i t i a l s  ( su b j e c t ' s  in i t i a l s  w i l l  o n ly  b e  r e c o r d e d  i f  a l low a b l e  by  lo c a l  
r eg u l a t io n s )  w i l l  b e  r e c o rd e d  in  th e  e CRF ,  w h e r e  p e rm i t t e d ;  i f  th e  su b j e c t' s  n am e  a p p e a r s  o n  a ny  o th e r  d o c um e n t  ( eg ,  l a b o r a to ry  r e p o r t ) ,  i t  mu s t  b e  o b l i t e r a t e d  o n  th e  c o py  o f  th e  d o c um e n t  to  b e  
su p p l i e d  to  th e  sp o n so r  o r  i t s  d e s ig n e e .   S tu dy  f in d in g s  s to r e d  o n  a  c omp u t e r  w i l l  b e  s to r e d  in  
a c c o r d a n c e  w i th  lo c a l  d a t a  p r o t e c t io n  l aw s .   T h e  su b j e c t s  w i l l  b e  in f o rm e d  th a t  r e p r e s e n t a t iv e s  o f  th e  sp o n so r  o r  i t s  d e s ig n e e ,  IRB  o r  IEC ,  o r  r eg u l a to ry  a u th o r i t i e s  m ay  in sp e c t  th e i r  m e d i c a l  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  65 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
r e c o r d s  to  v e r i fy  th e  in f o rm a t io n  c o l l e c t e d ,  a n d  th a t  a l l  p e r so n a l  in f o rm a t io n  m a d e  a v a i l a b l e  f o r  
in sp e c t io n  w i l l  b e  h a n d l ed  in  s t r i c t e s t  c o n f id e n c e  an d  in  a c c o r d a n c e  w i th  lo c a l  d a t a  p r o t e c t io n  
l aw s .  
10 . 5 .  F in an c i a l  D i s c lo su r e 
B e f o r e  s tu dy  in i t i a t io n ,  a l l  c l in i c a l  in v e s t ig a to r s  p a r t i c ip a t in g  in  c l in i c a l  s tud i e s  su b j e c t  to  FDA  
R eg u l a t io n  T i t l e  2 1  Co d e  o f  F e d e r a l  R eg u l a t io n s  (CFR )  P a r t  5 4  –  F in a n c i a l  D i s c lo su r e  by  
C l in i c a l  I n v e s t ig a to r s  ( i e ,  " c o v e r e d  s tu d i e s " )  a r e  r eq u i r e d  to  su bm i t  a  c omp l e t e d  C l in i c a l  
I n v e s t ig a to r  F in a n c i a l  D i s c lo su r e  f o rm  th a t  su f f i c i e n t ly  d e t a i l s  a ny  f in a n c i a l  in t e r e s t s  a n d  a r r a ng em e n t s  th a t  a p p ly .   F o r  th e  p u r p o s e  o f  th i s  r e g u l a t io n ,  " c l in i c a l  in v e s t ig a to r "  i s  d e f in e d  a s  
a ny  in v e s t ig a to r  o r  su b inv e s t ig a to r  w h o  i s  d i r e c t ly  in v o lv e d  in  th e  t r e a tm e n t  o r  e v a lu a t io n  o f  
r e s e a r c h  su b j e c t s ,  in c lu d in g  th e  sp o u s e  a n d  e a c h  d e p e n d e n t  c h i ld  o f  th e  c l in i c a l  in v e s t ig a to r  o r  su b in v e s t ig a to r .   T h e s e  r e q u i r em e n t s  a p p ly  to  b o th  US  a n d  f o r e ig n  c l in i c a l  in v e s t ig a to r s  
c o n d u c t in g  c o v e r e d  c l in i c a l  s tu d i e s .  
A ny  n ew  c l in i c a l  in v e s t ig a to r s  a d d e d  to  th e  c o v e r e d  c l in i c a l  s tu dy  d u r ing  i t s  c on d u c t  mu s t  a l so  
su bm i t  a  c omp l e t e d  I n v e s t ig a to r  F in a n c i a l  D i s c lo su r e  F o rm .   D u r ing  a  c o v e r e d  c l in i c a l  s tu dy ,  
a ny  c h a ng e s  to  th e  f in a n c i a l  in f o rm a t io n  p r e v io u s ly  r e p o r t e d  by  a  c l in i c a l  in v e s t ig a to r  mu s t  b e  
r e p o r t e d  to  th e  sp o n so r  o r  i t s  d e s ig n e e .   A t  th e  c o n c lu s io n  o f  th e  c o v e r e d  c l in i c a l  s tu dy ,  th e  c l in i c a l  in v e s t ig a to r s  w i l l  b e  r em in d e d  o f  th e i r  o b l ig a t io n s .   I n  th e  e v e n t  th a t  th e  c l in i c a l  
in v e s t ig a to r  i s  n o t  r em ind e d ,  th ey  n e v e r th e l e s s  w i l l  r em a in  o b l ig a t e d  to  r e po r t  to  th e  sp o n so r  o r  
i t s  d e s ig n e e  a ny  c h a ng e s  to  th e  f in a n c i a l  in f o rm a t io n  p r e v io u s ly  r e p o r t e d ,  a s  w e l l  a s  a ny  c h a ng e s  in  th e i r  f in a n c i a l  in f o rm a t io n  f o r  a  p e r io d  o f  1  y e a r  a f t e r  c omp l e t io n  o f  th e  c o v e r e d  c l in i c a l  s tu dy .  
10 . 6 .  Pub l i c a t ion  P o l i c y 
By  s ig n ing  th e  s tu dy  P r o to c o l ,  th e  in v e s t ig a to r  a n d  h i s  or  h e r  in s t i tu t io n  a g r e e  th a t  th e  r e su l t s  o f  
th e  s tu dy  m ay  b e  u s e d  by  th e  sp o n so r ,  I n cy t e  Co r po r a t io n  ( I n cy t e ) ,  f o r  th e  pu r p o s e s  o f  n a t io n a l  
a n d  in t e r n a t io n a l  r eg i s t r a t io n ,  p u b l i c a t io n ,  a n d  in f o rm a t io n  f o r  m e d i c a l  a n d  p h a rm a c e u t i c a l  p r o f e s s io n a l s .   S tu dy  r esu l t s  w i l l  b e  p u b l i sh e d  in  a c c o r d a n c e  w i th  a p p l i c a b l e  lo c a l  a n d  n a t io n a l  
r eg u l a t io n s .   I f  n e c e s s a ry ,  th e  a u th o r i t i e s  w i l l  b e  n o t i f i e d  o f  th e  in v e s t ig a to r ' s  n am e ,  a d d r e s s ,  
q u a l i f i c a t io n s ,  a n d  e x t e n t  o f  in v o lv em e n t .   T h e  t e rm s  r e g a r d ing  th e  p u b l i c a t io n  o f  s tu dy  r e su l t s  a r e  c o n t a in e d  in  th e  ag r e em e n t  s ig n e d  w i th  th e  sp o n so r  o r  i t s  d e s ig n e e .   A  s ig n e d  ag r e em e n t  w i l l  
b e  r e t a in e d  by  th e  sp o n so r  o r  i t s  d e s ig n e e .  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  66 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
11 .  REFERENCES 
C a n t l ey  LC .  T h e  p h o sp ho in o s i t id e  3 - k in a s e  p a thw ay .  S c i e n c e  2 0 0 2 ;2 9 6 :1 6 5 5 - 1 6 5 7 .  
Ch e so n  BD ,  F i sh e r  R I ,  B a r r ing to n  SF ,  e t  a l .  R e c omm e n d a t io n s  f o r  in i t i a l  e v a lu a t io n ,  s t a g ing ,  a n d  
r e sp o n s e  a s s e s sm e n t  o f  H o d g k in  a n d  n o n -H o dg k in  l ymp h om a :  th e  L ug a no  c l a s s i f i c a t io n .  J  C l in  
O n c o l  2 0 1 4 ;3 0 :3 0 5 9 - 3 0 6 8 .  
C l in i c a l  T r i a l  F a c i l i t a t io n  G r o u p  (CTFG ) .  R e c omm e n d a t ion s  r e l a t e d  to  c on t r a c e p t io n  a n d  
p r eg n a n cy  t e s t in g  in  c l in i c a l  t r i a l s .  S e p t emb e r  1 5 ,  2 0 1 4 .  h t tp : / /www . hm a . e u / c t f g . h tm l .  A c c e s s e d  
O c to b e r  8 ,  2 0 1 5 .  
Co u t r e  S ,  B a r r i e n to s  JC ,  B r ow n  JR ,  e t  a l .  M a n ag em e n t  o f  a d v e r s e  e v e n t s  a s so c i a t e d  w i th  
id e l a l i s ib  t r e a tm e n t :  e x p e r t  p a n e l  o p in io n .  L e u k  L ymp h om a  2 0 1 5 ;5 6 :2 7 7 9 -2 7 8 6 .  
Cu l t r e r a  JL ,  D a l i a  SM .  D i f f u s e  l a rg e  B- c e l l  l ymp hom a :  c u r r e n t  s t r a t eg i e s  an d  f u tu r e  d i r e c t io n s .   
C a n c e r  Co n t r o l  2 0 1 2 ;1 9 :2 0 4 - 2 1 3 .  
F i s c h e r  K ,  C r am e r  P ,  B u s c h  R,  e t  a l .  B e n d amu s t in e  c omb in e d  w i th  r i tu x im a b  in  p a t i e n t s  wi th  
r e l a p s e d  a n d /o r  r e f r a c to ry  c h r o n i c  l ymp h o cy t i c  l eu k em i a :  a  m u l t i c e n t e r  p h a s e  I I  t r i a l  o f  th e  g e rm a n  c h r o n i c  lymp h o cy t i c  l e u k em i a  s tu dy  g r o up .  J  C l in  O n c o l  2 0 1 1 ;2 9 : 3 5 5 9 - 3 5 6 6 .  
F o r e r o- T o r r e s A ,  W e r th e im  MS ,  Ph i l l ip s  T J ,  e t  a l .  P r e l im in a ry  s a f e ty ,  e f f i c a cy  a n d  
p h a rm a c o dy n am i c s  o f  a  h ig h ly  s e l e c t iv e  P I 3K δ  in h ib i to r ,  INCB 0 5 0 4 6 5 ,  in  p a t i e n t s  w i th  p r e v io u s ly  t r e a t e d  B -c e l l  m a l ig n a n c i e s .  Pr e s e n t e d  a t :  Am e r i c a n  A s so c i a t io n  o f  C a n c e r  R e s e a r c h;  
A p r i l  1 6 - 2 0 ,  2 0 1 6 ;  N ew  O r l e a n s ,  LA . 
F o o n  KA ,  T a k e sh i t a  K,  Z in z a n i  PL .  N o v e l  th e r a p i e s  f o r  ag g r e s s iv e  B -c e l l  lymp h om a .  A d v  
H em a to l  2 0 1 2 ;2 0 1 2 :3 0 2 5 7 0 .  
G o p a l  AK ,  K a h l  BS ,  d e  V o s  S ,  e t  a l .  P I 3K δ  in h ib i t io n  by  id e l a l i s ib  in  p a t i e n t s  w i th  r e l a p s e d  
in d o l e n t  lymp h om a .  N  En g l  J  M e d  2 0 1 4 ;3 7 0 :1 0 0 8 - 1 0 1 8 .  
INCB 0 4 0 0 9 3  I n v e s t ig a t o r ' s  B r o c h u r e  ( IB ) .  W i lm in g to n ,  DE :  I n cy t e  Co r p o r a t io n .  
INCB 0 5 0 4 6 5  I n v e s t ig a to r ' s  B r o c h u r e  ( IB ) .  W i lm in g to n ,  DE :  I n cy t e  Co r p o r a t io n .  
M a r t e l l i  M ,  F e r r e r i  A J ,  Ag n o s t in e l l i  C ,  D i  Ro c c o  A ,  P f r e u n d s c h u h  M ,  P i l e r i  SA .  D i f f u s e  l a rg e  
B - c e l l  lymp h om a .  C r i t  R e v  O n c ol  H em a to l  2 0 1 3 ;8 7 :1 4 6 - 1 7 1 .  
N a t io n a l  C a n c e r  I n s t i tu t e  (NC I) .  Commo n  T e rm in o lo gy  C r i t e r i a  f o r  A d v e r s e  E v e n t s  V e r s io n  
4 . 0 3 .  2 0 0 9 .  h t tp : / / e v s . n c i . n ih . g o v / f tp 1 /CTCAE /CTCAE _ 4 . 0 3 _ 2 0 1 0 - 0 6 -1 4 _Q u i c kR e f e r e n c e _ 5 x7 . p d f .  A c c e s s e d  M ay  2 1 ,  20 1 6 .  
N a t io n a l  C a n c e r  I n s t i tu t e  ( NC I) .  Su r v e i l l a n c e ,  E p id em io lo gy ,  a n d  E n d  R e su l t s  P r o g r am .  2 0 1 6 .  
h t tp : / / s e e r . c a n c e r .g o v / s t a t f a c t s /h tm l /n h l . h tm l .  A c c e s s e d  M ay  2 1 ,  2 0 1 6 .  
N a t io n a l  Comp r e h e n s iv e  C a n c e r  N e tw o r k  (NCCN ) .  C l in i c a l  P r a c t i c e  G u id e l in e s  in  O n c o lo gy :  
N o n-H o dg k in ' s  L ymp h om a s  V e r s io n  4 . 2 0 1 4 .  2 0 14 .  h t tp s : / /www . n c c n . o rg / a b o u t /n h l . p d f .  
A c c e s s e d  F e b r u a ry  2 3 ,  20 1 7 .  
O k e n  MM ,  C r e e c h  RH ,  T o rm ey  DC ,  e t  a l .  T o x i c i ty  a n d  r e sp o n s e  c r i t e r i a  o f  th e  E a s t e r n  
Co o p e r a t iv e  O n c o logy  G r o u p .  Am  J  C l in  O n c o l  1 9 8 2 ;5 :6 4 9 - 6 5 5 .  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  67 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
P a tn a ik  A ,  A p p l em a n  L J ,  T o l c h e r  AW ,  e t  a l .  F i r s t- in - h um a n  p h a s e  I  s tu dy  o f  c o p a n l i s ib  
(BAY  8 0 - 6 9 4 6 ) ,  a n  in t r av e n o u s  p a n - c l a s s  I  p h o sph a t idy l in o s i to l  3 - k in a s e  in h ib i to r ,  in  p a t i e n t s  
w i th  a d v a n c e d  so l id  tumo r s  a n d n o n -H o dg k in ’ s  lymp h om a s .  A n n  O n c o l  2 01 6 ;2 7 :1 9 2 8 - 1 9 4 0 .  
Ph i l ip  T ,  Ch a u v in  F ,  A rmi t a g e  J ,  e t  a l .  P a rm a  in t e r n a t io n a l  p r o to c o l :  p i lo t  s tu dy  o f  DHAP  
f o l low e d  by  in v o lv e d - f i e ld  r a d io th e r a py  a n d  BEAC  w i th  a u to lo g o u s  b o n e  m a r r ow  
t r a n sp l a n t a t io n .  B lo o d  1 99 1 ;7 7 :1 5 8 7 - 1 5 9 2 .  
T o r r e  LA ,  B r ay  F ,  S i eg e l  RL ,  F e r l ay  J ,  L o r t e t- T i eu l e n t  J ,  J em a l  A.   G lo b a l  C a n c e r  S t a t i s t i c s ,  
2 0 1 2 .  CA  C a n c e r  J  C l in  2 0 1 5 ;6 5 :8 7 - 1 0 8 .  
S i e g e l  RL ,  M i l l e r  KD ,  J em a l  A .  C a n c e r  s t a t i s t i c s ,  2 0 1 5 .  CA  C a n c e r  J  C l in  2 0 1 5 ;6 5 :5 - 2 9 .  
Sm i th  TC ,  K h a t c h e r e s s i an  J ,  L ym a n  GH ,  e t  a l .  2 00 6  u p d a t e  o f  r e c omm e n d a t io n s  f o r  th e  u s e  o f  
w h i t e  b lo o d  c e l l  g r ow th  f a c to r s :  a n  e v id e n c e - b a s ed  c l in i c a l  p r a c t i c e  g u id e l in e .  J  C l in  O n c o l  
2 0 0 6 ;2 4 :3 1 8 7 - 3 2 0 5 .  
Sw e r d low  SH ,  C amp o  E ,  H a r r i s  NL ,  e t  a l ,  e d s .  WHO C l a s s i f i c a t io n  o f  T umo u r s  o f  
H a em a to p o i e t i c  an d  L ymp h o id  T i s su e s .  4 th  e d .  L y o n ,  F r a n c e :  IARC  P r e s s ;  2 0 0 8 .  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  68 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
APPEND IX A . INFOR MAT ION  REGARD ING  EFFECT IVENESS  OF  
CONTRACEPT IVE  METHODS  
F o r  Sub j e c t s  P a r t i c ipa t ing  in  th e  S tudy : 
T h e  f o l low in g  m e th o d s  th a t  c a n  a c h i e v e  a  f a i lu r e  r a t e  o f  l e s s  th a n  1%  p e r  y e a r  w h e n  u s e d  
c o n s i s t e n t ly  a n d  c o r r e c t ly  a r e  c o n s id e r e d  a s  h ig h ly  e f f e c t iv e  b i r th  c o n t r o l  m e th o d s .   
Su c h  m e th o d s  in c lu d e :  
•  Comb in e d  ( e s t r o g e n  a n d  p r o g e s to g e n  c o n t a in ing )  h o rmo n a l  c o n t r a c e p t io n  a s so c i a t e d  
w i th  in h ib i t io n  o f  o v u l a t i o n1 
− o r a l 
− in t r a v ag in a l  − t r a n sd e rm a l  
•  P r o g e s tog e n- o n ly  h o rmon a l  c o n t r a c e p t io n  a s so c i a t e d  w i th  in h ib i t io n  o f  o v u l a t io n
1 
− o r a l 
− in j e c t a b l e  
− imp l a n t a b l e2 
•  I n t r a u t e r in e  d e v i c e  ( IUD )2 
•  I n t r a u t e r in e  h o rmo n e - r e l e a s in g  sy s t em  ( IUS )2 
•  B i l a t e r a l  tu b a l  o c c lu s io n2 
•  V a s e c tom i s e d p a r tn e r2 ,3 
•  S e xu a l  a b s t in e n c e4 
 
1  Ho rm on a l con t r a c ep t i on  m ay  b e  s u s c ep t i b l e  t o  i n t e r a c t i on  w i th  th e  IMP ,  w h i ch  m ay  r edu c e  t h e  e f f i c a cy  o f  th e  
con t r a c ep t i on  m e th od .  
2  C on t r a c ep t i on m e t h od s  th a t  i n  t h e  con t ex t  o f  th i s  g u i d an c e  a r e con s i d e r ed  t o  h av e  l ow  u s e r  d ep en d en cy .  
3  V a s e c t om i s ed p a r t n e r  i s  a  h ig h ly  e f f e c t i v e  m e th od  o f  av o id i n g  p r egn an cy  p rov i d ed  t h a t  p a r t n e r  i s  t h e  s o l e  s exu a l  
p a r t n e r  o f  t h e  WOCBP  t r i a l  p a r t i c i p an t  an d  th a t  t h e  v a s e c t om i s ed p a r t n e r  h a s  r e c e i v ed  m ed i c a l  a s s e s sm en t  o f  t h e  
s u rg i c a l  su c c e s s .   
4   In  t h e  con t ex t  o f  th i s  g u i d an c e ,  s ex u a l  ab s t i n en c e  i s  con s i d e r ed  a  h i g h ly  e f f e c t i v e  m e th od  on ly  i f  d e f i n ed  a s  
r e f r a i n ing  f rom  h e t e ro s ex u a l  in t e r cou r s e  du r in g  th e  en t i r e  p e r i od  o f  r i s k  a s s o c i a t ed  w i th  t h e  s t u dy  t r e a tm en t s .   Th e  r e l i ab i l i ty  o f  s exu a l  ab s t in en c e  n e ed s  t o  b e  ev a l u a t ed  in  r e l a t ion  t o  t h e  du r a t i on  o f  th e  c l in i c a l  t r i a l  an d  t h e  p r e f e r r ed  an d  u s u a l  l i f e s ty l e  o f  t h e  su b j e c t .  
S ou r c e :   CTFG 2014.  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  69 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
APPEND IX B .  CYTOCHROME  P45 0  AND  P -GLYCOPROTE IN  
INH IB ITORS  AND  CYTOCHROME  P45 0  INDUCERS  
U n iv e r s i ty  o f  W a sh in g ton  S c h o o l  o f  Ph a rm a c e u t i c s :  D r ug  I n t e r a c t io n  D a t ab a s e  P r og r am.  2 0 0 2 .  
h t tp : / /www . d r u g in t e r a c t io n in f o . o r g .  A c c e s s e d  M ay  2 0 1 5 .   H ig h l ig h t e d  r ow s  in d i c a t e  r e c e n t  a d d i t io n s  to  th e  l i s t s  a t  th e  t im e  th e  d a t a b a s e  s e a r ch  w a s  p e r f o rm e d .  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  70 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
In  V i v o  CYP 3A  Inh ib i t o r s 
 
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  71 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
 
 
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  72 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
In  V i v o  CYP 3A  Indu c e r s 
 
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  73 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
 
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  74 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV  201 9  
APPEND IX C . PROTOCOL  AMENDMENT  SUMMARY  OF  CHANGES 
D o cum en t D a t e 
Am en dm en t  (V e r s io n )  1:  3 0  AUG  2 0 1 6  
Am en dm en t  (V e r s io n )  2:  0 9  NOV  2 0 1 6  
Am en dm en t  (V e r s io n )  3:  2 3  FEB  2 0 1 7  
Am en dm en t  (V e r s io n )  3 - CAN:  1 2  DEC  2 0 1 7  
Am en dm en t  (V e r s io n )  4:  0 5  NOV  2 0 1 9  
Am endm en t  4  ( 0 5  NOV  2 0 1 9 )  
Ov e r a l l  R a t iona l e  fo r  th e  Am endm en t :  T h e  p r im a ry  p u r p o s e  o f  th i s  am e n dm e n t  i s  to  r e d u c e  
P r o to c o l - r e q u i r e d  p r o c e du r e s  f o r  su b j e c t s  w h o  r em a in  o n  s tu dy  t r e a tm e n t .   Su b j e c t s  sh o u ld  b e  mo n i to r e d  p e r  th e  s t a n d a r d  o f  c a r e  f o r  th e i r  c o n d i t io n  a s  d e t e rm in e d  by  th e  in v e s t ig a to r .  
1 .  Synop s i s ;  S e c t ion  4 . 1 ,  Ov e r a l l  S tudy  D e s ign ;  S e c t ion  6 ,  S tudy  A s s e s sm en t s  
( in c lud ing  n ew  Tab l e  6  and  Tab l e  7 ) ;  S e c t ion  7 ,  C ondu c t  o f  S tudy  A s s e s sm en t s  and  P r o c edu r e s ;  S e c t ion  7 . 3 . 1 . 1 ,  P r io r  and  C on c om i t an t  M ed i c a t ion s  and  P r o c edu r e s ;  
S e c t ion  7 . 4 ,  Sa f e t y  A s s e s sm en t s ;  S e c t ion  7 . 4 . 1 ,  Adv e r s e  Ev en t s ;  S e c t ion  7 . 4 . 5 ,  
Labo r a t o r y  A s s e s sm en t s ;  S e c t ion  7 . 5 . 1 ,  FDG -PET  o r  C ombin ed  PET - CT ;  S e c t ion 7 . 5 . 2 ,  C ompu t ed  Tom o g r aphy  S c an  o r  M a gn e t i c  R e sonan c e  Im a g ing ;  
S e c t ion  7 . 8 . 1 ,  Adm in i s t r a t ion  o f  S tudy  D rug ;  S e c t ion  7 . 8 . 2 ,  D i s t r ibu t ion  o f  Sub j e c t  
R em ind e r  C a rd s 
D e s c r ip t ion  o f  chang e :   T h e  s e c t io n s  w e r e  u p d a t ed  to  in c lu d e  in f o rm a t io n  o n  r e d u c e d  
P r o to c o l - r e q u i r e d  a s s e s sm e n t s  f o r  su b j e c t s  w h o  a r e  o ng o ing  in  th e  s tu dy . 
R a t iona l e  fo r  chang e :   T o  r e d u c e  th e  b u r d e n  o f  u n n e c e s s a ry  p r o c e d u r e s  fo r  th e  o ng o in g  
r em a in in g  su b j e c t s  a n d  th e  s i t e s .  
2 .  Synop s i s 
D e s c r ip t ion  o f  chang e :  T h e  c o o r d in a t ing  P I  f o r  th e  s tu dy  w a s  a d d e d  (  
MD ,  ) .  
R a t iona l e  fo r  chang e :  T o  id e n t i fy  th e  s tu dy ' s  c oo r d in a t in g  P I .  
3 .  S e c t ion  1 . 3 ,  INCB0 5 0 4 6 5  
D e s c r ip t ion  o f  chang e :   A d d e d  a  s t a t em e n t  to  r e f e r  to  th e  IB  f o r  c u r r e n t  inf o rm a t io n  o n  
INCB 0 5 0 4 6 5 .  
R a t iona l e  fo r  chang e :   T h e  IB  h a s  b e e n  u p d a t e d  a n d  i s  a  b e t t e r  so u r c e  f o r  th i s  
in f o rm a t io n .  
4 .  S e c t ion  4 . 6 ,  S tudy  T e rm ina t ion  
D e s c r ip t ion  o f  chang e :  S t a t em e n t  a d d e d  in d i c a t in g  th a t  u p o n  s tu dy  c lo su r e ,  su b j e c t s  w h o  a r e  s t i l l  r e c e iv in g s tu dy  t r e a tm e n t  w i l l  h a v e  th e  o p t io n  to  t r a n s i t io n  to  S tu dy  
INCB  5 0 4 6 5 - 2 1 4 ,  in  w h i c h  th ey  m ay  c o n t in u e  to  r e c e iv e  s tu dy  t r e a tm e n t .  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  75 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV  201 9  
R a t iona l e  fo r  chang e :  T o  in c lu d e  a  c r o s so v e r  op t io n  f o r  su b j e c t s  to  c o n t in u e  t r e a tm e n t  
a f t e r  s tu dy  c lo su r e .  
5 .  S e c t ion  7 . 4 . 1 ,  Adv e r s e  Ev en t s ;  S e c t ion  8 . 1 . 2 ,  R epo r t ing ;  S e c t ion  8 . 3 . 2 ,  R epo r t ing  
D e s c r ip t ion  o f  chang e :   S e r io u s  a d v e r s e  e v e n t s  (SAE s )  a n d  a d v e r s e  e v e n t s  l e a d in g  to  d i s c o n t in u a t io n  f r om  s tu dy  t r e a tm e n t  w i l l  b e  c o l l e c t e d  by  th e  sp o n so r .  
R a t iona l e  fo r  chang e :   Co l l e c t io n  o f  a l l  SAE s  a n d  AE s  l e a d ing  to  d i s c o n t in u a t io n  i s  
su f f i c i e n t  f o r  s a f e ty  mo n i to r in g  o f  th e  s tu dy  t r e a tm e n t  a t  th i s  p o in t  in  th e  s tu dy .  
6 .  In c o rpo r a t ion  o f  adm in i s t r a t iv e  chang e s .   O th e r  m in o r ,  a dm in i s t r a t iv e  c h a n g e s  h a v e  
b e e n  in c o r p o r a t e d  th r o ug h o u t  th e  P r o to c o l  a n d  a r e  n o t e d  in  th e  r e d l in e  v e r s io n  o f  th e  am e n dm e n t .  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  76 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
Am endm en t  3-CAN  ( 1 2  DEC  2 0 1 7 )  
Ov e r a l l  R a t iona l e  fo r  th e  Am endm en t :  T o  r emo v e  a  c r i t e r io n  f o r  s tu dy  t r e a tm e n t  
d i s c o n t in u a t io n  p e r  H e a l th  C a n a d a ' s  r e q u e s t .  
1 .  S e c t ion  5 . 5 . 1 ,  C r i t e r ia  fo r  S tudy  T r e a tm en t  D i s c on t inua t ion  
D e s c r ip t ion  o f  chang e :  T h e  f o l low in g  b u l l e t  h a s  b e e n  d e l e t e d  f r om  S e c t ion  5 . 5 . 1 :  
•  I f  a  su b j e c t  i s  f o u n d  n o t  to  h a v e  m e t  e l ig ib i l i ty  c r i t e r i a ,  th e n  th e  m e d i c a l  mon i to r  a n d  
in v e s t ig a to r  w i l l  c o l l a b o r a t e  to  d e t e rm in e  w h e th e r  th e  su b j e c t  sh o u ld  b e  w i th d r aw n  
f r om  th e  s tu dy .  
R a t iona l e  fo r  chang e :   T o  m e e t  H e a l th  C a n a d a  r e q u i r em e n t s . 
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  77 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
Am endm en t  3  ( 2 3  FEB  2 0 1 7 )  
Ov e r a l l  R a t iona l e  fo r  th e  Am endm en t : 
T h e  p r im a ry  p u r p o s e  o f  th i s  am e n dm e n t  i s  to  a d d r e s s  c h a ng e s  r e q u e s t e d  by  th e  E u r o p e a n  
R e g u l a to ry  Ag e n cy . 
T h i s  am e n dm e n t  in c lu d e s  th e  c h a ng e s  to  P r o to c o l  INCB  5 0 4 6 5 - 2 0 2  Am e ndm e n t  2  ( 0 9  NOV  
2 0 1 6 )  summ a r i z e d  b e low .   A  r e d l in e  v e r s io n  o f  th e  am e n dm e n t  d e p i c t in g  up d a t e d  a n d  p r e v io u s  
t e x t  i s  a l so  p r o v id e d .  
1 .  Synop s i s ;  S e c t ion  1 . 4 ,  S tudy  R a t iona l e ;  S e c t ion  3 . 1 ,  Sub j e c t  In c lu s ion  C r i t e r ia 
D e s c r ip t ion  o f  chang e :   Ch a n g e  th e  m in imum  n umb e r  o f  a l low e d  p r io r  sy s t em i c  
th e r a p i e s  f r om  1  to  2  a n d  p r o v id e  ty p e s  o f  p r io r  th e r a p i e s .  
R a t iona l e  fo r  chang e :  R e q u e s t e d  by  E u r o p e a n  R e g u l a to ry  Ag e n cy .  
2 .  Synop s i s ;  S e c t ion  1 . 5 ,  P o t en t ia l  R i sk s  and  B en e f i t s  o f  th e  T r e a tm en t  R eg im en ;  
S e c t ion  5 . 2 . 2 ,  Supp ly ,  P a cka g ing ,  and  Lab e l ing ;  S e c t ion  5 . 6 . 1 ,  Pn eumo c y s t i s  J i ro v e c i i 
P r ophy la x i s  
D e s c r ip t ion  o f  chang e :   R e q u i r e  th a t  a l l  su b j e c t s  r e c e iv e  p r o p hy l a x i s  a g a in s t  
P n e um o c y s t i s  j i ro v e c i i p n e umo n i a .  
R a t iona l e  fo r  chang e :  R e q u e s t e d  by  E u r o p e a n  R e g u l a to ry  Ag e n cy .  
3 .  S e c t ion  1 . 4 ,  S tudy  R a t iona l e  
D e s c r ip t ion  o f  chang e :   T h e  d o s e  r a t io n a l e  w a s  mo v e d  f r om  S e c t io n  1 . 5 ,  Po t e n t i a l  R i sk s  
a n d  B e n e f i t s  o f  th e  T r e a tm e n t  R e g im e n ,  to  S e c t ion  1 . 4 ,  S tu dy  R a t io n a l e .  
R a t iona l e  fo r  chang e :  T o  r e lo c a t e  th e  d o s e  ra t io n a l e  to  th e  a p p r o p r i a t e  s e c t io n  o f  th e  
P r o to c o l . 
4 .  S e c t ion  1 . 5 ,  P o t en t ia l  R i sk s  and  B en e f i t s  o f  th e  T r e a tm en t  R e g im en 
D e s c r ip t ion  o f  chang e :  A  p a r ag r a p h  w a s  a d d e d  s t a t in g  th a t  su b j e c t s  sh o u ld  a v o id  su n /u l t r a v io l e t  l ig h t .  
R a t iona l e  fo r  chang e :  R e q u e s t e d by  E u r o p e a n  R e g u l a to ry  Ag e n cy . 
5 .  S e c t ion  3 . 1 ,  Sub j e c t  In c lu s ion  C r i t e r ia ;  S e c t ion  6 ,  S tudy  A s s e s sm en t s  (Tab l e  5 ) 
D e s c r ip t ion  o f  chang e :  T h e  amo u n t  o f  t im e  th a t  m e n  sh o u ld  a v o id  f a th e r in g  a  c h i ld  w a s  
in c r e a s e d  to  9 3  d ay s  in  in c lu s io n  c r i t e r io n  8 c ;  a n  adm in i s t r a t iv e  e r r o r  w a s  co r r e c t e d  by  
r emo v in g  th e  p r eg n a n cy  t e s t  o n  D ay  1  in  in c lu s io n  c r i t e r io n  8 b .   P r eg n a n cy  t e s t  f o r  w om e n  o f  c h i ld b e a r ing  po t e n t i a l  w a s  a d d e d  a t  e a ch  3 -w e e k  v i s i t  in  T a b l e  5 . 
R a t iona l e  fo r  chang e :   R e q u e s t e d  by  E u r o p e a n  R e g u l a to ry  Ag e n cy . 
6 .  Se c t ion  3 . 2 ,  Sub j e c t  Ex c lu s ion  C r i t e r ia  
D e s c r ip t ion  o f  chang e :  E x c lu s io n  c r i t e r io n  1 3  w a s  mo d i f i e d  to  e x c lu d e  su b j e c t s  th a t  h a d  
e xp o su r e  to  a  l iv e  v a c c in e  w i th in  3 0  d ay s  o f  s tu dy  d r u g  a dm in i s t r a t io n .   
R a t iona l e  fo r  chang e :  R e q u e s t e d  by  E u r o p e a n  R e g u l a to ry  Ag e n cy . 
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  78 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
7 .  S e c t ion  3 . 2 ,  Sub j e c t  Ex c lu s ion  C r i t e r ia  ( c r i t e r ion  1 4 ) ;  S e c t ion  6 ,  S tudy  A s s e s sm en t s  
(Tab l e s  5  and  6 ) ;  S e c t ion  7 . 4 . 5 . 4 ,  H IV  S c r e en ing  T e s t  
D e s c r ip t ion  o f  chang e :  R e q u i r e  th a t  su b j e c t s  e n ro l l e d  o u t s id e  th e  U n i t e d  S t a t e s  h a v e  a n  
H IV  t e s t  a t  s c r e e n ing .  
R a t iona l e  fo r  chang e :  R e q u e s t e d  by  E u r o p e a n  R e g u l a to ry  Ag e n cy .  
8 .  S e c t ion  5 . 4 . 1 ,  C r i t e r ia  and  P r o c edu r e s  fo r  D o s e  In t e r rup t ion s  and  R edu c t ion s  o f  
INCB0 5 0 4 6 5  (Tab l e  2 )  
D e s c r ip t ion  o f  chang e :  P r o v id e  g u id a n c e  th a t  a l l  su b j e c t s  w i th  G r a d e  3  ANC  
(<  1 . 0  ×  1 09/L )  sh o u ld  h av e  INCB 0 5 0 4 6 5  a dm in i s t r a t io n  in t e r r u p t e d .  
R a t iona l e  fo r  chang e :  R e q u e s t e d  by  E u r o p e a n  R e g u l a to ry  Ag e n cy .  
9 .  In c o rpo r a t ion  o f  adm in i s t r a t iv e  chang e s .   O th e r m in o r ,  a dm in i s t r a t iv e  c h a n g e s  h a v e  
b e e n  in c o r p o r a t e d  th r o ug h o u t  th e  P r o to c o l  a n d  a r e  n o t e d  in  th e  r e d l in e  v e r s io n  o f  th e  
am e n dm e n t .  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  79 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
Am endm en t  2  ( 0 9  NOV  2 0 1 6 )  
Ov e r a l l  R a t iona l e  fo r  th e  Am endm en t :  
T h e  p r im a ry  p u r p o s e  o f  th i s  am e n dm e n t  i s  to  c h a ng e  th e  d o s e  o f  INCB 0 5 0 46 5 .  
T h i s  am e n dm e n t  in c lu d e s  th e  c h a ng e s  to  P r o to c o l  INCB  5 0 4 6 5 - 2 0 2  Am e ndm e n t  1  
( 3 0  AUG 2 0 1 6 )  summ a r i z e d  b e low .   A  r e d l in e  v e r s io n  o f  th e  am e n dm e n t  d e p i c t in g  u p d a t e d  a n d  p r e v io u s  t e x t  i s  a l so  p r o v id e d .  
1 .  Synop s i s ;  S e c t ion  1 . 4 ,  S tudy  R a t iona l e ;  S e c t ion  4 . 1 ,  Ov e r a l l  S tudy  D e s ign;  S e c t ion  
5 . 2 . 1 ,  D e s c r ip t ion  and  Adm in i s t r a t ion 
D e s c r ip t ion o f  chang e :   T h e  d o s e  o f  INCB 0 5 0 4 65  h a s  b e e n  c h a ng e d  f r om  3 0  mg  o n c e  
d a i ly  to  2 0  mg  o n c e  d a i ly  f o r  8  w e e k s  f o l low e d  by  2 0  mg  o n c e  w e e k ly . 
R a t iona l e  fo r  chang e :  A s  o f  0 2  SEP  2 0 1 6 ,  amo n g  a l l  su b j e c t s  ( n  =  4 6 )  in  s tu dy  
INCB  5 0 4 6 5 - 1 0 1 ,  1 1  ( 2 4% )  h a v e  d i s c on t in u e d  s tu dy  d r ug  d u e  to  a n  a d v e r s e  e v e n t  ( AE) .   Amo n g  th e  su b j e c t s  w i th  a n  o b j e c t iv e  r e sp o n s e  ( n  =  2 0 ) ,  7  ( 3 5% )  d i s c o n t in u e d  s tu dy  
t r e a tm e n t  d u e  to  a n  AE .   T h e  d o s e  h a s  b e e n  c h a ng e d  in  a n  e f f o r t  to  r e d u c e  th e  f r e q u e n cy  
o f  AE s  th a t  l e a d  to  s tu dy  d r u g  d i s c o n t in u a t io n . 
2 .  Synop s i s ;  S e c t ion  3 . 1 ,  Sub j e c t  In c lu s ion  C r i t e r ia 
D e s c r ip t ion  o f  chang e :   I n c lu s io n  c r i t e r i o n  1  w a s  mo d i f i e d  to  a l low  o n ly  su b j e c t s  ag e d  
1 9  y e a r s  o r  o ld e r  to  e n r o l l  in  So u th  K o r e a . 
R a t iona l e  fo r  chang e :  T h e  l eg a l  a d u l t  ag e  in  So u th  K o r e a  i s  1 9  y e a r s .  
3 .  S e c t ion  1 . 3 ,  INCB0 5 0 4 6 5  
D e s c r ip t ion  o f  chang e :  S a f e ty  a n d  e f f i c a cy  d a t a  h a v e  b e e n  u p d a t e d  b a s e d  o n  a  d a t a  c u t  
o f  0 2  SEP  2 0 1 6 .  
R a t iona l e  fo r  chang e :  T h e s e  c h a ng e s  w e r e  m a d e  to  p r o v id e  th e  mo s t  r e c e n t  em e rg ing  
d a t a  to  su p p o r t  th e  n e e d  fo r  a  d o s e  c h a ng e  a n d  th e  n ew  d o s e  r a t io n a l e .  
4 .  S e c t ion  1 . 5 ,  P o t en t ia l  R i sk s  and  B en e f i t s  o f  th e  T r e a tm en t  R e g im en 
D e s c r ip t ion  o f  chang e :  T h e  p o t e n t i a l  r i sk s  a n d  b e n e f i t s  o f  th e  t r e a tm e n t  r e g im e n  w e r e  u p d a t e d  b a s e d  o n  th e  0 2  SEP  2 0 1 6  d a t a  c u t ,  a n d  th e  d o s e  r a t io n a l e  w a s  p r ov id e d .  
R a t iona l e  fo r  chang e :  T h e  c h a ng e s  w e r e  m a d e  to  p r o v id e  a  c u r r e n t  in t e r p r e t a t io n  b a s e d  
o n  th e  mo s t  r e c e n t  d a t a .   T h e  d o s e  r a t io n a l  w a s  c h a n g e d  to  su p p o r t  th e  n ew  d o s e .  
5 .  S e c t ion  5 . 4 ,  T r e a tm en t  In t e r rup t ion s  and  Ad ju s tm en t s 
D e s c r ip t ion  o f  chang e :  T a bl e  2  (G u id e l in e s  f o r  I n t e r r u p t io n  a n d  R e s t a r t ing  S tu dy  D r ug )  a n d  T a b l e  3  (D o s e  L e v e l s  f o r  INCB 0 5 0 4 6 5 )  w e r e  u p d a t e d ,  a n d  th e  t e rm  " immu n e - r e l a t e d  
a d v e r s e  e v e n t "  w a s  d e f in e d .  
R a t iona l e  fo r  chang e :  N ew  g u id a n c e  w a s  p r o v id e d  f o r  AE s  th a t  h a v e  c au s e d  t r e a tm e n t  
d i s c o n t in u a t io n  in  S tu dy  INCB  5 0 4 6 5 - 1 0 1  to  a s s i s t  p hy s i c i a n s  m a n ag e  th e s e  AE s .   T h e  
t e rm  " immu n e - r e l a t e d  a dv e r s e  e v e n t "  w a s  d e f in e d  so  in v e s t ig a to r s  c a n  c o n s i s t e n t ly  a n sw e r  th e  f o l low in g  q u e s t io n  in  th e  eCRF :   " I s  th i s  e v e n t  a n  immu n e - r e l a t e d  a d v e r s e  
e v e n t ? "  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  80 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
6 .  S e c t ion  6 ,  S tudy  A s s e s sm en t s  (Tab l e  4 :   S ch edu l e  o f  A s s e s sm en t s ) 
D e s c r ip t ion  o f  chang e :  T h e  f r e q u e n cy  o f  d r ug  d i sp e n s in g  w a s  a l t e r e d .  
R a t iona l e  fo r  chang e :  B e c a u s e  th e  d o s e  s c h e d u l e  c h a ng e d  f r om  d a i ly  to  w e e k ly  a t  
W e e k 9 ,  th e  d o s e  d i sp e n s in g  s c h e du l e  w a s  c h a ng ed  to  r e d u c e  th e  amo u n t  o f  d r ug  th a t  w o u ld  o th e rw i s e  b e  d i s c a r d e d . 
7 .  S e c t ion  8 . 4 ,  Adv e r s e  Ev en t s  o f  Sp e c ia l  In t e r e s t 
D e s c r ip t ion  o f  chang e :  R a sh  ≥  G r a d e  2  w a s  a d d ed  to  th e  l i s t  o f  a d v e r s e  e v e n t s  o f  sp e c i a l  in t e r e s t ,  a n d  d i a r rh e a  w a s  c h a ng e d  to  ≥  G r a d e  2 .  
R a t iona l e  fo r  chang e :  R a sh  w a s  a d d e d  b e c a u s e  th i s  i s  a n  AE  th a t  h a s  l e d  to  s tu dy  
t r e a tm e n t  d i s c o n t in u a t io n  a n d  h a s  o c c u r r e d  w i th  som e  f r e q u e n cy  in  S tu dy  INCB  5 0 4 6 5 - 1 0 1 .   T h e  ch a n g e  in  d i a r r h e a  r e p o r t in g  w a s  m a d e  to  r e d u c e  th e  amo u n t  o f  
e xp e d i t e d  r e p o r t in g  f o r  th i s  e v e n t .  
8 .  In c o rpo r a t ion  o f  adm in i s t r a t iv e  chang e s .   O th e r m in o r ,  a dm in i s t r a t iv e  c h a n g e s  h a v e  
b e e n  in c o r p o r a t e d  th r o ug h o u t  th e  P r o to c o l  a n d  a r e  n o t e d  in  th e  r e d l in e  v e r s io n  o f  th e  am e n dm e n t .  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  81 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
Am endm en t  1  ( 3 0  AUG  2 0 1 6 )  
Ov e r a l l  R a t iona l e  fo r  th e  Am endm en t : 
T h e  p r im a ry  p u r p o s e  o f  th i s  am e n dm e n t  i s  to  f u l f i l l  a  r e q u e s t  f r om  th e  FDA  to  1 )  a d d  a n  
I n d e p e n d e n t  D a t a  Mo n i to r in g  Comm i t t e e  a n d  2 )  Co n d u c t  a n  in t e r im  a n a ly s i s  f o r  f u t i l i ty  in  
G r o u p  A .  
T h i s  am e n dm e n t  in c lu d e s  th e  c h a ng e s  to  P r o to c o l  INCB  5 0 4 6 5 - 2 0 2  ( 2 6  MAY  2 0 1 6 )  summ a r i z e d  
b e low .   A  r e d l in e  v e r s io n  o f  th e  am e n dm e n t  d e p i c t in g  u p d a t e d  a n d  p r e v io u s  t e x t  i s  a l so  p r o v id e d .  
1 .  Synop s i s ;  S e c t ion  4 . 1 ,  Ov e r a l l  S tudy  D e s ign ;  S e c t ion  9 . 2 ,  S e l e c t ion  o f  S amp l e  S i z e ;  
S e c t ion  9 . 6 ,  In t e r im  Ana ly s i s 
D e s c r ip t ion  o f  chang e :  A n  in t e r im  f u t i l i ty  a n a ly s i s  h a s  b e e n  a d d e d .   T h e  an a ly s i s  i s  
p l a n n e d  w h e n  th e  f i r s t  4 0  su b j e c t s  in  G r o u p  A  h a v e  b e e n  t r e a t e d  a n d  h a v e  b e e n  e v a lu a t e d  
f o r  r e sp o n s e  o r  h a v e  p e rm a n e n t ly  d i s c o n t in u e d  s tu dy  t r e a tm e n t  b e c a u s e  o f d i s e a s e  
p r o g r e s s io n ,  w i th d r aw a l  o f  c o n s e n t ,  o r  d e a th .   G r ou p  A  o f  th e  s tu dy  w i l l  b e  t e rm in a t e d  f o r  f u t i l i ty  i f  ≤  1 3  o f  th e  4 0  su b j e c t s  h a v e  r e sp o n d e d  ( i e ,  c omp l e t e  r e sp o n s e  [ CR] / c omp l e t e  
m e t a b o l i c  r e sp o n s e  [CMR]  o r  p a r t i a l  r e sp o n s e  [PR] / p a r t i a l  m e t a b o l i c  r e sp o n s e  [PMR] )  
b a s e d  o n  a s s e s sm e n t s  p r ov id e d  by  th e  in d e p e n d e n t  r e v i ew  c omm i t t e e ;  o th e rw i s e  th e  s tu dy  w i l l  c o n t in u e .  A  t im e ly  a s s e s sm e n t  o f  r e sp on s e  w i l l  b e  p e r f o rm e d  to  a v o id  th e  r i sk  
o f  o v e r e n r o l lm e n t .  N o  f o rm a l  f u t i l i ty  a n a ly s i s  w i l l  b e  c o n d u c t e d  f o r  G r o u p  B .  
S e c t io n 9 . 2  (S e l e c t io n  o f  S amp l e  S i z e )  w a s  u p d a t ed  to  b e  c o n s i s t e n t  w i th  th e  n umb e r s  u s e d  in  th e  a d d e d  in t e r im  a n a ly s i s . 
R a t iona l e  fo r  chang e :  R e q u e s t e d  by  th e  FDA . 
2 .  Synop s i s ;  S e c t ion  4 . 1 ,  Ov e r a l l  S tudy  D e s ign ;  S e c t ion  4 . 6 ,  S tudy  T e rm ina t ion ;  
S e c t ion  8 . 7 ,  Ind ep end en t  D a t a M on i t o r ing  C omm i t t e e ;  S e c t ion  9 . 5 ,  Ana ly s e s  fo r  th e  
Ind ep end en t  D a t a  M on i t o r ing  C omm i t t e e  
D e s c r ip t ion  o f  chang e :  A n  in d e p e n d e n t  D a t a  Mon i to r in g  Comm i t t e e  ( IDMC )  w a s  
in c lu d e d  in  th e  s tu dy  to  r e v i ew  s a f e ty  a n d  p e r f o rm  th e  f u t i l i ty  a n a ly s i s .  
R a t iona l e  fo r  chang e :  R e q u e s t e d  by  th e  FDA . 
3 .  Synop s i s ;  S e c t ion  2 ,  S tudy  Ob j e c t iv e s  and  Endpo in t s 
D e s c r ip t ion  o f  chang e :  T h e  p r im a ry  o b j e c t iv e  w a s  u p d a t e d  to  c l a r i fy  th a t  e f f i c a cy  w i l l  
b e  a s s e s s e d  in  t e rm s  o f  ob j e c t iv e  r e sp o n s e  r a t e  (ORR )  in  G r o u p  A ,  a n d  s tu dy  e n d p o in t s  w e r e  u p d a t e d  to  in d i c a t e  G r o u p  A  o r  G r o u p  B  w h e r e  a p p l i c a b l e . 
R a t iona l e  fo r  chang e :  F o r  c l a r i ty  a n d  to  m a k e  th e  o b j e c t iv e s  a n d  e n d p o in t s  c o n s i s t e n t .   
4 .  Synop s i s ;  S e c t ion  2 . 2,  S tudy  Endpo in t s ;  S e c t ion  4 . 1 ,  Ov e r a l l  S tudy  D e s ign ;  S e c t ion  
5 . 5 . 1 ,  C r i t e r ia  fo r  S t udy  T r e a tm en t  D i s c on t inua t ion ;  S e c t ion  6 ,  S tudy  A s s e s sm en t s ;  
S e c t ion  7 . 5 . 3 ,  Bon e  M a r r ow  Ex am ina t ion ;  S e c t ion  7 . 5 . 5 ,  R e spon s e  C r i t e r ia  –  Th e  
Lug ano  C la s s i f i c a t ion ;  S e c t ion  9 . 4 . 1 ,  E f f i c a c y  Ana ly s e s  
D e s c r ip t ion  o f  chang e :  Comp l e t e  r e sp o n s e  (CR ) ,  p a r t i a l  r e spo n s e  (PR ) ,  a nd  p r o g r e s s iv e  
d i s e a s e  (PD )  w e r e  c h a ng e d  th r o u g h o u t  th e  d o c um e n t  to  c omp l e t e  r e sp o n s e / c omp l e t e  
m e t a b o l i c  r e sp o n s e  (CR /CMR ) ,  p a r t i a l  r e sp o n s e /p a r t i a l  m e t a b o l i c  r e sp o n s e  (PR /PMR ) ,  a n d  p r og r e s s iv e  d i s e a s e /p r o g r e s s iv e  m e t a b o l i c  d i s e a s e  (PD /PMD ) .  
CONF IDENT IAL 
In cy t e  C o rpo r a t i on  P ag e  82 o f  82  
P ro t o c o l  INCB  50 465- 20 2  Am  4  V e r s i on  4 05  NOV 201 9  
R at iona l e  fo r  chang e :   T h e  c h a ng e  w a s  m a d e  to  b e  c o n s i s t e n t  w i th  th e  e nd p o in t s  o f  th e  
L ug a n o  C r i t e r i a ,  w h i c h  a r e  b e ing  u s e d  to  e v a lu a t e  th e  d i s e a s e  a s s e s sm e n t s . 
5 .  S e c t ion  5 . 4 . 1 ,  C r i t e r ia  and  P r o c edu r e s  fo r  D o s e  In t e r rup t ion s  and  R edu c t ion s  o f  
INCB0 5 0 4 6 5  (Tab l e  2 ) ;  S e c t ion  5 . 4 . 2 ,  Suppo r t iv e  C a r e  Gu id e l in e s  fo r  D ia r rh e a /C o l i t i s;  S e c t ion  1 1 ,  R e f e r en c e s 
D e s c r ip t ion  o f  chang e :  G u id a n c e  f o r  m a n ag em en t  o f  d i a r r h e a  a n d  c o l i t i s  w a s  a d d e d ,  
a n d  g u id a n c e  f o r  ALT /AST  e l e v a t io n  a n d  G r a d e  3  to x i c i t i e s  w a s  mo d i f i e d .  
R a t iona l e  fo r  chang e :   T o  su p p o r t  in v e s t ig a to r s  w h o s e  su b j e c t s  e xp e r i e n c e  
d i a r r h e a / c o l i t i s ,  w h i c h  h a s  b e e n  o b s e r v e d  in  th e  o ng o ing  INCB 0 5 0 4 6 5  Ph a s e  1  s tu dy .  
 
8 .  In c o rpo r a t ion  o f  adm in i s t r a t iv e  chang e s .   O th e r m in o r ,  a dm in i s t r a t iv e  c h a n g e s  h a v e  
b e e n  in c o r p o r a t e d  th r o ug h o u t  th e  P r o to c o l  a n d  a r e  n o t e d  in  th e  r e d l in e  v e r s io n  o f  th e  
am e n dm e n t .  
CONF IDENT IAL 
S igna tu re  Man i fes t
Documen t  Numbe r :IC -DEV -PROT -AMEND -0524 Rev is ion :1
T i t le :50465 -202  P ro to co l  Amendmen t  4
A l l  da tes  and  t imes  a re  in  Eas te rn  S tanda rd  T ime .
APPROVAL :  50465 -202  Am  4  Rev ised
App rova l  and  Re lease
Name /S igna tu re T i t le Da te Mean ing /Reason
05  Nov  2019 ,  06 :04 :48  PM App roved
 06  Nov  2019 ,  08 :33 :58  AM App roved
06  Nov  2019 ,  03 :58 :47  PM App roved
07  Nov  2019 ,  12 :47 :22  PM App roved